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Abstract
Background There have been many conflicting changes in the prevalence of
the risk factors for upper gastrointestinal bleeding and therefore it is not clear
what the current trends in mortality or incidence are, nor which factors are
important in driving these trends. As populations in many countries are age-
ing with an increasing burden of co-morbidity, this thesis investigates whether
the relationship between non gastrointestinal co-morbidity and upper gastroin-
testinal bleeding might be an explanation for current trends. I hypothesised
that non gastrointestinal co-morbidity was responsible for a large proportion of
bleeds in the population and the deaths that occur following a bleed.
Methodology Large scale routine population based data records were used
to assess the current incidence and mortality trends of upper gastrointestinal
bleeding in England, as well as more in depth studies of predictors of its occur-
rence and subsequent mortality. The databases were examined and compared
to external sources to assess their representativeness, and methods for defin-
ing cases in linked primary and secondary care were developed. The specific
questions addressed in the studies were:
1. What are the current trends and variations in occurrence of upper gas-
trointestinal bleeding? Incidence rates and adjusted incidence rate ratios
were calculated by quintiles of socioeconomic status, age group, sex, re-
i
gion, and calendar year.
2. Has there been an improvement in 30 day mortality following upper
gastrointestinal bleeding? A nested case control study using Hospital
Episodes Statistics from England 1999-2007 examined mortality trends by
age, sex, co-morbidity and type of bleed.
3. Does non gastrointestinal co-morbidity predict upper gastrointestinal
bleeding? A matched nested case control study used the linked Hospi-
tal Episodes Statistics and General Practice Research Database to exam-
ine non gastrointestinal co-morbidity as a risk factor adjusted for other
known risk factors for bleeding. Sequential population attributable frac-
tions were calculated to estimate what each risk factor contributed to the
disease burden.
4. What are the excess causes of death following upper gastrointestinal
bleeding? Causes of death by ICD 10 category were extracted follow-
ing a bleed from the linked Office for National Statistics death register.
Crude mortality rates and excess cumulative incidence functions were
calculated; the latter adjusted for the competing risks between different
causes of death.
Results
1. A higher incidence of upper gastrointestinal bleeding was observed in the
north of England, but this variation was dwarfed by the variation associ-
ated with deprivation. Areas of greater deprivation had 2-3 fold higher
rates of hospitalisation for upper gastrointestinal bleeding than areas of
less deprivation suggesting that strong modifiable risk factors exist.
2. Over the last decade therewas a 20% improvement in 28 daymortality fol-
ii
lowing upper gastrointestinal bleeding, and those admitted with bleeding
were increasingly older and had more co-morbidity.
3. A combined measure of non gastrointestinal co-morbidity was a signif-
icant independent predictor of upper gastrointestinal bleeding and ex-
plained a greater proportion of the burden of bleeding (19%) than any
other risk factor in the population, including medications such as aspirin
and NSAIDs.
4. More than half the absolute excess risk of death was due to co-morbidity
not related to the upper gastrointestinal tract.
Conclusions Non gastrointestinal co-morbidity both strongly predicts an event
of upper gastrointestinal bleeding, and is responsible for a large proportion of
the subsequent long term mortality. The magnitude of the association in the
population explains both why its incidence had not decreased, and why the
improvements in mortality were observed irrespective of endoscopic manage-
ment or bleed type. Furthermore a bleed can be an indicator for a re-assessment
of the severity of co-existing non gastrointestinal morbidity.
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CHAPTER 1
Introduction
2
CHAPTER 1: INTRODUCTION:
Upper gastrointestinal haemorrhage is the commonest emergency medical ad-
mission for gastroenterology in the UK and has a significant inpatient mortal-
ity of 10%1,2 that has not improved over the last two decades.3–5 Although the
overall incidence of gastro-duodenal ulcer bleeding has remained stable dur-
ing the 1990s, in the elderly it increased by over 30%.6,7 It is likely that this
increase is related to higher rates of co-morbidities, increased prescriptions for
these co-morbidities and interactions between the two. However outside of
critical care, where primary prevention for stress ulceration is routinely pre-
scribed, peptic ulceration is not thought to be related to co-morbidities.8 Pre-
vious studies modelling the predictors of upper gastrointestinal haemorrhage
have instead focused on medications, and have been limited by selected pop-
ulations, small numbers, limited ascertainment of co-morbidities or failure to
adjust for geographical variations.
As well as this increasing incidence, the elderly have a two fold higher long-
term mortality following an episode of upper gastrointestinal haemorrhage
compared to their controls.9,10 However it is not known if this is caused by co-
morbidity or whether the upper gastrointestinal haemorrhage itself increases
the mortality. If such bleeding is a marker of coexisting morbidity and an asso-
ciated decline in health, then focusing resources on improving acute treatment
may not improve mortality. Instead a comprehensive approach to care focused
on optimising the treatment of co-morbidities would be more effective, similar
to that currently provided for elderly patients following hip fractures.11
It is vital to understand the current occurrence, outcomes and causes of upper
gastrointestinal haemorrhage to inform and improve effective future manage-
ment and service provision for patients. Therefore, after summarising the liter-
ature on the epidemiology of upper gastrointestinal bleeding I will address the
following questions:
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CHAPTER 1: INTRODUCTION:
1. What is the occurrence of upper gastrointestinal haemorrhagewithin Eng-
land by region, year and deprivation?
2. Has there been a change in upper gastrointestinal mortality over the last
decade?
3. Do co-morbidities predict the occurrence of upper gastrointestinal haem-
orrhage independently of known risk factors?
4. What are the causes of excess death following an upper gastrointestinal
bleed?
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CHAPTER 2: BACKGROUND: Clinical summary
This chapter will examine the previously published literature on the occur-
rence, causes and outcomes of upper gastrointestinal haemorrhage for both
variceal and non variceal bleeding.
2.1 Clinical summary
Upper gastrointestinal haemorrhage is defined as acute bleeding into the lu-
men of the gastrointestinal tract above the ligament of Trietz, typically present-
ing with haematemesis or melaena. It is the commonest emergency medical
admission for gastroenterology,2 has an overall 28 day case fatality in the range
2-14%3,12 and is associated with a significant burden on health care resources.
Upper gastrointestinal bleeding is commonly categorised as variceal (from oe-
sophageal or gastric varices) or non variceal bleeding. Non variceal bleeding
is more common and can be further subdivided by its causes. The proportions
of upper gastrointestinal bleeding admissions in each category are shown in ta-
ble 2.1. Variceal bleeding is reported as a lower proportion of overall bleeds in
larger population based studies than in hospital derived case series. However
comparisons between studies are difficult as many hospital studies only report
cases that had an endoscopy performed, therefore excluding a large proportion
of patients who, without an endoscopy, do not have a specific category of bleed
identified.
2.2 Occurrence and trends
2.2.1 Non variceal bleeding
The reported incidence of upper gastrointestinal bleeding varies widely as can
be seen from table 2.2.
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Table 2.1: Diagnoses of patients presenting with upper gastrointestinal haemorrhage
Country Year Restricted to
endoscoped
cases?
Mallory-
Weiss
syndrome
Erosive in-
flammation
Varices Ulceration Malignancy Other Unspecified
diagnosis
Number
Hospital based studies
Cameroon13 1990 Yes 22% 14% 47% 172
Israel14 1994 Yes 20% 13% 46% 21% 321
Kenya15 1994 Yes 35% 36% 7% 97
Canada16 2004 Yes 25% *** 50% 5% 2,484
Zambia17 2008 Yes 1% 18% 26% 29% 8% 3% 15% 179
Italy18 2008 Yes 5% 13% *** 66% 6% 2% 7% 1,844
Togo19 2010 Yes 11% 16% 18% 41% 44
Europe20 2011 Yes 33% *** 35% 2,655
England*1 2011 Yes 5% 59% 11% 36% 4% 3% 17% 5,004
Egypt21 2011 Yes 2% 12% 31% 31% 2% 8% 16% 724
Population based studies
Scotland*22 1993 7% 47% 6% 28% 2% 7% 29% 1,882
England23 1993 No 5% 24% 4% 31% 4% 6% 25% 4,137
Crete24 1999 No 34% 4% 48% 3% 3% 7% 353
Netherlands3 2000 No 20% 7% 46% 5% 8% 14% 769
USA12 2006 No 12% 9% 34% 4% 41% **
Wales25 2007 No 6% 24% 3% 22% 1% 44% 22,299
Italy26 2009 No 3% 14% 12% 50% 5% 9% 5% 539
USA27 2009 No 17% 2% 53% 15% 30,500****
*Multiple diagnoses allowed
**Percentages from the population extrapolated from the 20% national inpatient sample of admissions.
Blank cells = Information not available in paper
***These studies excluded variceal bleeds
****Percentages extrapolated from Premier Perspective hospital discharge database, a non random database representing 1 in 6 USA admissions.
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Table 2.2: Variations in incidence of acute admissions for upper gastrointestinal bleeding
Year of estimate Country Number of
bleeds for
estimate
Crude Incidence
per 100,000 person
years
Indirect Age
Standardised
Incidence
95% Confidence
Interval
Study type
199128 USA 3,294 36* 71 (68 - 73) 139 Military facilities
199323 England 3,508 89 77 (74 - 79) 74 hospitals in 4 regions
199322 Scotland 1,720 157 135 (129 - 142) 19 hospitals in one region
199629 France 2,133 84 73 (70 - 76) 29 hospitals in one region
199924 Crete 21 149 137 (84 - 209) All hospitals in one region
1999-200725 Wales 22,299 119+ 99 (98 - 101) National admissions database
20003 Netherlands 769 48 45 (43 - 47) 10 hospitals in Amsterdam region
200230 Scotland 211 99 83 (72 - 95) Single Hospital
20034 Canada 13,017 53** 50 (49 - 51) National admissions database
200426 Italy 21 74 59 (36 - 90) Single Hospital
200531 Greece 353 98 85 (76 - 94) 3 hospitals in one region
200632 Spain 291 66 55 (49 - 62) Single Hospital
200612 USA N/A 82*** 89 (88 - 90) National Inpatient Sample
200733 Israel 864 17**** 17 (16 - 18) National admissions database
200927 USA 30,500 61*** 65 (64 - 66) Premier Perspective database
Where the paper reports incidence trends over time the most recent incidence estimate is shown (+apart from Button et al who report an average)
Blank cells = Information not available in paper
*Military population - standardised using 2010 military population estimates from the DoD, Population Representation of the Military Services, FY2010:
table B-15
**More restrictive definition requiring combinations of codes for non ulcer codes
***Estimates from the population extrapolated from the 20% national inpatient sample without including or Primier Perspective database. Both
estimates did not include unspecified bleeding which had an estimated admission rate of 56/100,000 and 53/100,000 population respectively in 2009.
****Only specific upper gastrointestinal bleed codes with a diagnosed underlying cause (e.g. no haematemesis, melaena or unspecified codes were
included)
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Recent large European and North American studies suggest figures for the inci-
dence of upper gastrointestinal bleeding in the region of 50-100/100,000 person
years. Though some of the geographical differences in incidence around the
world are doubtless genuine, some of the variation in the figures may be a con-
sequence of different case definitions, management systems, timing of studies
and study methodology. For example a low incidence has been reported from a
military population.28 However the highest incidence estimates were reduced
when indirectly standardised for age (table 2.2), and two of the lower incidence
figures came from studies which used restrictive definitions of upper gastroin-
testinal bleeds.33,34 Differences in clinical management may also account for
some of the geographical variation when the case definition depends on hos-
pitalisation; for example within the USA the proportion of patients managed
without a hospital admission varied by more than two fold between states (19-
45%).35
Regional incidence within one country can also vary widely. The incidence
in north west Scotland has been estimated to be 172/100,000,22 the incidence
in Wales has been estimated to be 134/100,000,25 and the incidence in mid-
dle England has been estimated to be between 43/100,000 around Oxford36 to
103/100,000 around the Thames and the Midlands.23
The reason for these large regional differences within the UK is often thought to
be deprivation. There is some prior, albeit limited, evidence of a socioeconomic
gradient in this disease from two UK base studies. A small study of less than
2000 patients from the north west of Scotland demonstrated a 2 fold difference
in the occurrence of upper gastrointestinal haemorrhage between the least and
most deprived, while a recent report from Wales also indicated that those from
most deprived areas have the highest rate of hospitalization for upper gastroin-
testinal haemorrhage.22,25 However both these studies found higher hospitali-
sation rates than previous studies and this raises questions of how their popu-
9
CHAPTER 2: BACKGROUND: Occurrence and trends
lations and cases were defined. Furthermore both studies only reported crude
combined variceal and non variceal haemorrhage estimates and their method-
ology and limited sizemean they did not investigate whether differences in age,
gender, year or region might be responsible for the socioeconomic gradient.
It is unclear to what extent changes in incidence over time are similarly ex-
plained, and towhat extent they reflect changes in underlying risk factors. Over
the last two decadesmany countries including the USA, Canada, Israel, Nether-
lands, Greece and Italy have reported reductions in overall upper gastrointesti-
nal bleeding admissions of between 10 and 40%.3,4,12,26,27,31,33 However, there
are also some conflicting studies, particularly from peptic ulcers in older age
groups.6,7,25,37
2.2.2 Variceal bleeding
In contrast to non variceal bleeding there is little literature on the occurrence of
variceal bleeding separately from non variceal bleeding, but the proportions of
variceal bleeding reported in the larger population based studies was between
3 and 9% (table 2.1) suggesting an incidence of between 2.1 and 8.1 per 100,000
person years. Reports from the USA National Inpatient Sample reported an
11% increase in variceal admission rates comparing 1998 to 2006,12 but in an-
other study in similar data comparing 2001 to 2009 there was a 9% decrease.27
The studies did however use different code lists, hospitals contributing to the
Premier perspective database might not be representative of the USA hospital
population, and the sampling frame used for the USA National Inpatient Sam-
ple more than doubled in size over the study periods. A Swedish study found
around 400 variceal bleed admissions a year, with a stable incidence between
4-6/100,000 since 1987.38 In the UK the prevalence and incidence of cirrhosis
is increasing,39,40 but the effect on the occurrence of variceal bleeding is not
10
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known.
2.2.3 Healthcare costs
Healthcare costs vary between countries, but the expense related to upper gas-
trointestinal bleeding is a consistently large proportion of these costs. Non
variceal haemorrhage is associated with a median length of hospital stay of
4-5 days1,35 and variceal haemorrhage 7-9 days.41 Using the National Inpa-
tient Sample from USA (restricted to patients who survived to discharge) the
costs for an uncomplicated non variceal bleed were $3402 and when associated
with complications $5632.42 For variceal haemorrhage the costs were $6612 and
$23,207 respectively. However within the USA a higher proportion of upper
gastrointestinal haemorrhage admissions are managed in an ITU setting.43 In
contrast, lower estimates were derived from Canada for non variceal haemor-
rhage at $1883, and these costs increased with age and decreased with previous
history of peptic ulcer disease. In Ireland the average cost for a non variceal
haemorrhage admission is €2,537, however interestingly 75% of the expendi-
ture is on patients with a Rockall score ≤ 3.44 In England the National Health
Service tariff pays £2,462 for an emergency admission for upper gastrointestinal
bleedwith complications, £1,268without complications and £416when patients
are discharged the same day.45 In the recent National Upper Gastrointestinal
Bleed Audit 6% of patients were discharged the same day, and 26% had ongo-
ing bleeding requiring further intervention or causing death.46 This suggests
a cost for the NHS in the region of £150,000,000 per 100,000 patients admitted
with bleeding.
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2.3 Mortality trends
2.3.1 Natural history
The natural history of a condition is the course it would take without an inter-
vention and, for a frequently mortal condition such as upper gastrointestinal
bleeding with established interventions we cannot simply observe this. What
we can do is to look at the outcome of the condition with treatment, and how
changes in therapy have altered mortality.
At the beginning of the 20th century hospital mortality from haematemesis and
melaena due to peptic ulcers was reported to be over 20% for patients over 40
years old.47 Mortality was higher in older patients and in those in whom bleed-
ing recurred. The first advance in bleeding management was the use of gener-
ous blood transfusions guided by measured haemoglobin concentration given
in a controlled intravenous drip.48 Surgery was advocated following resusci-
tation when bleeding continued or reoccurred for those who were diagnosed
with peptic ulceration, though the selection of patients and reported mortality
varied widely and was controversial.47,49 Indeed generous early eating regimes
apparently demonstrated a strikingly low hospital mortality.50
However comparisons of the mortality from these early case series are diffi-
cult, as cases and deaths not thought to be due to be directly from bleeding,
such as malignancy or cirrhosis, were often excluded.47 Concerning this Lewin
and Truelove commented “...it is noteworthy that the literature shows that most
series with a low fatality rate have come from interested single physicians pre-
senting their own cases, whereas studies of gross hospital figures commonly
indicate a much less favourable prognosis....We believe that mass hospital fig-
ures are more truly representative of the dangers of haematemesis than are
the results obtained by a few specialists, provided that the data are handled
12
CHAPTER 2: BACKGROUND: Mortality trends
with an appreciation of possible fallacies”.51 Lewin and Truelove’s case series
in 1949 (median age about 50 years) of all presentations with haematemesis and
melaena in Oxford estimated a high mortality of 19% following chronic ulcers,
7% following acute ulcers, 24% following other diagnoses, and 33% where no
diagnosis was made.
By the 1960-70s medical management was similar to that developed during the
1930swith early feeding and generous blood transfusions guided by haemoglobin
measurement. Following medical management over 70% of peptic ulcer bleeds
and 44% of variceal bleeds resolved with no further bleeding.52,53 Surgery was
mostly reserved for those with unstable ulcer bleeding, whereas other causes
such as varices and gastric cancer where not amenable to emergency treatment.
Gastroscopy was recommended acutely for early diagnosis where a barium
meal was inconclusive.54 In 1967-8 the overall mortality in Aberdeen was re-
ported to be 14% for all admissions over 12 years old with haematemesis and
melaena (median age about 60 years), but this increased to 29% if further bleed-
ing occurred.53 Age and co-morbidity were consistently predictors of further
bleeding, and for specific diagnoses mortality for peptic ulcer bleeding was 5%,
for variceal bleeding was 24%, for other causes was 47%, and for undiagnosed
bleeding was 12%.
Over the last few decades improvements in endoscopic therapy have been shown
to reduce risks of rebleeding, for example by the increased use of combination
therapies55 and variceal banding.56 The use of proton pump inhibitors has been
demonstrated to reduce stomach pH and promote clot stability,57 a similar ap-
proach to that originally intended by early feeding. For variceal haemorrhage
the use of antibiotics and glypression at the time of variceal bleeding has also
been shown to reduce mortality.58,59 At the same time that these improvements
have been developed, the age of those admitted has risen. The median age of
patients being admitted with bleeding from non variceal causes during the last
13
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two decades is around 70 years old.1,23
2.3.2 Recent trends in short term case fatality for non variceal
bleeding
There has been awide variation of overall short termmortality from non variceal
haemorrhage with low estimates from the USA and some of Europe, and higher
estimates from elsewhere in Europe (see table 2.3). However mortality in longi-
tudinal population cohorts of upper gastrointestinal bleeds remains unchanged
at about 10-14%.3,25 Increasing age and co-morbidity confounding the effects of
therapy improvements have been proposed as the likely explanation.60
The consistent tendency noted at the start of the last century for co-morbidity
and advanced age to predict worse short term outcomes has been extended
by a number of authors to develop risk stratification strategies to aid in se-
lecting the appropriate level of care. Well validated scores include the Rockall
and Blatchford scores63,64 which allow selection of the lowest risk patients for
early discharge.65–67 Major risk factors predicting death included old age, co-
morbidities, shock at presentation, continued or recurrent bleeding, and onset
of bleeding while hospitalized for other causes. Ulcers with active bleeding or
stigmata of recent bleeding, such as a visible vessel or an adherent clot, also
predict re bleeding and mortality risk.
2.3.3 Recent trends in short term case fatality for variceal haem-
orrhage
The inpatient mortality of variceal haemorrhage remains on average higher
than that of non-variceal bleeding with large studies suggesting a mortality
of 11-40%.68,69 Estimates of short term mortality are generally limited by small
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Table 2.3: 30 day or in hospital mortality for non variceal upper gastrointestinal haemorrhage reported from population based
studies with n>1000.
Year of study Country Size Inpatient or 28 day mortality+
1983-200426 Italy 1126 16-9%
199323 England 4486 14%
1993-20003 Netherlands 1582 14-13%
1993-20034 Canada 95,905 4%*
1996-200061 France 1165 12 - 7%
1996-200733 Israel 12,074 8-7%**
199722 Scotland 1882 7%
1998-200612 USA(NIS) (20% stratified sample) 4-3%
1999-200725 Wales 24,421 10%
2001-200927 USA(Premier Perspective) 30,500 3 -2%
200435 USA (Medicare) 5617 (5% stratified sample) 8%***
200562 France 1665 11%
+A range indicates the change in mortality over the course of the study
*Excluded melaena; gastrointestinal bleeding, unspecified; haemorrhage of oesophagus
**Excluded haematemesis; melaena; non specific GI bleeding
***Excluded melaena; non specific GI bleeding
Blank cells = Information not available in paper
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sample sizes, however studies withmore than 1000 patients show a persistently
higher mortality than for non variceal haemorrhage that is reducing over time
(table 2.4). Most deaths occur within the first 2 weeks.70 Variceal bleeding is
itself recognised as a prognostic indicator of the progression of cirrhosis.71 The
outcomes following variceal bleeding are generally related to the underlying
severity of cirrhosis as demonstrated by the fact that general prognostic scores
for cirrhosis, such as MELD or Child-Pugh, are useful predictors of mortality
and rebleeding following variceal haemorrhage.72–74
Table 2.4: Mortality from variceal haemorrhage from studies n>1000
Year Country Size Mortality + Follow up time
1970-200069 Many* 1475 55-40% Various follow up times
1981-199175 USA (Veteran Affairs) 4975 30 - 21% 30 days
1988-200476 USA (NIS) 18-12% In patient
1996-200061 France 5980 20% - 11% In patient
1998-200568 USA (NIS) 36,734 11% In patient
200477 USA (NIS) 6000 11% In patient
Blank cells = Information not available in paper
+A range indicates the change in mortality over the course of the study
*Control groups in randomised controlled trials
2.4 Risk factors for bleeding
2.4.1 Risk factors for non variceal upper gastrointestinal haem-
orrhage
Risk factors for the population burden of peptic ulcers Peptic ulceration and
erosion is the most frequently identified cause of upper gastrointestinal haem-
orrhage. Its incidence has been variously described as declining over the last
two decades (For example; Sweden 1987 - 2005 (64-35/100,000),78 Spain 1996
- 2005 (55-26/100,000),79 USA 2001-2009 (49-32/100,000)27) or as decreasing
16
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among young people but increasing in the elderly.3,6,7,26,37 Changes in the oc-
currence of peptic ulcer bleeding should reflect trends in underlying risk factors
if the diagnostic pathways remain consistent. For peptic ulceration a study by
Weil et al. identified that NSAIDs and anti platelet medication were associated
with the highest reported attributable fractions.80 HoweverWeil et al. used only
self reported illness, an unmatched analysis for matched data, and incorrectly
interpreted the adjusted fractions as being exclusive of each other and there-
fore summing them to 100%. In another hospital based study comparing cases
with peptic ulcer bleeds to controls attending cardiology and neurology clinics,
Helicobacter pylori was associated with a 5 fold increase in bleeding episodes
independently of aspirin and proton pump inhibitor use.81
Table 2.5: Estimated adjusted attributable fractions for peptic ulcer bleeding
(derived fromWeil et al.)80
Attributable Fraction
Previous Peptic Ulcer 19%
Smoking 2%
Heart failure 5%
Diabetes 4%
Steroids 3%
Anticoagulants 3%
NSAIDs 22%
Aspirin 11%
Helicobacter pylori Helicobacter pylori was historically the most important
cause of peptic ulceration. It is generally acquired during childhood, and preva-
lence is reducing with generations82 and among peptic ulcer bleeding admis-
sions.83,84 However a recent systematic review suggested that Helicobacter py-
lori prevalence in peptic ulcer bleeding is under estimated and that the mean
prevalence remains high at 72% in some study populations.85 The lowest preva-
lence estimates among peptic ulcer bleedswere reported fromUK, Italy, Nether-
lands and Denmark (< 50%), though country was not found to be a significant
predictor of Helicobacter pylori prevalence in multivariate analysis. Helicobac-
17
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ter pylori does not appear to further potentiate the individual risks of medi-
cations such as NSAIDS, rather the increased risk from Helicobacter pylori is
merely additive with that from medications.86
Medications NSAIDs: As stated above NSAIDs and anti platelet agents are
important risk factors for upper gastrointestinal bleeding. NSAID use carries
a relative risk of gastrointestinal bleeding events of 3.8 (3.6 - 4.1)87 which is
removed by cessation, and this translates for non selective NSAIDS users in
clinical trials into an incidence of upper gastrointestinal bleeding of up to 560
per 100,000 person years.88 Selective cyclo-oxygenase-2 inhibitors are associ-
ated with lower risks than non selective NSAIDs89 but although there has been
an increase in their prescription over the last decade, there has been minimal
change in the overall prescription of NSAIDS and it is unlikely the changes
account for any overall trends in bleeding incidence.30,31,90
Aspirin: 1% of patients on low dose aspirin (the most commonly used an-
tiplatelet agent) have a gastrointestinal bleedwithin 28months (number needed
to harm per year = 248).91 With increasing use of these drugs the contribution
of aspirin to bleeding is probably increasing as suggested by the near doubling
of the rate of bleeding admissions over 6 years that were prescribed aspirin or
anticoagulants in the north east of Scotland.30 Prescribing decisions are there-
fore a balance between the risks and benefits of these drugs. For example low
dose aspirin given for low risk primary prevention (1% cardiovascular risk over
5 years) prevents 1-4 myocardial infarctions a year and causes 2-4 gastrointesti-
nal bleeding events with no improvement in mortality.92 For patients with high
cardiovascular risk or for secondary prevention anti platelet and anti coagu-
lants are increasingly given in combinations and this can further increase risk
of a bleed. A recent meta analysis shows low dose aspirin increases the risk of
bleeding from the gastrointestinal tract by 31%, a further 81% when combined
18
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with clopidogrel, and a further 91% when combined with warfarin.93
PPIs: Proton pump inhibitors consistently reduce the risk of bleeding associated
with NSAIDS by 67%94 and their use has a demonstratable cost benefit.95 In pa-
tients on low dose aspirin the risk of bleeding is similarly reduced,93 however
there has been some concern about proton pump inhibitors reducing the effi-
cacy of clopidogrel when co prescribed. A large cohort study reassuringly did
not find an increased cardiovascular risk and estimated that only if the cardio-
vascular risk was increased by more than 19% would the risks of proton pump
inhibitors outweigh their benefits.96 A randomised controlled trial of proton
pump inhibitors for patients on dual anti platelet therapy found a reduction
in upper gastrointestinal bleeding (HR 0.13 (0.03-0.56)) with no difference in
cardiovascular outcomes (HR 0.99 (0.68-1.44)).97
Other medications: Other drug associations with bleeding which have been re-
ported include an up to 3 fold increased risk from SSRIs,98–100 2 fold increased
risk from spironolactone101,102, 2.5 fold increased risk from iron supplementa-
tion103, 2-4 fold increased risk from corticosteriods,104 and 3 fold increased risk
from bisphosphonates.105,106
Co-morbidities It is difficult to ascertain with certainty from current litera-
ture the role of co-morbidities in causing gastrointestinal bleeding independent
of their therapies. It is widely assumed that the high 1-3% incidence of gas-
trointestinal bleeding during the month following an acute coronary syndrome
(ACS)97,107,108 is largely related to therapies. However this is not necessarily the
case and cannot be assessed without an appropriate comparison group. Acute
renal failure also has a high incidence of upper gastrointestinal bleeding 13%109
with a subsequent increase in mortality (adjusted OR 2.6(1.3-5.1)), and follow-
ing surgical procedures at two university hospitals (n=25,845), a high gastroin-
testinal bleeding incidencewas reported at 0.39% of patients, with an associated
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mortality of 31%.110 Most of this bleeding was due to erosive gastritis (70%) or
ulceration (18%) and occurred in the sicker patients with sepsis and or multi
organ dysfunction, as well as in those who were prescribed NSAIDS during the
admission.
Other There are a number of other risk factors for gastrointestinal haemor-
rhage. Higher alcohol intake for example is associated with a higher risk.111 Ex
drinkers however remain at a slightly lower yet still elevated risk (after adjust-
ing for smoking, previous ulcers, aspirin and NSAIDS) suggesting that there
is an underlying confounder associated with alcohol excess.112 Smoking is also
a risk factor,80,113 and its effect may be mediated through altering the ulcer-
ative effects of Helicobacter pylori.114 It is possible likewise that smoking to
some extent mediates a steep socio-economic gradient long shown to exist for
peptic ulcer disease115 and more recently for upper gastrointestinal haemor-
rhage also.22,25 Differences in prescribing practices, alcohol consumption or He-
licobacter pylori prevalence may also contribute to this gradient. Finally high
altitudes are associated with an increased incidence of gastrointestinal haem-
orrhage among migrant workers,116 as well as among acclimatised people.117
This is possibly as part of the syndrome of both acute and chronic altitude sick-
ness,118 though interestingly in the latter bleeding can actually be therapeutic
in avoiding complications of high blood cell counts.
2.4.2 Risk factors for variceal haemorrhage
Oesophageal and gastric varices are a complication of portal hypertension usu-
ally due to cirrhosis. Among cirrhotic patients admitted with upper gastroin-
testinal haemorrhage, 78-87% are due to bleeding varices.70,119 The predictors
of variceal haemorrhage therefore are the causes of cirrhosis and its progres-
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sion, and the subsequent development of portal hypertension. That the in-
cidence of variceal haemorrhage is not increasing despite the increase in cir-
rhosis could therefore be because of improved primary prevention with in-
creased use of banding and beta blockers, or because cirrhosis is being diag-
nosed earlier.12,38Acute precipitants of variceal haemorrhage in patients with
known varices include excess alcohol consumption the week before admission,
constipation and vomiting.120
2.5 Causes of excess death
Causes of death following upper gastrointestinal haemorrhage have changed.
Papers published in the 1930s-1960s suggested that about 50% of patients who
died were dying from exsanguination before treatment or from re-bleeding. In
contrast more recent studies following endoscopic therapy have found only 18
- 30% of deaths were bleeding related.121–124 However these uncontrolled stud-
ies focused on small cohorts of patients who underwent endoscopy to diag-
nose peptic ulcers and therefore might not be representative of all those pre-
senting with upper gastrointestinal haemorrhage. Furthermore comparisons
with matched controls would be necessary to assess whether mortality from co-
morbidities is in excess of that expected in a similar population who have not
experienced bleeding. A recent trial has demonstrated that in the short term pa-
tients with known cardiovascular risk factors benefit from an early reintroduc-
tion of aspirin to reduce their cardiovascular death, and this supports the hy-
pothesis that treating co-morbidity and accepting some rebleeding risk reduces
excess death following a bleed, albeit in a restricted subgroup of patients.125
The only controlled studies of causes of death that have been donewere in small
bleeding peptic ulcer cohorts in the early 1990s, and these found mortality was
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elevated 2 fold for up to 5 years following a bleed, compared to the general
population.9,10,126Much of this long term increase inmortality appeared related
to co-morbidity, particularly cancer and cardiovascular disease10 and up to 50%
was associated with smoking related diseases.9 However both these studies
were small, and the study by Ruigomez et al.10 did not have cause of death
information but imputed the information from co-morbidity recorded prior to
the bleed, and the study by Hudson et al.9 found an expected survival greater
than 100% in controls and therefore used comparisons with national statistics
in their analysis.
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Outline and aims of thesis
3.1 Outline of thesis
This thesis investigates the contemporary trends in the occurrence and mortal-
ity of upper gastrointestinal bleeding (Chapter 5 - 6) and the underlying causes
and consequences that are driving these trends (Chapter 8 - 9). An unselected
study population was necessary to accurately ascertain occurrence and mortal-
ity estimates that are representative of the general population. Therefore the
English Hospital Episodes Statistics dataset was selected as it records all ad-
missions to English NHS hospitals. Its validity for this purpose is assessed and
discussed in chapter 4. For the more detailed studies on the causes of both up-
per gastrointestinal bleeding and its subsequent mortality it was necessary to
have longitudinal data with prospective recording of potential risk factors and
confounders. Therefore routine primary care data linked with both secondary
care and death certificate data were used. The validity of this linked data and a
new method for defining a cohort within it are discussed in chapter 7.
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3.2 Aims of thesis
1. What is the occurrence of upper gastrointestinal haemorrhagewithin Eng-
land by region, year and deprivation?
Chapter 5: Upper gastrointestinal haemorrhage occurrence and deprivation: a
nationwide cohort study of health inequality in hospital admissions
2. Has there been a change in upper gastrointestinal mortality over the last
decade?
Chapter 6: Reductions in 28-Day Mortality Following Hospital Admission for
Upper Gastrointestinal Hemorrhage
3. Do co-morbidities predict the occurrence of upper gastrointestinal haem-
orrhage independently of known risk factors?
Chapter 8: Co-morbidity is an important risk factor for the population burden
of non variceal upper gastrointestinal bleeding: A population based case control
study
4. What are the causes of excess death following an upper gastrointestinal
bleed?
Chapter 9: Excess long term mortality and its causes following non variceal
haemorrhage: A population based cohort study
24
CHAPTER 4
Validity of using HES to measure
upper gastrointestinal bleeding
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CHAPTER 4: VALIDITY OF HES: Introduction
4.1 Introduction
The Hospital Episodes Statistics database (HES) contains information on all
admissions to an NHS hospital in England, with over 12 million new records
added each year and is the largest national admissions database in the world.
It therefore provides an ideal population based dataset to assess occurrence
and outcomes of hospitalised conditions such as acute upper gastrointestinal
haemorrhage. However the dataset is fully anonymised and it is not possi-
ble to work backwards to identify upper gastrointestinal bleed patients from
the HES records for validation against hospital notes. There have been con-
cerns about the accuracy of routine hospital admissions coding, in particular
the coding of specific operations and the ascertainment of death for generat-
ing mortality rates for specific hospitals. However, a systematic review found
a 91% median accuracy in diagnostic coding prior to my study period, and
the most recent audit of selected samples of UK hospital data confirmed ac-
curacy approaching 90%.127 Other comparisons of procedure coding have re-
ported similar or higher rates of coding in the HES database compared to spe-
cialist clinical databases128,129 andwith specific regard to upper gastrointestinal
haemorrhage the incidence of peptic ulcer haemorrhage in the HES data from
1992-1995 has been shown to be comparable to the 1993 regional BSG audit (32
v 29 per 100,000 per year respectively).6 Furthermore within the study period of
this thesis there have been no systematic changes in coding as the ICD-10 cod-
ing system has been in continuous use in HES from 1995 to present. However a
more recent audit of upper gastrointestinal bleeding within England has been
carried out by the NHS Blood and Transplant and British Society of Gastroen-
terology in 2007. This has provided an opportunity for a more contemporary
and more comprehensive external validation of the coding of upper gastroin-
testinal bleeding in HES.
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4.2 Methods
The NHS Blood & Transplant and British Society of Gastroenterology’s 2007 au-
dit of upper gastrointestinal bleeding management was a prospective national
web based audit that occurred between 1st May and 31st June 2007.1 257 par-
ticipating hospitals were requested to identify all inpatient and acute bleeds
admitted to hospital in those 16 years and over during the 2 month period, and
217 hospitals participated. Bleeds were defined in the audit by haematemesis,
melaena or laboratory evidence for acute blood loss from the upper gastroin-
testinal tract. Patients with iron deficiency anaemia were not included unless
there was other evidence for an upper gastrointestinal haemorrhage.
Hospital Episodes Statistics (HES) is managed by the NHS information centre
and is available for research with ethical approval. All NHS hospitals within
England are required to contribute to the database. There are currently 168
acute trusts in England; however each of these trusts can manage more than
one hospital and over time trusts can merge and split. Over the 2 months of
the national audit approximately 150 - 200 providers were contributing to the
database.
The available data consists of a number of records for each admission, which are
called episodes. Each episode represents the time period of the admission that a
patient was under the clinical care of a particular consultant team during their
inpatient stay. A unique patient identifier allows all records for each patient
to be identified and linked together. Each episode’s time span is defined with
a start and finish date as well as being assigned an admission and discharge
date for the whole period of the inpatient stay. Each episode will have up to 14
diagnoses coded using ICD 10 (international classification of diseases, 10th re-
vision); and up to 12 procedures coded using the United Kingdom Tabular List
of the Classification of Surgical Operations and Procedures (version OPCS4).
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This database has been linked to the Office for National Statistics (ONS) death
register since 1998.
Table 4.1: ICD 10 codes used to define upper gastrointestinal bleeding
Variceal bleeding ICD 10 codes
Oesophageal varices with haemorrhage I85.0
Non variceal bleeding ICD 10 codes
Mallory Weiss syndrome K22.6
Oesophageal haemorrhage K22.8
Acute or chronic gastric ulcer with haemorrhage
including perforation with haemorrhage
K25.0, K25.2, K25.4, K25.6
Acute or chronic duodenal ulcer with haemor-
rhage including perforation with haemorrhage
K26.0, K26.2, K26.4, K26.6
Acute or chronic peptic ulcer with haemorrhage
including perforation with haemorrhage
K27.0, K27.2, K27.4, K27.6
Acute or chronic gastro-jejunal ulcer with haem-
orrhage including perforation with haemor-
rhage
K28.0, K28.2, K28.4, K28.6
Haematemesis K92.0
Melaena K92.1
Unspecified gastrointestinal haemorrhage* K92.2
*Admissions were excluded if they were coded with unspecified gas-
trointestinal haemorrhage (K92.2) and had a lower gastrointestinal en-
doscopy/diagnosis code but no upper gastrointestinal endoscopy code.
Initially all valid hospital admissions that were coded for an upper gastroin-
testinal haemorrhage during the audit time period were extracted from HES
along with the linked details of death from the Office for National Statistics
(ONS) national death register. All admissions were selected where the patient
was 15 years or older (chosen to allow the more detailed ONS 5 year age band
denominators to be used whilst being similar to the lower age limit of pre-
vious British Society of Gastroenterology audits of mortality in gastrointesti-
nal haemorrhage,1,23) and had an ICD 10 code that specifically implied either
variceal gastrointestinal haemorrhage or non-variceal haemorrhage (table 4.1).
This ICD 10 code list has previously been used in hospital data.4,25 Episodes
were excluded with: Day case admission codes with no overnight stay (the
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majority of these admissions were for an outpatient endoscopy and would not
have represented an acute presentation of haemorrhage but either a complica-
tion of endoscopy or a follow up endoscopy to a previous bleed), invalid date
codes as flagged by HES, date codes that were out of chronological order, in-
valid date of birth codes, invalid gender codes, or duplicate records for one
episode.
Subsequently, to allow comparisons with the audit, only those admissions in
the time period of the audit that occurred in hospitals contributing to the audit
were selected. The hospitals in which these admissions occurred were selected
initially based on the provider code within HES. Remaining admissions were
assigned to a hospital based on the closest hospital with a gastrointestinal de-
partment to the lower super output area of residence. Geographical details and
provider codes were obtained from NHS connecting for health. Records within
the national audit were also restricted to those that occurred within England
and would therefore be expected to be recorded within HES. Recorded num-
bers of admissions, deaths, and endoscopies were then compared across both
data sources. Short termmortality was defined as a date of deathwithin 28 days
of the start of the recorded episode of upper gastrointestinal haemorrhage. This
included deaths that occurred after discharge from hospital but within the 28
days. The date and fact of death was obtained from the ONS death register
using a deterministic matching algorithm based on NHS number, date of birth,
postcode and sex.130
4.3 Results
Figure 4.1 shows the initial selection of all valid bleed cases from HES. We se-
lected from these cases all that were in the time period of the audit and from
29
CHAPTER 4: VALIDITY OF HES: Results
hospitals contributing to the national audit (figure 4.2). Figure 4.3 shows the
selection of English cases made within the national audit. The national au-
dit identified 77% of the number of upper gastrointestinal bleeds recorded in
England. Endoscopy was recorded in 55.6% of all records in the BSG audit
compared to 46.3% of matched HES data.
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Figure 4.1: Flowchart of exclusions from study population
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Figure 4.2: Flow chart of cases identified in HES 1st May to 31st June 2007
9740 cases in
HES in audit
study period
1245 cases
from hospitals
not in audit
2868 records
matched on
geographi-
cal location
5627 cases
matched
on hospital
provider code
8495 cases
matched to
audit hospitals
in England
5213 acute
admissions
1068 deaths
within 28 days
3982 cases with
endoscopy
performed
(UGIB - upper gastrointestinal bleed)
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Figure 4.3: Flow chart of audit cases.
8939 cases
in audit
1455 cases
from hospitals
outside England
7484 cases
initially pre-
sented as UGIB
in England
5582 cases
confirmed
UGIB with
complete records
2099 incomplete
records or later
confirmed
non UGIB
5385 acute
admissions
463 deaths
within 28 days
4164 cases with
endoscopy
performed
(UGIB - upper gastrointestinal bleed)
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More deaths within 28 days and prior to discharge were identified using the
ONS linked HES dataset than in the national audit (p=0.007, chi2=7.2, d.f.=1)
(see table 4.2).
Similar numbers of procedures where recorded in the two datasets over the
audit period, however interventions such as blood transfusions were poorly
recorded in HES compared to the national audit (see table 4.3).
Table 4.2: Number of deaths recorded prior to discharge following upper
gastrointestinal bleed admissions
Dataset Number of deaths from Case fatality% (95% confidence intervals)
participating hospitals
BSG (complete records only) 463 8.3 (7.6 - 9.0)
HES (prior to discharge) 911 10.6 (10.0 - 11.4)
Table 4.3: Interventions recorded with upper gastrointestinal bleed admis-
sions
Number
in national
audit
Percentage
of all audit
records
Percentage
in complete
records only
Number in
HES dataset
Percentage
of HES
dataset
Upper GI Endoscopy 4164 55.64 74.60 3982 46.33
Therapeutic upper GI
Endoscopy
979 13.08 17.54 828 9.63
Upper GI operations 108 1.44 1.93 199 2.32
Blood transfusions 2367 31.63 42.40 351 4.08
4.4 Conclusions
During the recent national audit of upper gastrointestinal bleeding, HES recorded
reassuringly similar numbers for upper gastrointestinal bleed hospital admis-
sions and procedures. It was not possible to measure sensitivity and speci-
ficity as individual records can not be compared across the datasets due to the
anonymisation, however the similar numbers of bleeds in HES and audit in-
dicate that coding in HES had a reasonable sensitivity in recording the inci-
dence of upper gastrointestinal haemorrhage. Furthermore the similar propor-
tions of endoscopy performed in each dataset suggest that HES had not incor-
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rectly coded large numbers of admissions as upper gastrointestinal bleeding,
and therefore that HES has a reasonable specificity and accuracy in its coding
of bleed admissions. The value of HES data is its complete national coverage,
linkage to small area statistics, lack of selection bias, and accurate recording
of hospitalisation rates. It is therefore a suitable comprehensive data source for
measuring the incidence of upper gastrointestinal bleeding within England and
its variation therein. With its linkage to the Office for National Statistics death
register it is also able to capture all deaths within this population, and is there-
fore a suitable data source for an unbiased measurement of mortality following
a bleed.
However the strength of the audit in providing data to permit detailed analy-
sis of the predictors of bleeding and mortality, procedures, medications, blood
transfusions, and the calculation of risk scores cannot be reproduced in the HES
data. On its own HES can not therefore be used to answer all the questions
in this PhD that require details of risk factors for death and bleeding such as
medications and co-morbidities. The comprehensive nature of the UK primary
care service does provide this information at a population level, and within a
smaller sample of the English population routine electronic primary care data
has been linked to secondary care data. Chapter 7 examines the suitability of
this smaller dataset for the later more detailed studies in this PhD on upper
gastrointestinal bleeding. First, however, the following two chapters use the
HES data validated in this chapter to detail the current incidence and mortality
trends of upper gastrointestinal bleeding.
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CHAPTER 5: UPPER GASTROINTESTINAL BLEEDING OCCURRENCE:
Introduction
5.1 Introduction
The current patterns of occurrence of upper gastrointestinal bleeding over time
and across different geographical regions are important in understanding its
burden and to suggest potential modifiable risk factors. One study from Wales
reported that there had been no change in incidence between 1999 and 2007,
however it only assessed the combined variceal and non variceal incidence
and compared only two time points without assessing the data inbetween.25
Other national studies in the UK have only reported on gastro-duodenal ulcers
from England, Wales and Scotland.6,7 These demonstrated stable hospitalisa-
tion rates through the 1990s in England and Wales, but found an increase in
the elderly of over 30%. This is contrary to global reports of peptic ulcera-
tion declining as a result of falling Helicobacter pylori and peptic ulcer preva-
lence.5,12,90
Large differences in incidence also exist between regional studies within the
UK, as discussed in section 2.2.1, and these are often thought to be due to de-
privation. Identifying whether such a strong socioeconomic gradient exists is
important as it points towards identifiable and modifiable risk factors; for ex-
ample Helicobacter pylori can be eradicated, the consumption of alcohol re-
duced, and the prescribing of NSAIDs curtailed.
It would be expected that within England variceal bleeding might be increasing
as a consequence of the rise in the prevalence of cirrhosis,39 but whether this
has occurred is not known. Reports from the USA National Inpatient Sample
show an 11% increase in variceal admission rates comparing 1998 to 2006, but
a conflicting 9% decrease comparing 2001 to 2009.12,27 The studies did however
use different code lists, and the sampling frame used more than doubled in size
over the study periods. Other trend studies of upper gastrointestinal bleed-
ing admissions only reported proportions of variceal bleeding and were small
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(n<200 for each year).3,61
I therefore aimed to accurately estimate the hospitalisation rates for upper gas-
trointestinal haemorrhage and its relation to time, region and socioeconomic
status, whilst adjusting for differences in age and sex. To achieve this I used 7
years of all hospital admissions from the whole population of England.
5.2 Methods
5.2.1 Study population
A retrospective cohort studywas designed for thewhole English population us-
ing the Hospitals Episodes Statistics database (HES) to identify upper gastroin-
testinal bleeds between 1st January 1999 and 31st December 2007. Mid-year
estimates of the English population 15 years and older were available between
1999 and 2007 by region, 5 year age band, and sex, from the Office for National
Statistics (ONS) website under crown copyright. However mid year estimates
by small area statistics for socioeconomic status were only available between
2001 and 2007 and for broader age bands from 16 years. Small areas are defined
by lower super output areas and include around 400 homes. These are defined
to cover a consistent geographical area over the time of this study.
5.2.2 Admissions for gastrointestinal haemorrhage
Inclusion criteria
All admissions in patients 16 years or older, with a primary diagnosis of up-
per gastrointestinal haemorrhage in the admission episode between 1st January
1999 (2001 for the analysis by socioeconomic status) and 31st December 2007,
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were selected. Upper gastrointestinal haemorrhage was defined as an ICD 10
code using the same code list as table 4.1.
Exclusion criteria
Admissions were excluded for the same reasons as in chapter 4: Day case ad-
mission codes with no overnight stay (the majority of these admissions were
for an outpatient endoscopy and would not have represented an acute presen-
tation of haemorrhage but either a complication of endoscopy or a follow up en-
doscopy to a previous bleed), invalid date codes as flagged by HES, date codes
that were out of chronological order, invalid date of birth codes, invalid gender
codes, or duplicate records for one episode. Additionally inpatient bleeds with
a bleeding code later than the initial admission date were also excluded to select
admissions with a higher probability of being an acute bleed on admission.
5.2.3 Exposures
The main exposures of interest were year of bleed and the socioeconomic sta-
tus of the lower super output area of the residence of the patient. Lower super
output areas are small geographical areas defined by the Office for National
Statistics to include about 400 houses with consistent boundaries over time.
Lower super output areas from the whole country were grouped into quintiles,
from the least deprived to the most deprived, by their ranking in the Indices of
Multiple Deprivation for England (2007).131 The English indices of multiple de-
privation are derived from 38 indicators grouped into 7 empirically weighted
domains that are used to rank lower super output areas from the least to most
deprived. The 7 domains, their weights, and some of their indicators are listed
and discussed in detail in “The English Indices of Deprivation 2007”.131 Anal-
ysis by deprivation was limited to the years 2001-2007 as population data by
39
CHAPTER 5: UPPER GASTROINTESTINAL BLEEDING OCCURRENCE: Methods
lower super output area was only available for this time period.
Other exposures of age, sex, and regionwere extracted as potential confounders.
Region was defined by the regional government office of the home residence
at time of admission. The recorded age was grouped into age bands of 15-29
years, 30-59 years, 60-79 years, and older than 80 years. For analyses including
deprivation, the age bands chosen for men were 16-29, 30-44, 45-64, and >65,
and for women were 16-29, 30-44, 45-59, and >60. These age bands were chosen
as those available in the respective ONS denominator data and reflected UK
retirement ages at the time.
Associated diagnoses coded during an upper gastrointestinal bleeding admis-
sion were also extracted based on ICD 10 codes for Mallory Weiss tear (K22.6),
gastritis or duodenitis (K29._), oesophagitis (K20._), peptic ulcer (K25._, K26._,
K27._, K28._), or malignancy (C15-7._). Mortality was defined as in the previ-
ous study.
5.2.4 Statistical analysis
I analysed variceal and non-variceal haemorrhage admissions separately. After
the exclusions described above, hospitalisation rates were calculated by quin-
tiles of socioeconomic status, age group, sex, region, and year. Poisson regres-
sion was used to adjust the hospitalisation rates by year or by socioeconomic
status for each of these potential confounders. Variables that changed the in-
cidence rate ratios were judged to be confounders and remained in the model.
I examined whether the effect of socioeconomic status changed by year by in-
cluding interaction terms between socioeconomic status and year. Logistic re-
gression was used to adjust odds ratios for 28 day mortality in each deprivation
quintile for age, sex and year of admission. All analyses were performed using
Stata version 11 (Stata Corp).
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5.2.5 Subgroup and Sensitivity Analyses
I repeated analyses of the socioeconomic gradient by aetiological subgroups of
non variceal upper gastrointestinal haemorrhage (gastritis/duodenitis, Mallory
Weiss syndrome, oesophagitis, gastric ulcer, duodenal ulcer andmalignancy) to
determine whether relationships seen were specific to one or more of them. I
then performed four more sensitivity analyses. Firstly to assess the possibil-
ity of under reporting I expanded the definition for variceal haemorrhage to
include all admissions coded for oesophageal haemorrhage (K22.8). Secondly
to assess the effect of possible over reporting I restricted the definition of non
variceal haemorrhage to admissions with either an associated coded interven-
tion or outcome which I defined as an endoscopy, blood transfusion or death
within 14 days of the recorded bleed date. I then re-assessed whether any gra-
dients differed when the analysis was restricted to either the first admission
or a subsequent readmission for each patient. Finally I examined whether re-
stricting the analysis to patients with no previous recording of alcohol related
diseases altered any gradients I found.
5.3 Results
5.3.1 Study population
516,153 upper gastrointestinal bleed admissions were identified between 1999
& 2007 (see figure 4.1), of which 313,111 were coded as the primary diagnosis
in the first episode of an admission and were therefore used for the analysis of
incidence over time. Restricting to 2001-2007 and to people 16 years and older
for the analysis by deprivation (when linked socioeconomic data was available
for the denominator) reduced the number of bleeds to 245,438 (see figure 5.1).
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Figure 5.1: Flowchart of exclusions from study population for study of asso-
ciations with deprivation
237,145 (97%) bleed admissions were coded as non variceal haemorrhage and
8,293 (3%) as variceal haemorrhage.
5.3.2 Crude incidence rates
Incidence by year
The average annual hospitalisation rate from 1999 to 2007 for non-variceal haem-
orrhage was 85.3/100,000 (95% confidence interval 85.0 - 85.6/100,000). The
hospitalisation rate for non variceal bleeding was 82.4/100,000 (95% confidence
interval 82.1 - 82.7/ 100,000) and for variceal bleeding was 2.94/100,000 (95%
confidence interval 2.89 - 3.00). The crude hospitalisation rate of non variceal
bleeding was higher with older age, in the north and inmales, but it varied only
slightly by year, peaking in 2005 (table 5.1). Although the hospitalisation rates
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for variceal bleeding had greater uncertainty due to smaller numbers, there was
a similar lack of a trend by year (table 5.2). For variceal bleeding the relative
hospitalisation rates peaked between 60 and 79 years old and then decreased in
the older age group.
Incidence by deprivation
Between 2001 and 2007 the crude socioeconomic gradient between the most
and least deprived quintiles was greater for variceal haemorrhage than non
variceal haemorrhage (Rate Ratio (RR) for non variceal haemorrhage 2.00, 95%
confidence interval 1.98 - 2.03; RR for variceal haemorrhage 2.49, 95% confi-
dence interval 2.32 - 2.67). The regional hospitalisation rates for variceal and
non variceal haemorrhage are shown in figure 5.2, with higher rates of hos-
pitalisation in the north of the country. The increase in hospitalisation with
deprivation was observed in all regions, and was of far greater magnitude than
any regional differences for both variceal and non variceal bleeds (see figure
5.3, only non variceal bleeds shown). The gradient was also present in all age
strata (figure 5.4, only non variceal bleeds shown). During the study period
there was only a slight year on year change in hospitalisation rates. Cross tab-
ulations of crude rates for each IMD quintile by age group, gender, procedures,
and associated diagnoses are shown in table 5.3.
5.3.3 Multivariate analysis
Incidence by year
After adjusting for changes in age and sex there was no evidence for an asso-
ciation between variceal bleeding and year (test for association p=0.09, test for
trend p=0.11). Region did not alter the interpretation of a trend over time for
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Table 5.1: Hospitalisations and number of non variceal bleed admissions by
year, gender and age
Variable Number of up-
per non variceal
gastrointestinal
haemorrhage
admissions
Hospitalisations
per 100,000 per
year
IRR Adjusted
IRR*
95% confidence
interval
Year
1999 32025 80.83 1.00 1.00
2000 32561 81.65 1.01 1.00 ( 0.99 1.02 )
2001 32165 80.08 0.99 0.98 ( 0.96 0.99 )
2002 32348 80.01 0.99 0.97 ( 0.96 0.99 )
2003 33712 82.81 1.02 1.00 ( 0.99 1.02 )
2004 34548 84.25 1.04 1.02 ( 1.00 1.03 )
2005 35422 85.53 1.06 1.03 ( 1.01 1.05 )
2006 35076 83.99 1.04 1.01 ( 0.99 1.02 )
2007 34635 82.25 1.02 0.98 ( 0.97 1.00 )
Gender
Male 169504 95.29 1.00 1.00
Female 132988 70.28 0.74 0.62 ( 0.62 0.63 )
Age
<30 29202 33.79 1.00 1.00
30 to 59 90785 48.69 1.44 1.45 ( 1.43 1.47 )
60 to 79 99405 132.72 3.93 4.00 ( 3.95 4.05 )
≥80 83100 429.71 12.72 13.80 ( 13.61 13.98 )
Region
London 34511 63.74 1.00
North East 21385 113.54 1.78 ( 1.75 1.81 )
North West 48528 97.40 1.53 ( 1.51 1.55 )
Yorkshire and
Humber
32427 87.61 1.37 ( 1.35 1.40 )
East Midlands 27264 86.87 1.36 ( 1.34 1.38 )
West Midlands 33292 85.86 1.35 ( 1.33 1.37 )
East of England 27290 67.84 1.06 ( 1.05 1.08 )
South East 44454 74.64 1.17 ( 1.15 1.19 )
South West 33341 89.32 1.40 ( 1.38 1.42 )
IRR = Incidence Rate Ratio
*Poisson model with age, sex and year
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Table 5.2: Hospitalisations and number of variceal bleed admissions by
year, gender and age
Variable Number of upper
variceal gastroin-
testinal haemor-
rhage admissions
Hospitalisations
per 100,000 per
year
IRR Adjusted
IRR*
95% confidence
interval
Year
1999 1131 2.85 1.00 1.00
2000 1163 2.92 1.02 1.02 ( 0.94 1.11 )
2001 1099 2.74 0.92 0.95 ( 0.88 1.03 )
2002 1139 2.82 0.95 0.98 ( 0.90 1.06 )
2003 1177 2.89 0.98 1.00 ( 0.93 1.09 )
2004 1274 3.11 1.05 1.08 ( 1.00 1.17 )
2005 1160 2.80 1.03 0.98 ( 0.91 1.07 )
2006 1254 3.00 1.01 1.05 ( 0.97 1.14 )
2007 1222 2.90 0.98 1.02 ( 0.94 1.10 )
Gender
Male 6991 3.93 1.00 1.00
Female 3628 1.92 0.50 0.48 ( 0.46 0.50 )
Age
<30 269 0.31 1.00 1.00
30 to 59 6418 3.44 10.27 10.64 ( 9.42 12.02 )
60 to 79 3328 4.44 13.26 14.02 ( 12.38 15.87 )
≥80 604 3.12 9.32 10.88 ( 9.42 12.56 )
Region
London 1703 3.15 1.00
North East 657 3.49 1.11 ( 1.01 1.21 )
North West 1773 3.56 1.13 ( 1.06 1.21 )
Yorkshire and
Humber
963 2.60 0.83 ( 0.76 0.90 )
East Midlands 856 2.73 0.87 ( 0.80 0.94 )
West Midlands 1328 3.42 1.09 ( 1.01 1.17 )
East of England 787 1.96 0.62 ( 0.57 0.68 )
South East 1639 2.75 0.87 ( 0.82 0.94 )
South West 913 2.45 0.78 ( 0.72 0.84 )
IRR = Incidence Rate Ratio
*Poisson model with age, sex and year
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Table 5.3: Crude Hospitalisation Rates per 100,000 population (95% confi-
dence intervals)
Quintiles of
Deprivation
(IMD 2007)
1 = Least
deprived
2 3 4 5 = Most
deprived
Total
(million
person
years)
Age (years)
<30 5.13 6.48 8.64 13.16 22.99 63
(4.94,5.32) (6.27,6.69) (8.41,8.89) (12.86,13.46) (22.59,23.40)
30 to 44 8.13 10.33 14.29 21.64 38.56 79
(7.90,8.37) (10.07,10.60) (13.98,14.60) (21.25,22.02) (38.04,39.09)
45-64* 17.59 20.93 24.15 31.65 45.82 76
(17.25,17.94) (20.55,21.30) (23.75,24.55) (31.19,32.12) (45.25,46.39)
>=65* 73.50 86.01 88.91 90.72 93.16 65
(72.80,74.21) (85.26,86.77) (88.14,89.68) (89.93,91.51) (92.35,93.98)
Gender
Male 55.55 66.05 73.55 87.27 117.72 140
(54.94,56.16) (65.38,66.71) (72.85,74.25) (86.50,88.04) (116.81,118.64)
Female 48.81 57.70 62.44 69.90 82.82 150
(48.24,49.38) (57.09,58.33) (61.80,63.09) (69.21,70.59) (82.05,83.59)
Procedures
Upper GI
endoscopy
51.15 60.42 65.86 74.67 91.45
(50.57,51.74) (59.78,61.05) (65.20,66.53) (73.96,75.39) (90.65,92.26)
Therapeutic
endoscopy
8.35 9.76 10.48 11.57 13.79
(8.12,8.59) (9.51,10.02) (10.22,10.75) (11.29,11.85) (13.48,14.11)
Upper GI
surgery
2.90 3.32 3.56 4.14 4.78
(2.76,3.04) (3.18,3.48) (3.41,3.72) (3.97,4.31) (4.60,4.97)
Diagnoses
Gastric
Ulcer
10.07 11.95 12.52 14.17 16.82
(9.81,10.33) (11.67,12.24) (12.23,12.81) (13.86,14.48) (16.48,17.17)
Duodenal
Ulcer
13.16 15.38 16.57 17.85 20.90
(12.86,13.46) (15.06,15.71) (16.24,16.90) (17.50,18.20) (20.52,21.29)
Mallory
Weiss
5.29 6.44 7.32 9.45 13.47
(5.10,5.48) (6.24,6.65) (7.10,7.54) (9.20,9.71) (13.16,13.78)
Gastritis/
Duodenititis
12.50 15.20 16.82 19.58 24.56
(12.21,12.79) (14.89,15.53) (16.48,17.16) (19.22,19.95) (24.15,24.98)
Oesophagitis
13.63 15.84 17.41 19.53 23.06
(13.33,13.93) (15.52,16.17) (17.07,17.76) (19.17,19.90) (22.66,23.47)
Varices
2.87 3.48 3.99 4.92 7.28
(2.74,3.02) (3.33,3.64) (3.83,4.16) (4.74,5.11) (7.05,7.51)
Malignancy
3.00 3.45 3.60 3.54 3.71
(2.86,3.15) (3.30,3.61) (3.45,3.76) (3.39,3.70) (3.55,3.88)
Population
at risk over
whole study
period (mil-
lions)
57 58 58 56 54
46
CHAPTER 5: UPPER GASTROINTESTINAL BLEEDING OCCURRENCE: Results
Figure 5.2: Hospitalisation rates of upper gastrointestinal haemorrhage by
Regional Government Office
(a) Non variceal haemorrhage (b) Variceal haemorrhage.
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Figure 5.3: Average annual non variceal hospitalisation rate by quintiles of Index of Multiple Deprivation 2007 for each
Government Office
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Figure 5.4: Average annual non variceal hospitalisation rate by quintiles of Index of Multiple Deprivation 2007 for each age
band
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either variceal or non variceal bleeding so it was not included as a confounder
in the regression models. A sensitivity analysis for variceal bleeding using a
broader definition that included the code for oesophageal bleeding did not al-
ter the finding of no trend in hospitalisation by year (age and sex adjusted test
for trend p=0.507). A second sensitivity analysis restricting the definition of
variceal bleeding to admissions with an intervention (such as endoscopy) or
outcome (such as death) also did not demonstrate an association (p=0.225). In
contrast for non variceal bleeding although there was weak evidence for a mini-
mal year on year increase in hospitalisation (IRR 1.001, 95% confidence interval
1.000 - 1.003, test for trend p=0.0463) a sensitivity analysis restricted to admis-
sions with intervention or death actually demonstrated a fall in hospitalisation
(IRR 0.969, 95% confidence interval 0.967 - 0.971, test for trend p<0.0001).
Incidence by deprivation
Incidence rate ratios of hospitalisation by socioeconomic status were adjusted
for age and sex using Poisson regression, and this further increased the differ-
ence between the least and most deprived quintiles for non variceal (RR 2.22,
95% confidence interval 2.20-2.25) and variceal haemorrhage RR 2.93, 95% con-
fidence interval 2.73-3.14). The inclusion of region or year in the model did not
alter the estimates. However, a likelihood ratio test for an interaction between
year and socioeconomic status demonstrated that there was strong evidence for
an increase in inequality over the study period (non variceal p<0.0001, variceal
p=0.0068. See figure 5.5, only non variceal haemorrhage shown).
There was no significant association between socioeconomic status and ad-
justed 28 day mortality for non variceal haemorrhage (p=0.07, likelihood ratio
test for association), and although for variceal haemorrhage 28 daymortality in-
creased for some quintiles (p=0.004, likelihood ratio test for association), there
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Figure 5.5: Age and sex adjusted hospitalisation rate ratios for non variceal
haemorrhage by year for each quintile of deprivation compared
to the least deprived quintile.
was no clear pattern or trend observed with increasing deprivation (table 5.4).
Sub group analysis
The hospitalisation gradient by deprivation was found in all sub groups of di-
agnoses associated with non variceal haemorrhage admissions (table 5.5), and
consistent with the main analysis the 28 day case fatality was not significantly
associated with deprivation in any sub group (table 5.6).
Sensitivity analysis
The first sensitivity analysis for the socioeconomic gradient expanded the defi-
nition of variceal haemorrhage and this reduced the magnitude of the associa-
tion slightly, but the comparison of most to least deprived quintiles still showed
a significant difference RR 2.60, 95% confidence interval 2.44 - 2.76). The sec-
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Table 5.4: Crude and adjusted odds ratios for 28 day mortality in each depri-
vation quintile.
IMD 2007 Quintile Number of 28
day deaths
Crude OR Adjusted OR* 95%
Confidence
Interval
Non variceal haemorrhage
1=Least Deprived 3947 1 1
2 4819 1.02 1.04 (0.99 1.08)
3 5083 0.97 1.06 (1.01 1.11)
4 5209 0.86 1.06 (1.02 1.11)
5=Most Deprived 5348 0.69 1.04 (0.99 1.08)
Variceal haemorrhage
1=Least Deprived 195 1 1
2 255 1.13 1.14 (0.92 1.40)
3 268 0.96 1 (0.81 1.22)
4 396 1.26 1.33 (1.10 1.61)
5=Most Deprived 503 1.12 1.23 (1.03 1.49)
*Adjusted by logistic regression for age and sex
Table 5.5: Age and gender adjusted rate ratios for upper gastrointestinal
haemorrhage admission by associated diagnoses.
Age and gender adjusted IRR (95% confidence intervals)
IMD 2007 Quintiles 1 = Least deprived 2 3 4 5 = Most deprived
Gastritis/Duodenitis 1 1.21 1.39 1.71 2.22
(1.16,1.26) (1.33,1.44) (1.64,1.78) (2.14,2.31)
Mallory Weiss Syndrome 1 1.22 1.39 1.79 2.61
(1.15,1.29) (1.31,1.46) (1.70,1.89) (2.48,2.74)
Oesophagitis 1 1.16 1.33 1.57 2
(1.11,1.21) (1.28,1.39) (1.51,1.63) (1.92,2.08)
Gastric Ulcer 1 1.16 1.26 1.54 1.9
(1.11,1.21) (1.20,1.31) (1.48,1.61) (1.83,1.98)
Duodenal Ulcer 1 1.16 1.3 1.52 1.89
(1.12,1.21) (1.25,1.35) (1.46,1.57) (1.82,1.96)
Malignancy 1 1.16 1.22 1.31 1.49
(1.04,1.29) (1.09,1.35) (1.17,1.46) (1.34,1.66)
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Table 5.6: Age and gender adjusted odds ratios for 28 day mortality in each
deprivation quintile by associated diagnoses.
Age and gender adjusted OR for case fatality (95% confidence intervals)
IMD 2007 Quintiles 1 = Least deprived 2 3 4 5 = Most deprived
Gastritis/Duodenitis 1 1.09 1.09 1.14 1.07
(0.90,1.31) (0.90,1.32) (0.94,1.37) (0.88,1.29)
Mallory Weiss Syndrome 1 0.87 1.18 1.10 1.15
(0.58,1.31) (0.81,1.73) (0.75,1.61) (0.79,1.68)
Oesophagitis 1 0.88 1.01 1.09 1.08
(0.74,1.04) (0.86,1.19) (0.93,1.28) (0.92,1.27)
Gastric Ulcer 1 1.01 1.04 1.05 1.22
(0.87,1.17) (0.90,1.20) (0.91,1.21) (1.06,1.40)
Duodenal Ulcer 1 1.11 1.10 1.17 1.19
(1.00,1.25) (0.99,1.23) (1.04,1.30) (1.06,1.33)
Malignancy 1 1.13 0.98 1.06 1.21
(0.90,1.41) (0.78,1.23) (0.84,1.33) (0.96,1.52)
ond sensitivity analysis restricted the definition of non variceal haemorrhage to
admissions coded with an intervention or death, and following this the socioe-
conomic gradient was still apparent RR 1.92 (95% confidence interval 1.89-1.95,
adjusted for age and sex).
The third sensitivity analysis was stratified by initial admission and subsequent
readmission. Restricting to the first admission for each patient did not substan-
tially alter the gradients by deprivation (tables 5.7 & 5.8). However there was
a steeper gradient by deprivation for readmissions for both non variceal haem-
orrhage (adjusted rate ratio comparing most to least deprived 3.25 (3.15-3.36))
and variceal haemorrhage (adjusted rate ratio comparingmost to least deprived
2.69 (2.45-2.94)). Finally, excluding patients with a previous admission related
to alcohol did not alter any of the overall deprivation gradients.
Regression diagnostics
The deviance statistic and Pearson statistic were calculated for the Poissonmod-
els and neither were significant (p=1.0 for both deprivation and time trend
models) consequently there was no evidence to reject the use of the Poisson
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Table 5.7: Hospitalisation by deprivation quintile for first and subsequent
non variceal upper gastrointestinal haemorrhage admission
IMD 2007 Quintiles Crude hospitalisation rates * Adjusted rate ratios** 95% confidence
intervals
First Admission
1 = Least Deprived 50.96 1
2 60.18 1.17 ( 1.15,1.18 )
3 65.18 1.29 ( 1.27,1.31 )
4 74.64 1.56 ( 1.54,1.59 )
5 = Most Deprived 93.99 2.05 ( 2.02,2.08 )
Readmission
1 = Least Deprived 8.89 1
2 11.25 1.26 ( 1.22,1.31 )
3 13.35 1.54 ( 1.48,1.59 )
4 16.83 2.04 ( 1.97,2.11 )
5 = Most Deprived 25.90 3.25 ( 3.15,3.36 )
*per 100,000 population
**adjusted for age and gender
model for this data.
5.4 Discussion
There was no strong evidence for large changes in the occurrence of variceal or
non variceal bleeding over the time period of the study. There was strong evi-
dence for large regional variations in the occurrence of bleeding, but these were
dwarfed by the variation in occurrence by socioeconomic status. Those who
live in the most disadvantaged areas of England have a 2 to 3 times higher rate
of hospitalisation for upper gastrointestinal haemorrhage compared to people
living in the most affluent areas. It is improbable that living in a particular res-
idential area itself causes upper gastrointestinal haemorrhage, but rather that
more deprived people have risk factors that more affluent people have been
able to avoid. According to my findings if the whole population experienced
the same levels of risk as the most affluent, up to 10,000 admissions costing
a total of at least £20 million ($34 million),42 and over 1000 deaths could be
prevented each year in England. As the causes of many upper gastrointestinal
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Table 5.8: Hospitalisation by deprivation quintile for first and subsequent
variceal upper gastrointestinal haemorrhage admission
IMD 2007 Quintiles Crude hospitalisation rates * Adjusted rate ratios** 95% confidence
intervals
First Admission
1 = Least Deprived 1.21 1
2 1.45 1.21 ( 1.10,1.34 )
3 1.68 1.47 ( 1.33,1.62 )
4 1.98 1.85 ( 1.68,2.03 )
5 = Most Deprived 2.74 2.69 ( 2.45,2.94 )
Readmission
1 = Least Deprived 0.68 1
2 0.78 1.16 ( 1.01,1.33 )
3 0.98 1.52 ( 1.34,1.73 )
4 1.28 2.09 ( 1.85,2.36 )
5 = Most Deprived 1.98 3.35 ( 2.98,3.76 )
*per 100,000 population
**adjusted for age and gender
haemorrhages are known and are modifiable, the prevention of these admis-
sions and deaths is potentially achievable.
My study provides a complete national picture for England of the increased
risk of upper gastrointestinal haemorrhage hospitalisation associated with ar-
eas of higher deprivation. It therefore provides the first demonstration that this
steep gradient is present in all regions of the country and is independent of age
and sex. My large study population allows us for the first time to demonstrate
socioeconomic associations with both variceal and non variceal haemorrhage,
and by including all hospital admissions for upper gastrointestinal bleeding in
England I have minimised the effect of selection bias and have adequately ad-
justed for the effects of demographic differences across England. There are of
course weaknesses in the methodology of using small area statistics. Firstly
by assessing deprivation at lower super output area level I may incorrectly as-
sign an area’s average risk of deprivation to individuals with very different
personal economic circumstances. This may explain the lesser association with
deprivation observed in London, where the close proximity of rich and poor
households might have increased the possibility of this type of misclassifica-
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tion. However, although the effects of this ecological bias could have been
in either direction and were unknown, I believe that the misclassification was
most likely to be non-differential and the effect would therefore be to reduce
observed associations. The other possible error from using small area statis-
tics was some residual confounding by age due to the use of broad age cate-
gories chosen to match those in ONS denominator data. However this residual
confounding is unlikely to explain the association I observed, since the age ad-
justment that was possible increased the strength of the association rather than
reduced it. Apart from small area statistics the other potential weakness in my
study is the accuracy of routine hospital admissions coding. However it seems
unlikely that coding inaccuracies would have been associated with the socioe-
conomic status of a patient, so any coding errors would have reduced rather
than caused the magnitude of the association I observed. Furthermore this er-
ror is likely to be small as the most recent audit of UK hospital data shows ac-
curacy approaching 90%,127 and the incidence of peptic ulcer haemorrhage in
HES data from 1992-1995 has been shown to be comparable to the 1993 regional
BSG audit (32 v 29 per 100,000 per year respectively).6
One specific concern about the coding in my study is the possibility of under-
reporting of variceal haemorrhage which I found to be less frequently reported
than in the recent BSG audit.1 However my finding was similar to that of the
1993 BSG audit (4%) and other studies,3,23 and the socioeconomic gradient was
robust against a sensitivity analysis that broadened the definition of variceal
bleeding. Another concern about coding is that over reporting of cases that
were not real bleeds may have occurred. However restricting cases to only
those with a recorded intervention (such as endoscopy) or outcome (such as
death) did not substantially alter the association with socioeconomic status.
Previous studies support the validity of my findings; Button et al. in a recent
study fromWales used routine data to demonstrate a crude two fold difference
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in upper gastrointestinal bleed hospitalisation between the least and most de-
prived.25 However their study was ten times smaller than ours and did not
investigate if this inequality was confounded by type of bleed, region, age, gen-
der or year. Blatchford et al, in a regional study of 1,882 patients in the north
west of Scotland 15 years ago, found no association of case fatality with socioe-
conomic status measured by Carstairs score, but observed a two fold increase
in the unadjusted incidence of upper gastrointestinal haemorrhage between the
least andmost affluent quartiles.22 I have expanded on these studies and used a
more comprehensive measure of deprivation than the latter to demonstrate that
this gradient is present in all regions of the country, for all ages, both men and
women, and is steeper for variceal than non variceal haemorrhage. My study
also found a North to South gradient in crude hospitalisation that was mostly
explained by deprivation, and this is similar to the report of Woods et al. who
identified a North to South gradient in all cause mortality that was also mostly
attributable to deprivation.132
Deprivation influenced mortality in my study far less than it influenced hos-
pitalisations. This reassuringly suggests that admissions from deprived areas
are receiving comparable hospital care to those from less deprived areas, how-
ever it also implies that the focus for reducing inequality in upper gastroin-
testinal bleeding should be to prevent and treat its causes rather than further
modify acute services. This is potentially achievable as many risk factors are
already known and modifiable. For example Helicobacter pylori, which is sim-
ple to eradicate, is known to have a higher prevalence in deprived areas from
crowded childhood living conditions.133Other lifestyle risk factors for causes of
bleeding such as smoking, larger waist circumferences, and alcohol related dis-
eases, are also more common in populations with higher levels of deprivation
and could be modifiable through effective public health interventions.134–136
However, the sub group analysis excluded previous alcohol related admissions
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and this did not reduce any of the inequality in bleeding occurrence. Another
potential cause of the inequality observed is that harmful prescribing practices
have been shown to be increased for people with lower socioeconomic sta-
tus;137 lower skilled occupations had a higher chronic NSAID use (OR 1.4) than
skilled workers despite a higher prevalence of dyspepsia.138 This latter study
included NSAIDs purchased without a prescription (i.e ’over the counter’), so
as omeprazole is also obtainable in the UK without prescription, proton pump
inhibitor use could be encouraged with NSAIDS in deprived areas.
In conclusion, I have demonstrated that people from areas of greater depriva-
tion have higher rates of hospitalisation for upper gastrointestinal haemorrhage
than are explained by random error or measured confounding. There are there-
fore opportunities to identify modifiable risk factors, and therefore interven-
tions, to prevent disease in more deprived areas and to reduce the 10,000 excess
admissions and 1000 excess deaths associated with deprivation, and thus make
the most of currently scarce economic resources.
Additionally I have not demonstrated the decrease in the occurrence of non
variceal haemorrhage that might have been expected following reported de-
creases in peptic ulcers world wide.139 My findings show that the persisting
incidence observed by Higham et al of peptic ulcer admissions in the 1990s has
continued for upper gastrointestinal haemorrhage admissions in the 2000s.6
Both findings in this study raise questions about which risk factors are respon-
sible for the burden of upper gastrointestinal bleeding in the general popula-
tion, and therefore are responsible for its persisting incidence over time and the
higher incidence observed with deprivation. One potential explanation is that
age and co-morbidity are increasing over time, and I examine this in chapter 6
along with the trends in upper gastrointestinal bleed mortality.
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Reductions in 28-Day Mortality
Following Hospital Admission for
Upper Gastrointestinal Bleeding
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6.1 Introduction
Changes in management have been shown in randomised controlled trials to
improve outcome from gastrointestinal haemorrhage, but the largest obser-
vational studies of mortality trends following upper gastrointestinal haemor-
rhage report no improvement in overall mortality over the last two decades.3–5
This failure to demonstrate an improvement suggests either, that clinical guide-
lines140,141 derived from the results of randomised controlled trials are not gen-
eralisable to the clinical population, that they are not being implemented appro-
priately, or that the patients have changed at the same time as the treatments.
This latter explanation, with increasing age and co-morbidity confounding the
effects of therapy, has been proposed as the likely explanation.60,121 However
this has not been proven because to reliably measure the effect of changes in age
and co-morbidity on mortality necessitates larger studies than have been pub-
lished. Therefore, I aimed to investigate current trends in mortality following
admission from upper gastrointestinal haemorrhage in England and investigate
whether these can be explained by population changes in age and co-morbidity.
6.2 Methods
6.2.1 Study population
Inclusion criteria
All admissions 15 years or older which had an ICD 10 code for upper gastroin-
testinal haemorrhage (as described in table 4.1), with a date of haemorrhage
between January 1st 1999 and December 31st 2007 were extracted. Data was
available for 2008 to allow complete follow up of mortality for admissions oc-
curring in December 2007. Subsequent re-admissions with upper gastrointesti-
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nal haemorrhage were included in the study and recorded as a re-admission.
Exclusion criteria
The study population was geographically limited to patients who were resi-
dent within England at the time of hospital admission and exclusions made as
described in chapter 4.1.
6.2.2 Outcome
Short term mortality was defined as in previous chapters as a date of death
within 28 days of the start of the recorded episode of upper gastrointestinal
haemorrhage. This included deaths that occurred after discharge from hospital
but within the 28 days. The date and fact of death was obtained from the ONS
death register using a deterministic matching algorithm based onNHS number,
date of birth, postcode and sex.130
6.2.3 Exposures
The main exposure of interest was defined as the year of upper gastrointestinal
haemorrhage. Charlson index,142 sex, and age were assessed as potential con-
founders. The Charlson index was calculated for each upper gastrointestinal
haemorrhage admission based on the diagnoses coded for all admissions up to
and including the first upper gastrointestinal haemorrhage admission for each
patient. This is a well validated weighted co-morbidity score derived from un-
selected hospital admissions that predicts 1 year mortality following hospital
discharge. It has since been used in many contexts and has repeatedly mea-
sured the burden of co-morbidity reliably. The original paper demonstrated a
graded increase in the risk in mortality associated with a cumulative score. The
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different co-morbidities were assigned weights of 1, 2, 3 and 6 depending on
their association with mortality. Where a graded effect was observed within
a disease, for example in diabetes or malignancy, these diseases were further
stratified according to their severity. The conditions included in the original
score (in order of weighting) were myocardial infarction, congestive heart fail-
ure, peripheral vascular disease, cerebrovascular disease, dementia, chronic
pulmonary disease, connective tissue disease, peptic ulcer disease, mild liver
disease, diabetes, hemiplegia, moderate or severe renal disease, diabetes with
end organ damage, leukemia, lymphoma, moderate or severe liver disease,
metastatic solid tumor, and acquired immunodeficiency syndrome. For anal-
ysis and reporting the score was combined into 3 groups; no co-morbidity(0),
a single co-morbidity(1) and multiple or serious co-morbidity(2). For analysis
of variceal haemorrhage the co-morbidity of liver disease was excluded from
the calculation of Charlson index, as most variceal patients will have liver dis-
ease. The Charlson index has been adapted and validated for ICD 10 coding in
administrative data143,144 and has previously been used in HES.145
The recorded age was grouped into age bands of 15-29 years, 30-59 years, 60-79
years, and older than 80 years. I calculated the length of inpatient stay as the
number of days between admission and discharge dates. I categorised admis-
sions as either having a higher probability of being an acute bleed on admis-
sion (if an upper gastrointestinal haemorrhage was coded on the first episode
in a non-elective admission) or as lower probability of being an acute bleed on
admission with a higher probability of being an inpatient bleed (if the coding
occurred after the first episode within a non-elective admission, or during an
elective (non-emergency) admission). Hereafter these are referred to respec-
tively as acute admissions and inpatient bleeds.
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6.2.4 Statistical analysis
I analysed variceal and non variceal haemorrhage admissions separately. After
the exclusions described above, 28 day case fatalities were calculated by age
group, sex, year, grouped Charlson index, and acute or inpatient haemorrhage.
A case control study analysis was carried out with cases defined as patients
who had died by 28 days and controls as patients who were alive at 28 days.
The primary exposure of interest was defined as year of upper gastrointesti-
nal haemorrhage. A logistic regression model was constructed to adjust for
the change in mortality over the study period by sex, age group and Charlson
index. Variables that changed the odds of mortality were judged to be con-
founders. I assessed whether there was a trend in mortality over time, and
whether this could be modelled as a linear trend using likelihood ratio tests.
In addition, to determine if the changes in mortality varied for different ages,
gender and co-morbidities, the model was also tested for interactions between
each of the variables and year of bleed with likelihood ratio testing. If there
was evidence against the null hypothesis of no interaction, stratified results
were presented. The use of the a priori age groups was assessed against alter-
native groupings of 5 year age bands or age as a linear variable. All analysis
was performed using Stata version 10 (StataCorp LP, Texas).
6.2.5 Sensitivity analyses
First I assessed the use of an alternativemeasure of co-morbidity called the Elix-
hauser index146 that was derived to predict mortality during the inpatient stay.
However it combined the outcome of mortality with financial costs and has
not been previously validated within HES, so it was not used for my primary
analysis.
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Secondly, I performed two sensitivity analyses to assess the effect of inaccura-
cies in coding. To assess the effect of under reporting I expanded the defini-
tion for variceal haemorrhage to include all admissions coded for oesophageal
haemorrhage (K22.8) and then re-assessed the trends in mortality. Then to as-
sess whether there was over reporting of cases that might not be a genuine
upper gastrointestinal haemorrhage, I analysed separately those who had and
those who did not have an intervention of upper gastrointestinal endoscopy
recorded (as defined by an OPCS4 code for an endoscopic procedure of the up-
per gastrointestinal tract).
Further sensitivity analyses were performed stratifying mortality trends by ad-
ditional diagnoses for gastritis/duodenitis, Mallory Weiss syndrome, any pep-
tic ulcer, gastric ulcer, duodenal ulcer and malignancy. I also performed a sen-
sitivity analysis comparing trends in mortality that occurred before discharge
and trends in mortality that occurred after discharge. The calculation of post
discharge mortality excluded patients who had died as inpatients. Finally I
assessed whether using a higher minimum age limit of 18 years altered the re-
sults.
6.3 Results
6.3.1 Study Population and exclusions
There were 516,153 upper gastrointestinal haemorrhage admissions identified
after exclusions (shown in figure 4.1 in chapter 4) of which 501,471 (97%) were
non variceal bleeds, and 14,682 (3%) were variceal bleeds.
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6.3.2 Mortality ascertainment
74,992 deaths occurred within 28 days of the date of upper gastrointestinal
haemorrhage giving an overall case fatality rate of 14.5% (95% confidence in-
terval 14.4-14.6%). Of these 10,977 deaths (15%) occurred after discharge from
hospital but within 28 days of haemorrhage. Only 312 (3%) of post discharge
deaths were coded as a subsequent hospital admission within the HES dataset.
The population characteristics for non variceal and variceal haemorrhage are
shown in table 6.1. The median age for non variceal bleeds was 71 years (inter
quartile range 50-81 years) and for variceal bleeds was 55 years (inter quar-
tile range 45-66 years). 46% of those presenting with non variceal haemor-
rhage had no co-morbidity recorded, compared to 67% of those presenting with
variceal haemorrhage after the exclusion of liver disease from the calculation of
co-morbidity. The population age structure and co-morbidity varied over the
study period (figure 6.1) with a peak in the proportion of non variceal admis-
sions over 80 years old in 2002. This matched the peak in case fatality in the
same year (table 6.1). There was a reduction over time in the proportion of
those presenting with variceal haemorrhage who were over 60 years old (fig-
ure 6.1). The co-morbidity for both groups increased over the study period.
Median length of stay for non variceal haemorrhage was 4 days (inter quartile
range 1-8 days) and for variceal haemorrhage was 7 days (inter quartile range
4-12 days). The length of stay reduced over the study period for non variceal
haemorrhage from 4 (2-8 days) to 3 (1-6 days) (p<0.001 non parametric test for
trend) but there was no reduction for variceal haemorrhage.
Non variceal and variceal haemorrhage
The overall 28 day case fatality following a non variceal haemorrhage admis-
sion was 14%, and following a variceal haemorrhage admission was 23% (table
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Table 6.1: Population Characteristics for mortality study
Non-variceal bleed admissions Variceal bleed admissions
Number
of
Admissions
(n)
Percentage
of all
Admissions
28 Day
Deaths
(n)
28 Day
Case
Fatality
(%)
Number
of
Admissions
(n)
Percentage
of all
Admissions
28 Day
Deaths
(n)
28 Day
Case
Fatality
(%)
Year
1999 51843 10.3 7644 14.7 1559 10.6 384 24.6
2000 53206 10.6 7865 14.8 1592 10.8 399 25.1
2001 53268 10.6 7952 14.9 1496 10.2 374 25.0
2002 53735 10.7 7990 14.9 1581 10.8 383 24.2
2003 55656 11.1 8155 14.7 1619 11.0 382 23.6
2004 57450 11.5 8075 14.1 1768 12.0 395 22.3
2005 59362 11.8 8251 13.9 1612 11.0 349 21.7
2006 58737 11.7 8042 13.7 1736 11.8 360 20.7
2007 58214 11.6 7632 13.1 1719 11.7 360 20.9
Total 501471 100.0 71606 14.3 14682 100.0 3386 23.1
Gender
Male 276304 55.1 36681 13.3 9565 65.1 2201 23.0
Female 225167 44.9 34925 15.5 5117 34.9 1185 23.2
Age
<30 39973 8.0 213 0.5 375 2.6 40 10.7
30 to 59 135507 27.0 7488 5.5 8749 59.6 1858 21.2
60 to 79 174181 34.7 26300 15.1 4688 31.9 1216 25.9
≥80 151810 30.3 37605 24.8 870 5.9 272 31.3
Charlson index
0 229941 45.9 15657 6.8 9825 66.9 2120 21.6
1 150004 29.9 20462 13.6 3832 26.1 964 25.2
2 121526 24.2 35487 29.2 1025 7.0 302 29.5
Bleed as acute admission or as inpatient
Acute 295887 59.0 31199 10.5 10176 69.3 2041 20.1
Inpatient 205584 41.0 40407 19.7 4506 30.7 1345 29.8
Number of admissions
Single 373132 74.4 61564 16.5 6802 46.3 2269 33.4
Multiple 128339 25.6 10042 7.8 7880 53.7 1117 14.2
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Figure 6.1: Trends in age and co-morbidity measured by grouped Charlson
Index .
(Percentage of population shown) A Percentage of non variceal haemorrhage
patients in each age band. B Percentage of non variceal haemorrhage patients
in each co-morbidity group. C Percentage of variceal haemorrhage patients in
each age band. D Percentage of variceal haemorrhage patients in each
co-morbidity group.
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6.1). From 1999 - 2007 the unadjusted 28 day mortality following non variceal
haemorrhage reduced from 14.7% to 13.1% (unadjusted odds ratio 0.87 (0.84-
0.90, 95% confidence interval). The unadjusted mortality following variceal
haemorrhage reduced from 24.6% to 20.9% (unadjusted odds ratio 0.81 (0.69-
0.95, 95% confidence interval).
Acute haemorrhage on admission compared with inpatient haemorrhage
28 day mortality for an acute admission with haemorrhage reduced over the
study period for non variceal haemorrhage from 11.3% to 9.3% (unadjusted
odds ratio 0.81, 95% confidence interval 0.77-0.85), and for variceal haemor-
rhage from 21.3 to 17.3% (unadjusted odds ratio 0.77, 95% confidence interval
0.62-0.95). 28 day mortality for cases with an inpatient haemorrhage also re-
duced over the study period, for non variceal haemorrhage from 20.0% to 18.4%
(unadjusted odds ratio 0.91, 95% confidence interval 0.86-0.95), and for variceal
haemorrhage from 32% to 29% (unadjusted odds ratio 0.88, 95% confidence in-
terval 0.67-1.14).
6.3.3 Multivariate analysis
The odds of mortality for each year were altered when adjusted separately for
each of the potential confounders of age, sex and Charlson Index. The slight
peak in mortality in 2002 was removed when adjusting for the increase in age
in 2002. Adjusting for increases in co-morbidity had the largest effect on the
reduction in mortality. The multivariate model adjusting for all these variables
is shown in table 6.2. Age and co-morbidity were stronger confounders for non
variceal than variceal haemorrhage.
Therewas evidence of a linear trend inmortality over time, for both non variceal
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Table 6.2: Logistic regression model predicting 28 day mortality
Non-Variceal bleeding Variceal bleeding
Year of
Presentation
Unadjusted
odds ratio
Adjusted
odds
ratio*
95% CI Unadjusted
odds ratio
Adjusted
odds
ratio*
95% CI
1999 1.00 1.00 1.00 1.00
2000 1.00 0.98 ( 0.94 - 1.01 ) 1.02 1.02 ( 0.87 - 1.20 )
2001 1.01 0.97 ( 0.93 - 1.00 ) 1.02 1.02 ( 0.86 - 1.20 )
2002 1.01 0.95 ( 0.92 - 0.99 ) 0.98 0.98 ( 0.83 - 1.15 )
2003 0.99 0.94 ( 0.90 - 0.97 ) 0.94 0.95 ( 0.80 - 1.11 )
2004 0.95 0.90 ( 0.86 - 0.93 ) 0.88 0.88 ( 0.75 - 1.03 )
2005 0.93 0.89 ( 0.86 - 0.92 ) 0.85 0.83 ( 0.70 - 0.98 )
2006 0.92 0.85 ( 0.82 - 0.88 ) 0.80 0.79 ( 0.67 - 0.94 )
2007 0.87 0.80 ( 0.77 - 0.83 ) 0.81 0.80 ( 0.67 - 0.94 )
Age
<30 years 1.00 1.00 1.00 1.00
30-59 years 10.09 7.22 ( 6.37 - 8.19 ) 1.93 1.92 ( 1.44 - 2.55 )
60-79 years 30.04 16.80 ( 14.84 - 19.02 ) 2.51 2.37 ( 1.77 - 3.17 )
>=80 years 55.62 34.14 ( 30.15 - 38.65 ) 3.26 3.05 ( 2.22 - 4.20 )
Sex
Male 1.00 1.00 1.00 1.00
Female 1.20 1.01 ( 0.99 - 1.03 ) 1.01 0.96 ( 0.88 - 1.04 )
Charlson Index
0 1.00 1.00 1.00 1.00
1 2.16 1.70 ( 1.66 - 1.74 ) 0.99 1.17 ( 1.07 - 1.27 )
2 5.64 4.37 ( 4.28 - 4.47 ) 1.31 1.37 ( 1.18 - 1.58 )
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haemorrhage and variceal haemorrhage (p<0.001), and there was minimal evi-
dence to suggest that a linear model was inappropriate for the data (test for de-
parture from a linear trend; non variceal haemorrhage p=0.061, variceal haem-
orrhage p=0.94). The adjusted average annual reduction in odds of mortality
for non variceal haemorrhage was 2.5% (average annual OR 0.97, 95% confi-
dence interval 0.97-0.98) and for variceal haemorrhage was 3.5% (average an-
nual OR 0.96, 95% confidence interval 0.95-0.98).
Further analyses for interactions demonstrated different time trends for dif-
ferent ages and different levels of co-morbidity for non variceal haemorrhage
(likelihood ratio tests for interactions of both age and co-morbidity with year
p<0.001), but not for variceal haemorrhage (year and age p=0.29, year and
co-morbidity p=0.67). Consequently the age stratum specific average annual
changes in odds of mortality for non-variceal haemorrhage were presented in
table 6.3. The annual improvement in odds of mortality was minimal for those
presenting 80 years and older compared to all the other age groups. Further
stratifying the model by age and co-morbidity (table 6.4) demonstrated that
within each age specific stratum the improvement in mortality did not differ
by the level of co-morbidity. Therefore the final model of a linear trend in 28
day mortality for non variceal haemorrhage is the model shown in table 6.3,
with confounding by co-morbidity adjusted for by logistic regression, and effect
modification demonstrated by stratifying the results by age. The final model of
a linear trend in 28 day mortality for variceal haemorrhage demonstrated only
confounding by both co-morbidity and age with no effect modification.
6.3.4 Sensitivity analyses
The first sensitivity analysis used the Elixhauser index to adjust for co-morbidity
and this showed a slightly increased average annual reduction compared to us-
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Table 6.3: Age stratified logistic regression model predicting 28 day mortal-
ity for non variceal haemorrhage
Adjusted Odds ratio* 95 % confidence interval
Change in mortality for an increment of one year**
< 30 years 0.92 ( 0.88 - 0.97 )
30-59 years 0.97 ( 0.96 - 0.97 )
60-79 years 0.97 ( 0.96 - 0.97 )
>= 80years 0.99 ( 0.98 - 0.99 )
*Adjusted for co-morbidity by Charlson index and sex
**Year as a continuous variable
Table 6.4: Age and co-morbidity stratified logistic regression model predict-
ing 28 day mortality
Age Charlson Index Adjusted Odds ratio* 95 % confidence interval
Change in mortality for an increment of one year**
<80 years
0 0.96 ( 0.95 - 0.97 )
1 0.96 ( 0.95 - 0.97 )
2 0.95 ( 0.95 - 0.96 )
>=80 years
0 1.00 ( 0.99 - 1.01 )
1 0.99 ( 0.98 - 0.99 )
2 0.98 ( 0.97 - 0.99 )
* Adjusted for sex
**Odds ratio for year as a continuous variable
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ing the Charlson index to adjust for co-morbidity (non variceal haemorrhage
OR 0.96, 95% confidence interval 0.96-0.97). However the overall model with
the Elixhauser index did not have as good a fit to the data as when the Charlson
index was used to adjust for co-morbidity.
Secondly, I performed two sensitivity analyses to assess the effect of inaccura-
cies in coding. A repeat analysis was conducted including oesophageal haem-
orrhage codes (K22.8) as a variceal haemorrhage admission, and this estimated
an annual reduction in odds of mortality of 3.6% (average annual OR 0.96, 95%
confidence interval 0.95-0.98). I then found a similar reduction in non variceal
haemorrhage admissions that had an endoscopy recorded (average annual OR
0.97, 95% confidence interval 0.96-0.97), to those that did not have an endoscopy
recorded (average annual OR 0.96, 95% confidence interval 0.96-0.97). This was
also the case for variceal haemorrhage, though as only a few cases did not have
an endoscopy there was greater uncertainty (with endoscopy: average annual
OR 0.98, 95% confidence interval 0.96-0.99; without endoscopy: average annual
OR 0.95, 95% confidence interval 0.92-0.98).
Stratifying the results by associated diagnoses of gastritis/duodenitis, Mallory
Weiss syndrome, any peptic ulcer, gastric ulcer, duodenal ulcer or malignancy,
associated with non variceal haemorrhage found similar reductions in mortal-
ity following all these diagnoses (see table 6.5). Re-analysing the trends only
for mortality prior to discharge demonstrated the same reduction in inpatient
mortality as in the main analysis (non variceal average annual adjusted mor-
tality OR=0.97, 95% confidence interval 0.97- 0.98). In contrast the mortality
after discharge increased slightly, (non variceal average annual adjusted mor-
tality OR=1.02, 95% confidence interval 1.02-1.03). Finally the use of alternative
5 year groupings for age did not alter the analysis neither did an alternative
minimum age limit of 18 years.
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Table 6.5: Trends in 28 day mortality for diagnoses associated with an upper
gastrointestinal haemorrhage
Diagnosis associated with upper gas-
trointestinal haemorrhage
Adjusted odds ratio* 95% confidence intervals
Change in mortality for an increment of one year**
No specific diagnosis 0.97 (0.97– 0.98)
Gastritis/Duodenitis 0.96 (0.94– 0.98)
Mallory Weiss Syndrome 0.96 (0.95– 0.97)
Any Peptic Ulcer 0.96 (0.93— 0.99)
Gastric Ulcer 0.94 (0.93–0.95)
Duodenal Ulcer 0.96 (0.95– 0.97)
Malignancy 0.95 (0.95–0.96)
*Adjusted for age, sex and co-morbidity by Charlson index
**Year as a continuous variable
6.3.5 Regression diagnostics
Delta beta statistics were calculated for the final model and these were all less
than one. These measured the standardised change in the coefficients when
observations with each covariate pattern were deleted. This indicated that no
individual covariate pattern was particularly influential on the estimated co-
efficients. Outliers with influence on the overall model fit were estimated by
delta Chi-squared statistics values over 3. This measured the change in Chi-
squared value for the model with the deletion of each observation. These out-
liers were generally patients with a lower predicted mortality who nevertheless
died. These accounted for 1% of the study population and if excluded the over-
all reduction in mortality over the study remained at 20%.
6.4 Discussion
The failure of previous studies to demonstrate improvements in mortality after
upper gastrointestinal haemorrhage at the population level calls into question
the value of therapeutic changes which are of proven benefit to individuals. In
an increasingly challenging economic environment clinicians will need to be
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able to demonstrate that increased therapeutic expenditure really does bring
benefits. That 28 day mortality for equivalent patients, following hospital ad-
mission for both non variceal and variceal upper gastrointestinal haemorrhage,
has reduced by 2 and 3% respectively year on year in England over the period
1999 to 2007 is therefore of great importance.
6.4.1 Strengths and limitations
When, as in this case, a study’s findings differ from the previous literature, we
must ask whether this is because the current or previous studies were in error,
or whether they are in reality observing different things. The data source cho-
sen for my study provides key advantages. The study is the largest to date of
mortality after hospital admission for gastrointestinal haemorrhage and there-
fore has power to demonstrate trends that would be missed in smaller studies.
It also has power to demonstrate variations in trends between subgroups of the
population such as the smaller reduction in mortality in those over 80 years old
with non variceal haemorrhage. The provision within the dataset of informa-
tion on the previously suggested confounders of age and co-morbidity is also
of great benefit, and has allowed us to clearly show and correct for this con-
founding.
Another key advantage of the current study is the linkage of clinical data with
the ONS death register, ensuring that almost all deaths are captured in the study
population. Hospital admission data only captures deaths occurring before dis-
charge, which I found to be 86% of the deaths occurring within 28 days. Studies
without such linkage will have missed a proportion of these deaths, since post
discharge deaths will have been difficult to capture. Furthermore any change in
this capture over time may have biased results. The linkage used in the current
study, depending as it does on deterministic matching, still leaves potential for
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some underestimation of mortality but the robustness of the linkage coupled
with its uniform methodology throughout the study period mean that bias due
to this is unlikely to have occurred. The reduction in length of stay over the
course of the study further emphasises the importance of identifying deaths
following discharge to accurately calculate trends in mortality. The slight in-
crease in post discharge mortality might imply that the observed earlier dis-
charge of patients was inappropriate, however if management in hospital was
no longer of benefit to a patient who is dying, then discharge might well be the
most appropriate decision. The observed trends might therefore indicate a shift
of previously unavoidable inpatient mortality into the post discharge period.
Patients who died in the emergency department before admission for endoscopy
were not included in my study, as hospital admissions data contains informa-
tion only on admitted patients. However, as acute admission to hospital for
all upper gastrointestinal haemorrhage was standard practice within England,
the admissions data will have captured almost all other relevant bleed presen-
tations. Patients who had a non specific code for gastrointestinal haemorrhage
with a colonoscopy but no gastroscopy were excluded, but it is possible that
these could have had an upper gastrointestinal bleed if they had died before a
planned gastroscopy. However this would be unlikely as usual practice would
be to perform a gastroscopy before colonoscopy due to the easier access and
greater therapeutic potential of gastroscopy.
The coding of upper gastrointestinal haemorrhage has been discussed in chap-
ter 4. This of course does not exclude variation in rates of coding over the
study period affecting my estimates. For example if the potential error in cod-
ing was systematically changing over time with increased coding of patients’
co-morbidity rather than patients having more co-morbidity, then clearly that
could bias my results. However the different trends in co-morbidity for variceal
and non variceal bleed admissions, and different trends in mortality in differ-
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ent age and co-morbidity strata, suggests that there was no systematic change
in co-morbidity coding over the time period of my study. Under-reporting of
the co-morbidities in the Charlson index may have resulted in incomplete ad-
justment for co-morbidity. However, although the alternative Elixhauser index
assessed almost twice the number of co-morbidities, it did not alter the adjust-
ment of co-morbidity in the model. Co-morbidity adjustment by either index
increased the magnitude of the mortality reduction, and therefore any residual
confounding in this regard would only, I believe, cause an underestimate of the
real mortality trend in my study.
6.4.2 Other studies
A PubMed search, to December 2012, found the largest comparable population
based study for non variceal haemorrhage mortality trends used a Canadian
hospital discharge database with ICD 10 and ICD 9 codes. However it iden-
tified less than a third of the number of bleeds used for this study (n=142,363)
andwas not able to identify a reduction in case fatality for non variceal haemor-
rhage between 1993 and 2003.4 The researchers adjusted for changes in age, but
not for changes in co-morbidity. They also only identified deaths that occurred
before discharge. The low mortality identified in this study (3.5%) is similar
to other North American,12 and Mediterranean studies,5,147 but is much lower
than other European studies.3,26,61 However, a study ofMedicare patients in the
US found that the proportion being managed as outpatients varied between
states from 18.6%-45.3%.35 These differences in practice would lead to differ-
ences in inpatient study populations and confound comparisons with countries
such as England where outpatient management is not routine.
Although reports from US National Inpatient Sample showed a 23% reduc-
tion in upper gastrointestinal haemorrhage mortality from 96/100,000 in 1998
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to 82/100,000 in 2006,12 and a similar 23% reduction from 78/100,000 in 2001
to 61/100,000 in 2009,27 these incidence estimates are inconsistent with each
other despite being from the same data source with the same case definitions.
Another report from the US National Inpatient Sample noted an adjusted re-
duction in variceal haemorrhage from 18% to 12%.76 However, the number of
cases in these studies is extrapolated from a 20% sample and although a number
of weighting procedures are used, the estimates remain susceptible to selection
bias. Furthermore in the study period of these reports, the number of states in
the sampling frame almost doubled from 22 to 40. The reports therefore com-
pare different populations from each time period.
One smaller study from Wales (n=24,421) used the same ICD 10 definitions as
my study and also found an overall reduction in case fatality, but did not report
variceal and non variceal haemorrhage mortality trends separately or trends in
different age and co-morbidity strata.25 Other non variceal haemorrhage stud-
ies from Spain(n=17,663),5 theNetherlands (n=1,720),3 Greece (n=1,304)147, France
(n=1,165)61 and Italy (n=1,126),26 did not identify reductions in non variceal in-
patient mortality. Although these were large studies they may have been un-
derpowered to detect a change, and none of them adjusted the trends in case
fatality for changes in co-morbidity. Furthermore, none of these studies identi-
fied deaths that occurred after discharge. The remainder of studies contained
less than 1000 patients and therefore could not provide accurate estimates of
mortality trends.
For variceal haemorrhage the largest study on mortality after hospitalisation
due to varices (n=12,281; compared to 14,682 for this study) did not differ-
entiate between haemorrhage and non-haemorrhage admissions.38 The next
largest study (n=1475) compared variceal haemorrhage mortality between con-
trol groups in randomised trials 1960-2000 and showed a similar reduction in
mortality.69 However these control groups were from different geographical
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populations with different study exclusion criteria. Comparisons were there-
fore susceptible to selection bias. Other studies of trends in variceal haemor-
rhage mortality contained less than 1000 patients.
The other finding of note in my study, in relation to variceal haemorrhage,
was the small proportion of overall haemorrhages which they represent. In the
context of the increasing burden of liver disease39 and an apparent increase in
variceal haemorrhage in the recent BSG audit,1 a higher proportion might have
been expected. My finding however was similar to that from the 1993 BSG audit
(4%) and to other studies.23 It is possible that some of the variceal haemorrhage
in my study may have been incorrectly coded to oesophageal haemorrhage,
but a sensitivity analysis, assuming the most likely misclassification of all oe-
sophageal haemorrhage codes being miscoded variceal bleeds, did not alter the
adjusted reduction in mortality.
The previous difficulties in detecting a reduction in mortality might imply that
we are reaching the point where mortality becomes unavoidable due to age
and co-morbidity. However as the mortality in my study continued to improve
right up to the end of the study period, improvements in management would
appear to be continuing to have an impact on mortality following gastrointesti-
nal haemorrhage. The reasons for the reduction in mortality I have observed
are likely to be complex. There were similar reductions in mortality whether or
not an endoscopy was recorded and for all associated diagnoses, implying that
endoscopic therapy was not a major contributor to the reduction in mortality.
Instead my data perhaps suggests that improvement in standard non endo-
scopic care has led to improved survival; such as the routine administration of
intravenous proton pump inhibitor infusions, the routine use of risk scoring,
the implementation of standardised clinical guidelines, and subsequent local
auditing of practice.140,141,148
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In conclusion, contrary to previous smaller studies, I have found an encour-
aging substantial improvement in mortality following hospital admission for
upper gastrointestinal haemorrhage. My study shows that this is partially ob-
scured by increases in age and co-morbidity. This improvement is likely the re-
sult of changes in the care of gastrointestinal haemorrhage over the last decade,
but it also suggests the need to focus our ongoing attention on the elderly who
may not yet have benefited to themaximumpossible extent from these changes.
The recent demonstration of underutilisation of endoscopic techniques in the
UK, coupled with the fact that other interventions such as use of proton pump
inhibitors are more readily available to the admitting physician worldwide,
may suggest areas which could be further improved.57,140,141,149,150
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7.1 The Linked Dataset as a Sample of the GPRD
Electronic health records are cheap, convenient, and provide power for stud-
ies that would be unfeasible in bespoke patient cohorts. Previously in this
PhD (chapter 4) I have used secondary care data (Hospital Episodes Statistics
- HES) to measure upper gastrointestinal haemorrhage and found the num-
bers of cases and procedures identified were comparable to a national hospi-
tal audit.151 However for the remaining studies in this PhD, more comprehen-
sive prescription and co-morbidity data were required for each patient prior to
their hospital admission. As this was either unavailable or incomplete in sec-
ondary care data, I used primary care data (General Practice Research Database
- GPRD) inwhich the coding for upper gastrointestinal bleeding has been shown
to be valid in 99% of cases by chart review (95 cases confirmed out of 96 cases
assessed).100 To retain the advantages of hospital data procedural coding, mul-
tiple hospital diagnoses, and accurate admission dates, I took the opportunity
to use linked GPRD, HES and ONS (Office for National Statistics) data. The
linkage did not cover the entire GPRD at the time of the PhD, but had only
been performed for consenting practices. This might have selected an unrepre-
sentative sample of the underlying database. Therefore comparisons between
the linked dataset, the whole GPRD, and the UK population are assessed in this
chapter in section 7.2.2. Individuals have been mapped between the databases
by anonymised patient identifiers as part of the linking process for the GPRD
by a trusted third party. However the clinical events and coding within these
linked individuals have not been defined. Therefore in section 7.3 different
methods of identifying the codes that correspond to the same event within the
linked dataset are assessed by comparing the effect of different case definitions
on mortality and occurrence.
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7.2 Comparison of linked dataset toGPRD andONS
populations
7.2.1 Description of linked dataset
Hospital Episodes Statistics.
The HES database has been described in chapter 4.
General Practice Research Database.
The GPRD contains longitudinal primary care data that are validated and in-
dividualised for over 46 million person years since 1987, and reflect the obser-
vations, diagnoses made, and therapies prescribed by general practitioners in
addition to any information communicated from secondary care.152 The com-
prehensive English primary care system means that the population registered
to the GPRD is representative of the general English population.153 The data
are subject to regular checks to ensure data is being recorded reliably and con-
sistently, and a practice’s data is only used when it is of high enough quality
to be used in research, referred to as “up to standard.”154 The GPRD has been
extensively validated for a wide range of diagnoses with a mean positive pre-
dictive value of 89%.155 The data are coded using the Read code system (in use
in the NHS since 1985 and managed by the UK Terminology Centre)
Linkage.
The anonymised patient identifiers from GPRD, HES, and ONS death register
have been linked with deterministic matching using the NHS number, date of
birth, postcode and sex156 (as was previously done to link ONS data to HES130).
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As HES only covers English hospitals, practices in Northern Island, Wales and
Scotland were excluded. For this study I used the January 2011 download of
GPRDGOLD data, in which 51.3% of GPRD primary care practices within Eng-
land consented for their data to be linked.
7.2.2 Comparison of linked dataset with estimates of the UK
population
The representativeness of the population in the linked dataset was assessed by
comparisons with the whole GPRD and estimates of the general UK population
available from the ONS. The comparisons were made on June 30th 1999 and
June 30th 2009.
Age and sex
Figures 7.1 and 7.2 show the population pyramids in 1999 and 2009.
The population pyramid in the linked dataset had a similar age and sex struc-
ture to that in the whole GPRD in both 1999 and 2009. However infants and
young adults were under-represented when compared to the ONS data. The
GPRD database and the linked dataset included a lower proportion of 12-28
years old in 1999 and 18-28 years old in 2009 when compared to the ONS esti-
mates. Older ages were conversely slightly over-represented.
Region
Figures 7.3 and 7.4 show the proportion of the population from each region in
the GPRD database, linked dataset and ONS estimates. As the linkage was only
available for English primary care practices only English regionswere included.
Yorkshire, East Midlands and the North East were under represented in the
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Figure 7.1: Proportion of GPRD, linked dataset and ONS UK population estimates by age and sex in 1999
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Figure 7.2: Proportion of GPRD, linked dataset and ONS UK population estimates by age and sex in 2009
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Figure 7.3: Proportion of GPRD, linked dataset and ONS UK population estimates by region in 1999
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Figure 7.4: Proportion of GPRD, linked dataset and ONS UK population estimates by region in 2009
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GPRD database and linked dataset compared to the ONS data in both 1999 and
2009. Other regions were correspondingly over represented.
7.2.3 Interpretation
The North East, East Midlands and Yorkshire were under represented by an ab-
solute proportion of 5% of the GPRD. This is likely to be a consequence of the
lower uptake in these regions of first the DOS based VAMP (’Value AddedMed-
ical Products’) and then the Microsoft-Windows based Vision software systems
by primary care.157 This software was the basis for the GPRD data collection.
Interestingly these regions that were under-represented in the GPRD were the
same regions that have been over-represented in the QRESEARCH database
that utilises the competing EMIS software system (’Egton Medical Information
Systems’).158
As the regional differences were associated with deprivation and upper gas-
trointestinal haemorrhage, potential selection bias might be introduced into my
studies. However I have already identified that the variation by region was
mostly explained by the socioeconomic status within that with region, there-
fore the GPRD linkage to the ONS Index of Multiple Deprivation quintiles per-
mits the assessment of any potential confounding by deprivation and there-
fore by region. Furthermore as the planned studies involve comparisons with
controls matched from the patients’ primary care practice, controls will be ex-
actly matched by region, and so internal comparisons will be less susceptible to
bias. With regard to generalisability to the English population, there will still
be considerable numbers of participants from the under-represented regions
contributing to the study and its results.
There was a low proportion of the population in the GPRD compared to the
population in the ONS who were younger than one year. This potentially re-
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flects a delay in parents registering infants with a general practitioner. Teenagers
and young adults were also under represented in the GPRDdatabase and linked
dataset, and this probably reflects the transitory nature of this life stage. Young
adults are theoretically more mobile after leaving home whilst they develop
new careers and training (for example by attending university) and this might
delay registering with a general practitioner until they become more estab-
lished or have ill health. With respect to this PhD however, upper gastroin-
testinal bleeds were relatively infrequent in this age group (8% of non variceal
bleeds in my earlier studies in HES with a 30 day mortality of 0.5%), so this is
unlikely to have an important effect on my results. Furthermore comparisons
are to be made with age matched controls, and there are considerable numbers
from these age groups still contributing to the study population allowing valid
internal comparisons to be made.
7.2.4 Conclusion
The linked dataset is likely to provide a representative sample of the UK pop-
ulation with regard to those who experience upper gastrointestinal bleeding.
Infants and young adults are under represented, but these are not groups that
contribute to the majority of bleeding episodes according to the secondary care
data already examined in chapter 5, and therefore the linkage is unlikely to
introduce any significant bias or confounding to the studies in this PhD. How-
ever any observations that are made in those under 30 years old will need to be
interpreted with caution.
For the same reasons any investigation of variations in incidence of bleeding
by region within the GPRD or linked dataset might also be effected by selection
bias and need to be treated cautiously. However for the planned studies on
aetiology and outcomes of upper gastrointestinal bleeding only internal com-
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parisons were made and the effect of region cannot assessed as controls were
matched exactly on the primary care practice of the cases.
7.3 Defining upper gastrointestinal bleeding from
linked primary and secondary care data and the
effect on occurrence and 28 day mortality
7.3.1 Introduction
The initial attempts to define a cohort of upper gastrointestinal bleeding from
the linked HES and GPRD demonstrated discrepancies in the cases detected. I
have therefore investigated the reasons for this by studying alternative meth-
ods of defining cases (separately in each dataset or various combinations from
both datasets) and to what extent the choice between these methods effects my
results.
7.3.2 Aim and Objectives
To investigate in a defined population with primary and secondary care data
how case definition sensitivity and specificity is associated with 28 day mortal-
ity.
To achieve this I will:
1. Define upper gastrointestinal haemorrhage separatelywithin primary care
and secondary care data.
2. Define time windows and acceptable codes for concurrent coding of bleed
events in the linked datasets.
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3. Assess the effect of different case definitions made in linked primary and
secondary care data on 28 day mortality.
7.3.3 Methods
Defining upper gastrointestinal haemorrhage separately within primary
care and secondary care data.
Defining cases in the General Practice Research Database Primary care bleed
events were defined in GPRD using Read codes that indicated a definite di-
agnosis or symptom of upper gastrointestinal bleed. Codes for unspecified
gastrointestinal bleeding were also included to be consistent with previously
published ICD 10 code lists in chapter 4.1,25,159,160 and were similarly excluded
if they had a code for a lower gastrointestinal diagnosis or procedure.
Primary care bleed events were excluded if the patient was 15 years old or
younger, had temporary registration, had invalid date codes, was coded as
elective or daycase, or occurred outside the observed and up to standard time
period. The start of the observed and up to standard time period was defined
as the latest of; the up to standard data collection date, 1st April 1997 (start
of matching of GPRD and HES), or 3 months post current primary care regis-
tration. The purpose of the latter exclusion was to avoid matching of preva-
lent events recorded during a new patient registration. Previously Lewis et al
reported that 3 months was an appropriate time window to exclude for acute
events,161 and I have confirmed this by assessing the incidence of specific upper
gastrointestinal bleed codes in the GPRD by month over the first year (figure
7.5). This demonstrated that the incidence of new bleed codes fell close to the
baseline level by 3 months. The end of the observed time period was defined by
the earliest of; date of death, date of transfer out of practice, 31st August 2010
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(end of matched HES data in current linkage) or the last collection date for the
practice.
Figure 7.5: Incidence of upper gastrointestinal bleeding in GPRD by month
from current registration date
Defining cases in the Hospital Episodes Statistics database Secondary care
bleed admissions were defined in HES using the ICD 10 code list used in chap-
ter 4.1.159,160 Multiple admissions were included for each patient.
Secondary care events were excluded if the patient was 15 years old or younger,
had temporary registration in primary care, had invalid date codes, was coded
as elective or daycase, or occurred outside the observed and up to standard
time period as defined in the previous section for GPRD.
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Defining concurrent events in the linked datasets
Defining time windows for concurrent codes in primary and secondary care
The standard within the NHS for hospital communications is that a discharge
letter, with aminimumof themain discharge diagnosis and prescriptions, should
be sent to the primary care doctor within 24 hours of discharge.162 A time dif-
ference greater than 2 months was judged too long for delivery of discharge
letters and its subsequent coding, and I therefore used 2 months as the cut off
for associating separate events from the linked datasets. Time periods allow-
ing for intermediate delays in primary care coding were defined for less than
2 months, 1 month, 2 weeks, or 1 week pre or post the event defined in either
primary or secondary care. An event of upper gastrointestinal bleeding might
have been coded first in either primary care prior to referral or in secondary
care on the admission date. I therefore selected the earlier of the two dates as
the index date for the 28 day case fatality analysis.
Defining acceptable concurrent codes in primary and secondary care An up-
per gastrointestinal bleed code in one database could have a number of legiti-
mate corresponding codes in the linked datasets instead of a specific code for
upper gastrointestinal bleeding - for example outcomes such as death or col-
lapse, underlying diagnoses such as cancer, or procedures such as oesopha-
gogastroduodenoscopy. To allow for this heterogeneity in coding, ‘probable’
and ‘possible’ groups of ICD 10 and Read codes were selected that could plau-
sibly be coded following an upper gastrointestinal bleed. ‘Probable’ codes were
defined as those specifying a likely symptom, cause, therapy, investigation or
outcome of upper gastrointestinal haemorrhage. ‘Possible’ codes were defined
as those that non specifically indicated a change in health state without indi-
cating an alternative diagnosis to a gastrointestinal bleed (see table 7.1, 1=Most
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probable, 16=Less probable, full code lists are in appendix A.1 and A.2). This
was based on the clinical judgement of the authors (2 consultant gastroenterol-
ogists and 1 trainee gastroenterologist).
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Category
Order
Group name Group definition Probable
or pos-
sible
codes
1 Upper GI bleed
cause
Code for known upper GI bleed diagnosis or
cause. e.g. ulcer, oesophagitis, NSAID or As-
pirin use, cirrhosis, upper GI malignancy etc.
Probable
2 Upper GI bleed
symptom
Symptoms indicating upper GI bleed e.g.
melaena, haematemesis etc.
Probable
3 Upper GI
endoscopy
Any upper GI endoscopy code (Not
ERCP/EUS).
Probable
4 Death (any cause) Any code associated with death. Probable
5 Blood transfusion Any code for blood transfusion or cross
matching.
Probable
6 Upper GI
procedure
Any code for an upper GI procedure plausi-
ble for managing a bleeding episode.
Probable
7 GI bleed symptom Any general code for GI bleed (not specifi-
cally upper or lower).
Probable
8 Upper GI
diagnosis
Any other code for an upper GI pathology
that might be associated with an upper GI
bleed.
Possible
9 Hospital Any code for referral, admission or discharge
to hospital in a general or related specialty.
Possible
10 Upper GI
symptom
Any other code for symptoms of upper GI
pathology e.g. vomiting.
Possible
11 GI symptom or
diagnosis
Other GI diagnoses or non specific GI symp-
toms(e.g. pain) excluding lower GI symp-
toms.
Possible
12 Alcohol Any code indicating alcohol consumption or
complications.
Possible
13 Anaemia Any code for anaemia excluding chronic de-
ficiency anaemias and fatigue.
Possible
14 Coagulation Any code indicating primary or secondary
clotting abnormality, or use of anti coagula-
tion therapy.
Possible
15 Collapse Any code indicating collapse, fall or loss of
consciousness.
Possible
16 Other codes Other codes specifying a change in health
state with no specific diagnosis
Possible
Table 7.1: Categories of Read or ICD 10 Codes thatMight be Associatedwith
a Hospital Admission for Upper Gastrointestinal Haemorrhage.
Listed in Order of how Probable a Code Category Would be Associated with an Upper
Gastrointestinal Haemorrhage Admission (1=Most Probable)
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Classification of case definitions of upper gastrointestinal bleeding in
linked primary and secondary care data.
I defined four case definitions of differing specificity and assessed how this al-
tered my study population with regard to occurrence and case fatality. All four
case definitions required at least a specific upper gastrointestinal bleeding code
from one database with or without a code from the linked dataset that was of
differing specificity; from the broad and sensitive case definition 1 that requires
no linked code, to the restrictive and specific case definition 4 requiring a spe-
cific bleeding code. For each case definition the cases that were initially defined
from the individual datasets (identified as (a) for HES and (b) for GPRD) were
pooled and duplicates excluded. Duplicate events were identified as those that
occurred within the 2 month time window I used for defining corresponding
codes.
Definition 1 - All secondary and primary care defined events This broad and
sensitive definition selected all possible cases of upper gastrointestinal bleeding
from the linked data. All cases defined by a specific Read or ICD 10 bleed code
in either database were combined and duplicate events were excluded.
Definition 2a & 2b- Primary and secondary care events that had a concurrent
‘Probable’ or ‘Possible’ code in the linked dataset This definition selected
all cases of upper gastrointestinal bleeding that had either a supporting code
(probable code) in the linked data or a less specific code (possible code) that
did not contradict the bleeding diagnosis. Therefore for each upper gastroin-
testinal bleed defined in either dataset from definition 1, a specific bleed code,
probable code or possible code was searched for in the linked dataset within the
2 month time window and selected in the hierarchical order of the categories
listed in table 7.1 . Each primary care event was matched to only one hospital
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admission that was closest in time and vice versa.
Definition 3a & 3b) - Primary and Secondary care events that had a concurrent
‘Probable’ code in the linked dataset This definition selected all cases of upper
gastrointestinal bleeding that had a code in the linked data that supported the
diagnosis of bleeding. This required restricting the cases defined in 2a & 2b to
only those with a more specific probable code in the linked dataset.
Definition 4 - Primary and secondary care events with specific bleed codes in
bothGPRDandHES To provide a very specific case definition only thosewith
a specific upper gastrointestinal bleed code in both primary and secondary care
datasets were selected.
Analysis: Incidence and 28 day all cause case fatality by case definition
The incidence was calculated per 100,000 person years using the underlying
number of people registered in the GPRD as the denominator. Incidence was
calculated by pooling each of the case definitions from the GPRD and HES by
combining cases from both (a) and (b) for each of the definitions above and
removing duplicates.
Finally I assessed the effect of each of these case definitions on the results of my
intended studies in linked primary and secondary care data. Within the general
population registered to a linked GPRD primary care practice, I calculated the
numbers of cases identified by each case definition and the subsequent all cause
28 day case fatality. Dates of all deaths within 28 days following an upper gas-
trointestinal bleed admission date or primary care event date were ascertained
using the linkage between the GPRD primary care practices and the UK ONS
death register.
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7.3.4 Results
Defining upper gastrointestinal bleeding separately within primary care
and secondary care data.
Between 1st April 1997 and 30th August 2010 26,957 acute upper gastrointesti-
nal bleed admissions were defined in HES by specific ICD 10 bleed codes and
30,223 acute upper gastrointestinal bleed events were defined in GPRD by the
specific Read bleed codes. Combining these events defined 45,510 unique up-
per gastrointestinal bleed events, 26%with a specific code in both datasets, 34%
with a code only in HES and 41% with a code only in GPRD. The proportion of
all events defined by specific bleed codes from both databases varied by year
between 22%-27% but there was no clear trend over time.
Classification of case definitions of upper gastrointestinal bleeding in
primary and secondary care
The flow chart in figure 7.6 shows the selection of adult upper gastrointestinal
bleeding events for each of my four case definitions. The percentages given
in the flow chart are of the 45,472 pooled unique events in box 1. Of the 26,964
secondary care defined bleeds in box 1a, 81% had a ‘Probable’ or ‘Possible’ code
in primary care within 2 months (box 2a, figure 7.6). By comparison 62% of
the 30,176 primary care defined bleeds in box 1b had a ‘Probable’ or ‘Possible’
secondary care code within 2 months (box 2b, figure 7.6). Further details of
the timings of the closest ‘Possible’ or ‘Probable’ codes to the defining upper
gastrointestinal bleed code date are shown in tables 7.2 & 7.3.
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(1) 45472 Unique
acute upper GI bleed
admissions defined in
HES and/or GPRD
(1a) 26964, (59.3%)
Acute upper GI
bleed admissions
defined in HES
(1b) 30176, (66.4%)
Acute upper GI
bleed events de-
fined in GPRD
5129, (11.3%)
events excluded
with no probable
or possible Read
code within 2
months in GPRD
11485, (25.3%)
events excluded
with no probable
or possible ICD
10 code within 2
months in HES
(2a) 21835, (48%) HES
admissions with a
probable or possible
Read code within
2 months in GPRD
(2b) 18691, (41.1%)
GPRD events with a
probable or possible
ICD 10 code within
2 months in HES
3793, (8.3%)
events excluded
with no probable
code within 2
months in GPRD
2025, (4.5%)
events excluded
with no probable
code within 2
months in HES
(3a) 18042, (39.7%)
HES admissions
with a probable
Read code within
2 months in GPRD
(3b) 16666, (36.7%)
GPRD events with
a probable ICD
10 code within 2
months in HES
(4) 11668, (25.7%)
HES and GPRD de-
fined upper GI bleeds
Figure 7.6: Flowchart of Selection of GPRD Events Closest in Time to an Upper Gastrointestinal Bleed Admission Defined in
HES
Percentages shown are percentage of pool of combined unique events in box 1.
GPRD- General Practice Research Database; HES - Hospital Episodes Statistics; ICD 10 - International Classification of Diseases 10th
Edition; GI - Gastrointestinal; READ- Read code
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Table 7.2: Timing of probable or possible primary care events to secondary
care defined upper gastrointestinal bleed admissions
Time difference between hospital and primary care event:
Frequency Percentage Cumulative percentage
Exact match 17020 63.12 63.12
1 day prior or 1 week post 2004 7.43 70.55
2 weeks pre or post event 710 2.63 73.19
1 month pre or post event 1005 3.73 76.91
2 months pre or post event 1099 4.08 80.99
> 2 months or no associated code 5126 19.01 100.00
Total 26964 100.00
Table 7.3: Timing of probable or possible secondary care events to primary
care defined upper gastrointestinal bleed events
Time difference between hospital and primary care event:
Frequency Percentage Cumulative percentage
Exact match 15672 51.93 51.93
1 day prior or 1 week post 1352 4.48 56.41
2 weeks pre or post event 470 1.56 57.97
1 month pre or post event 615 2.04 60.01
2 months pre or post event 578 1.92 61.92
> 2 months or no associated code 11490 38.08 100.00
Total 30177 100.00
Incidence and 28 day all case fatality by case definition
Incidence was calculated for each of the pooled case definitions and these are
shown in table 7.4. Incidence followed a similar pattern by case definition to
the crude numbers in figure 7.6.
Pooled case definitions Incidence per 100,000 95% confidence interval
1a & 1b 224 (222-226)
2a & 2b 136 (134-138)
3a & 3b 114 (112-115)
4a & 4b 58 (57-59)
Table 7.4: Pooled incidence for each case definition per 100,000 person years.
(Pooled between GPRD defined cases and HES defined cases)
4,916 deaths were identified within 28 days of a bleed event using the linked
ONS death register. 28 day mortality was calculated for each of the different
case selections (figure 7.7). Secondary care defined events had almost twice
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(1) Unique acute
upper GI bleed
admissions defined in
HES and/or GPRD.
10.8% (10.5% - 11.1%)
Unique events from
combined datasets
(1a) Acute upper GI
bleed admissions
defined in HES.
13.1% (12.7% - 13.5%)
Unique events from HES
(1b) Acute upper
GI bleed events
defined in GPRD.
7.7% (7.4% - 8%)
Unique events from GPRD
(2) HES and GPRD
defined events
with a probable
or possible code.
10.3% (10% - 10.7%)
(2a) HES admissions
with a probable or
possible Read code
within 2 months
in GPRD. 11.6%
(11.1% - 12%)
(2b) GPRD events
with a probable
or possible ICD
10 code within 2
months in HES.
7.5% (7.1% - 7.9%)
(3) HES and GPRD
events with a
probable code within
2 months. 10.5%
(10.1% - 10.9%)
(3a) HES admissions
with a probable
Read code within 2
months in GPRD.
12.0% (11.6% - 12.5%)
(3b) GPRD events
with a probable
ICD 10 code within
2 months in HES.
7.2% (6.8% - 7.6%)
(4) HES and GPRD
defined upper
GI bleeds. 8.1%
(7.6% - 8.6%)
Figure 7.7: 28 Day Case Fatality of Different Definitions of Upper Gastrointestinal Bleed Events From HES and GPRD Linked
Data
Percentages shown with 95% Confidence Intervals
GPRD- General Practice Research Database; HES - Hospital Episodes Statistics; ICD 10 - International Classification of Diseases 10th
Edition; GI - Gastrointestinal; READ- Read code; PATID - Patient Identifier in GPRD
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the case fatality of primary care defined events; 13.1% compared to 7.7% (box
(1a) versus box (1b) in figure 7.7). Overall 28 day case fatality for all events
defined in either GPRD or HES was 10.8% (box (1)). Selecting events from the
combined datasets with an associated ‘Probable’ or ‘Possible’ code reduced the
28 day case fatality slightly (10.3%, box (2)) in figure 7.7). Restricting the events
to only those with a ‘Probable’ code had minimal effect on case fatality (10.5%,
box (3)) in figure 7.7). However further restricting events to those that were
defined by specific upper gastrointestinal haemorrhage codes in both primary
and secondary care was associated with a much lower case fatality (8.1%, box
(4) compared to 10.5%, box (3)) in figure 7.7).
7.3.5 Discussion
This study assessed the effect of different case definitions of upper gastroin-
testinal bleeding on its measured incidence and mortality in linked primary
and secondary care data. I used the record linkage between the world’s largest
hospital admissions database and one of the most commonly used primary care
databases from the UK. Cases defined only in hospital data were at twice the
risk of dying compared to those defined only in primary care data. Furthermore
I found that the most specific case definition, which was restricted to specific
bleed codes from both datasets, excluded severe cases and resulted in a lower
28 day case fatality. In contrast the more sensitive case definitions, using the
broader possible or probable code lists, retained the more severe cases and did
not reduce the overall case fatality. Therefore studies that are too restrictive in
their case definitions will fail to capture the full heterogeneity of coding that
follows complex or severe clinical events, and potentially introduce selection
bias.
Reassuringly I found that 81% of upper gastrointestinal bleed events coded in
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secondary care had a probable or possible record in primary care within two
months. However less than two thirds of upper gastrointestinal bleed events
coded in primary care were associated with a hospital admission within the
same timewindow. This seems to conflict with previous validation of the GPRD
using anonymised chart review in which upper gastrointestinal bleed coding
was found to have a positive predictive value of 99% (95 cases confirmed out of
96 cases assessed)100. This could represent the bias in assessing a small sample
of records from self selecting GP practices. Alternatively primary care could
potentially be recording sub acute bleeding episodes or symptoms that were
historical at the time of the consultation, and therefore these patients did not
require acute hospital admission. This is supported by the lower 28 day case
fatality in events defined in GPRD alone compared to those also defined in
HES. Coded bleeding events with no hospital admission were potentially inter-
esting to investigate but were not representative of the acute bleeds described
in studies of upper gastrointestinal bleeding management.141,163
One of the limitations of this study is that it is not permissible to validate in-
dividual records from the national HES database against the original clinical
chart records. However HES has been comparable with national gastrointesti-
nal bleed audits (chapter 4) and I believe that the linkage of GPRD and HES,
and the comparison presented in this chapter, provides a more comprehensive
and less biased assessment of the validity of the coding from both datasets than
from small sample validation, as all potential cases were assessed and com-
pared. Furthermore this linkage allows the comparison of coding by primary
care doctors against the coding by trained hospital personnel using secondary
care doctors’ notes, thereby supporting any resulting case definitions from two
separate and independent data sources.
There have been other databases linked for a range of purposes. However
many, like those based on Health Maintenance Organisations, are limited by in-
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complete or selected population coverage because they are not based on a com-
prehensive population based primary health care system.164,165 Scandinavian
linked databases are the most established,166,167 but they do not have the rich-
ness of the data collection in primary care that the GPRD offers, such as lifestyle
factors, practice and individual socioeconomic status, occupation status, diag-
noses, procedures, health promotion, referrals, and now the linkages with the
respective hospital admission data, national death register and specialist clini-
cal databases. Prior to the linkage of HES and GPRD it has only been possible
to compare these databases using aggregated measures,168 such as in chapter
4, however the record level linkage in this study avoids the ecological bias to
which aggregated comparisons are susceptible. The use of both primary and
secondary care has previously been shown to be beneficial in defining chronic
diseases such as diabetes,169,170 but primary care data had been found to have
a lower positive predictive value for acute events.171 My study supports this
finding for the acute event of upper gastrointestinal haemorrhage, and I pro-
pose that this issue can be addressed and improved upon by the use of linked
hospital data.
I initially began this investigation to develop specific case definitions that min-
imise misclassification bias on effect estimates when testing aetiological hy-
potheses.172 To achieve this I now intend to use a specific upper gastrointestinal
bleed code in one dataset with a probable or specific code in the linked dataset
(box 3a & 3b, figure 7.6). This will select the most plausible cases of acute upper
gastrointestinal haemorrhage without excluding severe cases (box 3, figure 7.7).
This definition will therefore be used to derive a cohort of upper gastrointesti-
nal bleed patients for the studies in the remainder of this PhD.
In contrast to an aetiological study, studies that estimate incidence require a
broader and more sensitive case definition to be sure of capturing all cases of
the disease in question.172 For incidence studies I therefore propose using all
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hospital defined cases with the addition of primary care defined cases that have
a plausibly coded hospital admission (figure 7.6, box (1a) and box (2b)). A sen-
sitivity analysis that also included the events defined only in primary care (box
1b) would then provide an upper estimate of bleed events in the population.
The previous studies in this PhD on trends in mortality and incidence in chap-
ters 5 & 6were performed before this linked datawas available. However based
on the study in this current chapter over 80% of cases identified in HES would
be expected to have a plausible code in primary care. The inclusion of primary
care defined cases that had a plausibly coded hospital admission would have
been expected to then identify an additional 12% of cases. The benefits in us-
ing this smaller linked dataset for investigating incidence and mortality trends
would have therefore been far outweighed by the larger size, information on
areas of residence, and the comprehensive national coverage of HES.
In this study I have been able to establish case definitions for upper gastroin-
testinal bleeding based on linked primary and secondary care data, and shown
that linked data can be used to avoid excluding severe events. I have shown
that hospital datawas invaluable in accurately identifying acute bleeding events
in primary care data that were severe enough to require hospital admission, and
the primary care introduced a wealth of long term diagnosis data and prescrip-
tion data to the secondary care data. In addition there was a close match in
timing in primary and secondary care between relevant codes for upper gas-
trointestinal haemorrhage. Finally I have shown that the choice of definition
in linked data has a clear effect on the mortality of the chosen population. My
methods may not be generalisable to the definition of chronic diseases in linked
databases, as chronic disease diagnoses are usually made in outpatient clinics
and primary care. However I believe my findings are likely to be generalisable
and relevant to other acute severe events, such as myocardial infarction or ve-
nous thromboembolism that are investigated, diagnosed, and managed during
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an acute hospital admission.
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8.1 Introduction
Helicobacter pylori infection, non steroidal anti inflammatorymedications (NSAIDs)
and aspirin are believed to be the main causes of non variceal upper gastroin-
testinal bleeding,173 and with the discovery of proton pump inhibitors (PPIs)
and Helicobacter pylori eradication therapy the burden of peptic ulcer disease
has been decreasing.139 Despite this upper gastrointestinal haemorrhage re-
mains the commonest acute medical admission for gastroenterology,2 and its
incidence in population based studies remains almost unchanged.160,174 This
suggests that other (previously unidentified) risk factors are contributing to its
population burden.
Although historically non gastrointestinal co-morbidity was believed to be as-
sociated with stress ulceration,175 this role of co-morbidity in the aetiology of
gastrointestinal bleeding is not now recognised apart from in extreme illness:
Sicker cirrhotic patients have an increased risk of variceal bleeding,176 and
sicker patients in intensive therapy units (ITU) have an increased risk of non
variceal bleeding.177 However outside of ITU, the effect of co-morbidity has
only been assessed indirectly as a confounder in studies that focussed on the ef-
fect of medications on gastrointestinal bleeds.103 Though these studies do sup-
port a role for co-morbidity they do not allow us to understand whether it is an
important contributor to the persisting burden of upper gastrointestinal bleed-
ing. However over the last decade, as the proportion of bleed patients with
co-morbidity has increased,160 it is plausible that this exposure to co-morbidity
could itself be responsible for the persisting incidence of bleeding.
I have therefore conducted a study aimed primarily at assessing whether co-
morbidity may have an important role in the aetiology of upper gastrointesti-
nal bleeding. To do this I have conducted a case control study and formed a
model fully corrected for known measured risk factors of upper gastrointesti-
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nal bleeding. I have then calculated the additional explanatory effect of adding
co-morbidity to my model.
8.2 Methods
8.2.1 Study design
A matched case control study.
8.2.2 Data
To provide the detailed longitudinal data and necessary power for this study I
have used the recently linked English Hospital Episodes Statistics (HES) data
andGeneral Practice ResearchDatabase (GPRD). Ethical approval for this study
was obtained from the Independent Scientific Advisory Committee for MHRA
database research. 51% of English practices in GPRD have consented to record
level linkage of their population to HES. This records all hospital admissions
from the defined primary care population between 1st April 1997 to 31st Au-
gust 2010.
8.2.3 Cases definition
All subjects with a specific code for non variceal upper gastrointestinal bleed in
either primary or secondary care were selected who also had a corresponding
code for a likely symptom, cause, therapy, investigation or outcome of upper
gastrointestinal haemorrhage in the linked dataset (chapter 7). Variceal bleeds
or non specific gastrointestinal bleed codes with either a lower gastrointestinal
diagnosis or procedure were excluded. Further exclusions were temporary pa-
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tients, children 15 years old and younger, cases with invalid date codes or cases
outside the ’up to research standard’ observed time periods. Patients were re-
quired to be registered with the primary care practice for at least 3 months prior
to an upper gastrointestinal bleed event to avoid including prevalent cases that
might have been coded at the initial registration consultation. Only the first
event for each patient was included. I have previously demonstrated that this
selection strategy minimises selection bias in studies of upper gastrointestinal
bleeding in these data.178 A secondary analysis was then stratified by whether
the specific bleed code or supporting code referred to a peptic ulcer (Read codes
J11.... to J14.... or ICD 10 codes K25.. to K28..). These codes had the highest
positive predictive values (>95%) for peptic ulcers and upper gastrointestinal
complications when validated in English primary care routine records.179
8.2.4 Matched Controls
Each case was age (+/- 5 years) and sex matched, without replacement, to 5
controls who were alive at the time of the gastrointestinal bleed and registered
to the same primary care practice. Controls were required to have been reg-
istered with the primary care practice for at least 3 months prior to the match
date to be consistent with the definition for cases.
8.2.5 Exposures
Potential final common causal pathways were defined a priori for; erosions &
ulceration, varices, angiodysplasia, fistula & trauma, and coagulopathy; and
code lists were derived for diagnoses and medications that might be associated
with each pathway based on published literature (figure 8.1, unlinked boxes
represent potential confounders).
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Figure 8.1: Risk factors for upper gastrointestinal haemorrhage
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Medication risk factors were included if there was a coded prescription within
the year prior to the admission. Exposures codedwithin 2 months of the admis-
sion date were excluded to avoid identifying events and prescriptions related
to the actual bleed event. Proton pump inhibitors (PPIs) were included as an
indicator of physicians’ judgement of the risk of upper gastrointestinal haem-
orrhage that was not captured by other measured risk factors. Alcohol con-
sumption was classified as either non drinker, alcohol mentioned, ex alcohol
dependency, alcohol excess, alcohol complications and missing. Smoking was
classified as never smoked, current smoker, ex smoker and missing. Although
patients with coded variceal bleeds were excluded, cirrhosis was included as
a risk factor as cirrhotic patients can have non variceal bleeds. Cirrhosis was
classified as uncomplicated, with varices, with ascites, or with encephalopathy
or liver failure coded. All other exposures were binary variables.
8.2.6 Co-morbidity
Co-morbidity was defined using the Charlson index.142 This is a well validated
weighted co-morbidity score that predicts 1 year mortality following hospital
discharge. Any codes used to define risk factors of upper gastrointestinal bleed-
ing in figure 8.1 were excluded when calculating the index, i.e. peptic ulcer and
cirrhosis codes. For clarity in reporting the index was summarised as no co-
morbidity, single co-morbidity, and multiple or severe co-morbidity.
8.2.7 Analysis
Unadjusted analysis
Unadjusted odds ratios were calculated for each exposure using conditional
logistic regression to allow for the matched study design.
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Multivariate analysis
Adjusted odds ratios for each exposure of interest were calculated with condi-
tional logistic regression adjusting for all exposures in addition to age, proton
pump inhibitor use and previous gastrointestinal procedures. As calendar year,
gender and primary care practice were precisely matched on, it was not neces-
sary to include them in the model. Co-morbidity was added last, and its asso-
ciation with bleeding tested using a likelihood ratio test. The variance inflation
factor (a measure of the increase in model variance due to correlation between
variables) was calculated for each exposure of interest to assess the effect of cor-
relation between variables. All exposures with a variance inflation factor over
5 were excluded from the final conditional logistic regression model.180 The fi-
nal model was then stratified into cases with a recording of peptic ulcer and
those without. All analysis was performed using Stata version 12 (StataCorp
LP, Texas).
Sequential (or ‘extra’) population attributable fractions
Sequential (or ‘extra’) population attributable fractions (PAF) were calculated
for each exposure, using the prevalence among the cases and the respective
coefficients from the conditional logistic regression model.181 Sequential pop-
ulation attributable fractions differ from the standard adjusted population at-
tributable fractions that are usually presented in papers. Sequential population
attributable fractions are calculated by estimating the additional proportion of
cases attributable to each exposure, after removing the proportion of cases al-
ready attributed to the combined effect of all remaining exposures in the model
(see algorithm 1). 95% confidence intervals for these estimates were obtained by
bootstrapping with 500 repetitions for each exposure.182 The final model was
then stratified into cases with a recording of peptic ulcer and those without.
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Algorithm 1 Adjusted sequential population attributable fractions
Exposure sets stratified by:
i =1....I Risk factors
j =1....J Levels of confounders
For each strata RRi|j & ρi,j are estimated:
RRi|j= stratum odds ratio for the effect of Xi|j compared to X0|j
ρi,j = Proportion of cases in each stratum exposed to Xi and level of
confounders j
Then the total PAF predicted for the model can be estimated:
PAFi|j = 1−
I
∑
i=1
J
∑
j=1
ρijRR
−1
i|j
Each risk factor i=I is alternately assigned as another level of the confound-
ing j,i=I .
The odds ratios for the remaining set of risk factors m =1...M are then
re-estimated:
(
XI|j ∈ Xi|j
)⋂ (
XI|j /∈ Xm|j
)
RRm|j,i=I = stratum odds ratio for the effect of Xm|j,i=I compared to X0|j,i=I
The extra or sequential PAF for each risk factor i is then calculated:
extraPAF1|j = PAFi|j − PAFm|j
The risk ratio is estimated by the odds ratio from the case control study
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Sensitivity analyses
Previous studies of risk factor medications such as NSAIDs87 have been con-
ducted in study populations that excluded patients with known risk factors
for gastrointestinal bleeding. To allow comparisons with these, I therefore re-
estimated the crude odds ratios for each of the risk factor medications after ex-
cluding any cases and their controls with non medication bleed risk factors. To
assess the effect the choice of the exposure time window around the bleed event
on the effect of NSAIDs we also re-estimated a model that included NSAID use
up to 30 days before the index date.
Two further sensitivity analyses were performed to assess the effect of poten-
tial under reporting. First the analysis was restricted to those over 65 years old,
who were eligible for free prescriptions, to assess the effect of potential under
reporting of non prescribed NSAID use. With regard to this ’over the counter
use’, non differential under reporting has been shown to reduce the measured
effect of prescribed medications.183 This in our study would cause an underes-
timate of the effect of NSAIDs. However in England certain groups receive free
prescriptions, such as patients over 65 years old or those with certain chronic
disease, and these groups have been shown to purchase far fewer medications
over the counter than those who have to pay for prescriptions.184,185 Therefore
restricting the analysis to patients over the age of 65 should reduce any con-
founding by ’over the counter use’.
Secondly, multiple imputation was used to re-estimate the association with co-
morbidity by imputing missing values for alcohol and smoking status. Alco-
hol and smoking were categorised as binary exposures of excess alcohol or
current smoking to fit the logistic regression imputation model. All previ-
ously extracted exposures were used in the imputation model with addition
of the socio-economic status, and 20 sets of imputations were calculated. Socio-
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economic status was measured by the Index of Multiple Deprivation quintiles
obtained from linked Office for National Statistics data.
Finally, to assess the effect of using the aggregated and weighted Charlson in-
dex, the model was re-estimated to assess the effect of the individual compo-
nent co-morbidities from the Charlson index.
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8.3 Results
8.3.1 Cases and matching
16,355 unique cases were identified with a first non variceal bleed; 13,372 with
specific code in HES, 10,938 with a specific code in GPRD, and 7,955 with a
specific code in both datasets. 99.7% (16,304) of the cases were matched to 5
controls each and only 8 cases (0.05%) were not matched to any controls. The
median observed time prior to admission for cases was 7.4 years (inter quartile
range 3.4-11.5) compared to 7.5 years (inter quartile range 3.5 - 11.5) for controls.
8.3.2 Unadjusted analysis
Table 8.1 shows the proportion of cases and controls with each exposure. The
proportion of cases with no co-morbidity recorded was lower than previously
found in HES cases (21% versus 46%, chapter 6), and this demonstrates the
benefit of the linked primary care data in providing a more detailed longitu-
dinal medical record than hospital admissions alone. As expected aspirin and
NSAIDs were the most frequently prescribed risk factor medications, and pep-
tic ulcer and gastritis/duodenitis/oesophagitis were the most frequent risk fac-
tor diagnoses. All a priori risk factors were associated with upper gastrointesti-
nal bleeding. Peptic ulcers were coded in 4,823 patients, 29% of cases, and the
exposures stratified by coding of peptic ulcer are shown in table 8.2.
8.3.3 Multivariate analysis and population attributable fractions
There was strong evidence for an association between the non gastrointestinal
Charlson index and upper gastrointestinal bleeding after adjusting for all mea-
sured risk factors (single co-morbidity adjusted OR 1.43 (1.35-1.52), multiple
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Table 8.1: Proportion of cases and controls exposed 2 months prior to bleed
date or match date
Controls (n) Percentage
exposed
Cases (n) Percentage
exposed
CHARLSON INDEX . . . .
No Co-morbidity 30194 37.0 3440 21.0
Single Co-morbidity 18714 22.9 3222 19.7
Multiple or Severe 32728 40.1 9693 59.3
GASTROINTESTINAL . . . .
Cirrhosis-none coded 81385 99.7 16004 97.9
Cirrhosis-only 65 0.1 63 0.4
Cirrhosis-Varices 62 0.1 65 0.4
Cirrhosis-Ascites 86 0.1 172 1.1
Cirrhosis-Encephalopathy 38 0.0 51 0.3
Gastritis, duodenitis or oesophagitis 7904 9.7 3051 18.7
Peptic Ulcer 3830 4.7 1852 11.3
H pylori 1964 2.4 609 3.7
Angiodysplasia 14 0.0 6 0.0
Mallory Weiss syndrome 34 0.0 96 0.6
Crohns disease 222 0.3 114 0.7
GI cancer 2494 3.1 1174 7.2
LIFESTYLE
Alcohol-Not coded 61536 75.4 11026 67.4
Alcohol-Non Drinker 1485 1.8 375 2.3
Alcohol-Ex Drinker 176 0.2 64 0.4
Alcohol-Mentioned 4317 5.3 977 6.0
Alcohol-Over limits 14073 17.2 3763 23.0
Alcohol-Complications 49 0.1 150 0.9
Smoking-Not coded 51751 63.4 9187 56.2
Smoking-Non Smoker 11666 14.3 2332 14.3
Smoking-Ex Smoker 4075 5.0 888 5.4
Smoking-Passive 5574 6.8 1455 8.9
Smoking-Current 8570 10.5 2493 15.2
MEDICATIONS
Aspirin 18079 22.1 5392 33.0
NSAIDs 12722 15.6 3820 23.4
COX II inhibitors 168.7 2.1 605 3.7
Clopidogrel 1297 1.6 668 4.1
Oral steroids 4135 5.1 1578 9.6
Anticoagulants 3799 4.7 1617 9.9
SSRIs 4813 5.9 2025 12.4
OTHER DIAGNOSES
Aortic stenosis 782 1.0 350 2.1
Repair of AAA 307 0.4 115 0.7
Dialysis 70 0.1 88 0.5
CONFOUNDERS
Upper GI procedure 10471 12.8 3438 21.0
PPI 10909 13.4 4585 28.0
Age (median and interquartile range) 72 57-81 73 57-82
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Table 8.2: Proportion of cases exposed 2 months prior to bleed date stratified
by coding of peptic ulcer
Peptic
ulcer coded
(frequency)
Percentage
exposed
No peptic
ulcer coded
(frequency)
Percentage
exposed
CHARLSON INDEX . . . .
No Co-morbidity 883 18.3 2557 22.2
Single Co-morbidity 916 19.0 2306 20.0
Multiple or Severe 3024 62.7 6669 57.8
GASTROINTESTINAL . . . .
Cirrhosis-none coded 4753 98.5 11251 97.6
Cirrhosis-only 17 0.4 46 0.4
Cirrhosis-Varices 8 0.2 57 0.5
Cirrhosis-Ascites 32 0.7 140 1.2
Cirrhosis-Encephalopathy 13 0.3 38 0.3
Gastritis, duodenitis or oesophagitis 710 14.7 2341 20.3
Peptic Ulcer 864 17.9 988 8.6
H pylori 162 3.4 447 3.9
Angiodysplasia 1 0.0 5 0.0
Mallory Weiss syndrome 11 0.2 85 0.7
Crohns disease 19 0.4 95 0.8
GI cancer 254 5.3 920 8.0
LIFESTYLE . . . .
Alcohol-Not coded 3299 68.4 7727 67.0
Alcohol-Non Drinker 97 2.0 278 2.4
Alcohol-Ex Drinker 20 0.4 44 0.4
Alcohol-Mentioned 284 5.9 693 6.0
Alcohol-Over limits 1105 22.9 2658 23.0
Alcohol-Complications 18 0.4 132 1.1
Smoking-Not coded 2753 57.1 6434 55.8
Smoking-Non Smoker 646 13.4 1686 14.6
Smoking-Ex Smoker 288 6.0 600 5.2
Smoking-Passive 405 8.4 1050 9.1
Smoking-Current 731 15.2 1762 15.3
MEDICATIONS . . . .
Aspirin 1831 38.0 3561 30.9
NSAIDs 1431 29.7 2467 21.4
COX II inhibitors 222 4.6 383 3.3
Clopidogrel 198 4.1 470 4.1
Oral steroids 428 8.9 1150 10.0
Anticoagulants 427 8.9 1190 10.3
SSRIs 460 9.5 1565 13.6
OTHER DIAGNOSES . . . .
Aortic stenosis 125 2.6 225 2.0
Repair of AAA 36 0.7 79 0.7
Dialysis 30 0.6 58 0.5
CONFOUNDERS . . . .
Previous upper GI procedure 817 16.9 2621 22.7
Previous PPI use 906 18.8 3679 31.9
Age (median and interquartile range) 75 64-83 72 54-82
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or severe co-morbidity adjusted OR 2.26 (2.14-2.38), p<0.0001 likelihood ratio
test). Table 8.3 shows the adjusted odds ratios and PAFs from the final model
for each exposure. The variables for angiodysplasia and dialysis had the high-
est variance inflation factors, 1.48 & 2.35 respectively. As both of these were
less than the a priori threshold of 5, all exposures were included in the final con-
ditional logistic regression model. Stratifying this model demonstrated similar
associations with co-morbidity whether or not peptic ulcer coding was present,
and slightly higher associations for a peptic ulcer with exposure previous pep-
tic ulcers, NSAID or aspirin use (table 8.4). Associations with other risk factors
were higher in the non peptic ulcer cohort.
The proportion of cases attributable in the population to the combined effect
of all available measured exposures was 48%, not including the effect of non
gastrointestinal co-morbidity. The additional proportion of cases attributable
to non gastrointestinal co-morbidity (or the sequential population attributable
fraction (PAF)) was 20%, and this was higher in magnitude than for any other
measured exposure (Table 8.5). The next largest PAFs were 3%, for aspirin and
NSAID use. The PAF for co-morbidity associated with peptic ulcer bleeds was
slightly lower than that for non ulcer bleeds (18 vrs 21%) with a higher contri-
bution from previous peptic ulcer bleeds and aspirin and NSAIDs (table 8.6). In
contrast, for non ulcer bleeds the SAFwas slightly increased for gastrointestinal
cancer, alcohol, anticoagulants and SSRIs.
8.3.4 Sensitivity analyses
The crude odds ratios were re-estimated for medications after excluding cases
with nonmedication risk factors and these are shown in table 8.7. NSAID use in
the main analysis was strongly associated with bleeding with an OR 1.67, and
this increased to 2.80 with the exclusion of non medication risk factors. The cor-
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Table 8.3: Final adjusted model with Charlson Index measuring co-
morbidity for non variceal upper gastrointestinal bleeding .
Adjusted OR Lower 95% CI Upper 95% CI
CHARLSON INDEX . . .
No Co-morbidity 1.00 1.00 1.00
Single Co-morbidity 1.43 1.35 1.52
Multiple or Severe 2.26 2.14 2.38
GASTROINTESTINAL
Cirrhosis-none 1.00 1.00 1.00
Cirrhosis-only 3.89 2.61 5.77
Cirrhosis-Varices 3.75 2.51 5.61
Cirrhosis-Ascites 5.96 4.46 7.96
Cirrhosis-Encephalopathy 5.05 3.14 8.10
Gastritis, duodenitis or oesophagitis 1.46 1.39 1.55
Peptic Ulcer 2.11 1.98 2.26
H pylori 0.96 0.86 1.07
Angiodysplasia 1.67 0.58 4.80
Mallory Weiss syndrome 12.39 8.16 18.82
Crohns disease 2.19 1.71 2.81
GI cancer 2.13 1.97 2.31
LIFESTYLE
Alcohol-Not 1.00 1.00 1.00
Alcohol-Non Drinker 1.25 1.10 1.42
Alcohol-Ex Drinker 1.39 1.01 1.92
Alcohol-Mentioned 1.05 0.96 1.14
Alcohol-Over limits 1.42 1.35 1.49
Alcohol-Complications 9.33 6.48 13.44
Smoking-Not 1.00 1.00 1.00
Smoking-Non Smoker 0.97 0.92 1.04
Smoking-Ex Smoker 0.94 0.86 1.02
Smoking-Passive 1.03 0.95 1.11
Smoking-Current 1.29 1.22 1.37
MEDICATIONS
Aspirin 1.50 1.43 1.57
NSAIDs 1.59 1.52 1.66
COX II inhibitors 1.52 1.37 1.69
Clopidogrel 1.74 1.57 1.94
Oral steroids 1.38 1.29 1.48
Anticoagulants 1.94 1.81 2.08
SSRIs 1.72 1.62 1.83
OTHER DIAGNOSES
Aortic stenosis 1.58 1.38 1.82
Repair of AAA 1.29 1.02 1.64
Dialysis 3.59 2.55 5.05
CONFOUNDERS
Upper GI procedure 1.10 1.04 1.15
PPI 1.59 1.52 1.67
age 1.09 1.08 1.10
(age, year, practice and gender matched)
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Table 8.4: Final adjusted model with Charlson Index measuring co-
morbidity for non variceal upper gastrointestinal bleeding strat-
ified by coding of peptic ulcer.
Peptic ulcer Non peptic ulcer
Adjusted
OR
Lower
95% CI
Upper
95% CI
Adjusted
OR
Lower
95% CI
Upper
95% CI
CHARLSON INDEX . . . . . .
No Co-morbidity 1.00 1.00 1.00 1.00 1.00 1.00
Single Co-morbidity 1.45 1.30 1.62 1.42 1.33 1.52
Multiple or Severe 2.28 2.06 2.52 2.27 2.13 2.42
GASTROINTESTINAL . . . . . .
Cirrhosis-none 1.00 1.00 1.00 1.00 1.00 1.00
Cirrhosis-only 3.98 2.03 7.80 3.80 2.30 6.27
Cirrhosis-Varices 2.33 0.92 5.94 4.15 2.63 6.54
Cirrhosis-Ascites 4.67 2.63 8.29 6.85 4.85 9.65
Cirrhosis-Encephalopathy 3.16 1.39 7.20 6.66 3.70 12.01
Gastritis, duodenitis or oesophagitis 1.22 1.10 1.36 1.58 1.48 1.68
Peptic Ulcer 4.36 3.92 4.85 1.37 1.25 1.49
H pylori 1.04 0.85 1.27 0.94 0.83 1.06
Angiodysplasia 1.71 0.16 18.64 1.49 0.44 5.00
Mallory Weiss syndrome 3.75 1.43 9.84 16.54 10.23 26.77
Crohns disease 1.18 0.68 2.05 2.65 1.99 3.54
GI cancer 1.45 1.23 1.69 2.45 2.23 2.70
LIFESTYLE . . . . . .
Alcohol-Not 1.00 1.00 1.00 1.00 1.00 1.00
Alcohol-Non Drinker 1.14 0.89 1.47 1.30 1.11 1.51
Alcohol-Ex Drinker 1.58 0.89 2.81 1.30 0.88 1.93
Alcohol-Mentioned 1.02 0.87 1.20 1.04 0.94 1.16
Alcohol-Over limits 1.34 1.22 1.47 1.45 1.36 1.54
Alcohol-Complications 3.88 1.70 8.87 11.85 7.76 18.10
Smoking-Not 1.00 1.00 1.00 1.00 1.00 1.00
Smoking-Non Smoker 0.99 0.88 1.11 0.96 0.90 1.04
Smoking-Ex Smoker 0.96 0.82 1.13 0.92 0.83 1.03
Smoking-Passive 0.95 0.82 1.09 1.06 0.97 1.16
Smoking-Current 1.35 1.21 1.51 1.28 1.19 1.37
MEDICATIONS . . . . . .
Aspirin 1.69 1.56 1.82 1.42 1.34 1.50
NSAIDs 2.21 2.04 2.39 1.37 1.29 1.45
COX II inhibitors 1.81 1.51 2.17 1.42 1.24 1.62
Clopidogrel 2.04 1.68 2.48 1.70 1.49 1.93
Oral steroids 1.31 1.16 1.49 1.40 1.29 1.51
Anticoagulants 1.67 1.47 1.90 2.10 1.94 2.28
SSRIs 1.47 1.30 1.66 1.84 1.71 1.97
OTHER DIAGNOSES . . . . . .
Aortic stenosis 1.79 1.41 2.26 1.46 1.23 1.75
Repair of AAA 1.33 0.87 2.04 1.27 0.95 1.68
Dialysis 5.56 2.95 10.48 2.92 1.94 4.41
CONFOUNDERS . . . . . .
Previous upper GI procedure 0.88 0.80 0.98 1.20 1.13 1.28
PPI 0.82 0.74 0.91 2.01 1.90 2.13
Age 1.10 1.08 1.11 1.09 1.08 1.10
(age, year, practice and gender matched)
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Table 8.5: Sequential Population Attributable Fractions (PAF) for each risk
factor for non variceal upper gastrointestinal haemorrhage.
Sequential Population Attributable Fractionsa,b (Percentages) 95% confidence intervals
NON GASTROINTESTINAL CO-MORBIDITY 19.80 18.43 21.18
GASTROINTESTINAL . . .
Cirrhosis 0.49 0.41 0.57
Gastritis, duodenitis or oesophagitis 1.98 1.66 2.30
Peptic Ulcer 2.05 1.81 2.28
Helicobacter pylori -0.04 -0.15 0.08
Angiodysplasia 0.01 -0.01 0.02
Mallory Weiss syndrome 0.29 0.22 0.37
Crohns disease 0.14 0.08 0.19
GI cancer 1.11 0.96 1.27
LIFESTYLE . . .
Alcohol use 2.89 2.39 3.39
Smoking 0.83 0.27 3.42
MEDICATIONS . . .
Aspirin 2.95 2.54 3.36
NSAIDs 3.07 2.72 3.42
COX II inhibitors 0.33 0.23 0.44
Clopidogrel 0.34 0.26 0.43
Oral steroids 0.59 0.44 0.74
Anticoagulants 1.19 1.04 1.35
SSRIs 1.58 1.36 1.80
OTHER DIAGNOSES . . .
Aortic stenosis 0.16 0.10 0.22
Repair of aorta 0.03 0.00 0.06
Dialysis 0.07 0.04 0.09
aAge, year, practice and gender matched and adjusted for PPI use, previous upper
gastrointestinal procedures and age. bThe estimate in each row are calculated separately
conditional on all the other variables in the model. They should therefore not be interpreted as
summing over the column to 100%. Sequential PAF estimates the additional proportion of non
variceal bleeding cases attributable to each risk factor after cases attributable to all the other
risk factors in the model have been removed.
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Table 8.6: Sequential Population Attributable Fractions (PAF) for each risk
factor for non variceal upper gastrointestinal haemorrhage strati-
fied by peptic ulcer coding.
Sequential Population Attributable Fractionsa,b (percentage) Peptic ulcer Non peptic ulcer
NON GASTROINTESTINAL CO-MORBIDITY 18.44 20.50
GASTROINTESTINAL . .
Cirrhosis 0.32 0.57
Gastritis, duodenitis or oesophagitis 0.69 2.74
Peptic Ulcer 5.31 0.69
Helicobacter pylori 0.05 -0.07
Angiodysplasia 0.01 0.00
Mallory Weiss syndrome 0.06 0.39
Crohns disease 0.02 0.19
GI cancer 0.35 1.48
LIFESTYLE . .
Alcohol use 1.93 3.30
Smoking 0.80 0.81
MEDICATIONS . .
Aspirin 3.99 2.42
NSAIDs 5.40 2.00
COX II inhibitors 0.47 0.28
Clopidogrel 0.38 0.35
Oral steroids 0.36 0.66
Anticoagulants 0.78 1.41
SSRIs 0.74 2.02
OTHER DIAGNOSES . .
Aortic stenosis 0.22 0.12
Repair of aorta 0.02 0.03
Dialysis 0.09 0.05
aAge, year, practice and gender matched and adjusted for PPI use, previous upper
gastrointestinal procedures and age. bThe estimate in each row are calculated separately
conditional on all the other variables in the model. They should therefore not be interpreted as
summing over the column to 100%. Sequential PAF estimates the additional proportion of non
variceal bleeding cases attributable to each risk factor after cases attributable to all the other
risk factors in the model have been removed.
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responding adjusted odds ratios associated with NSAIDs were 1.59 with non
medication risk factors included and 1.78 without. Altering the exposure win-
dow for NSAIDs to 30 days rather than 60 days prior before the bleed slightly
increased the effect of NSAIDS, but did not alter effect on the other results in-
cluding co-morbidity
Table 8.7: The association of medications with upper gastrointestinal bleed-
ing after excluding patients with non medication risk factors .
Crude OR Adjusted*
OR
Lower
95% CI
Upper
95%
CI
Aspirin 2.39 1.73 1.60 1.87
NSAIDs 2.80 1.78 1.64 1.93
COX II inhibitors 2.59 1.50 1.23 1.83
Clopidogrel 7.30 2.15 1.70 2.73
Oral steroids 1.23 1.23 1.08 1.41
Anticoagulants 4.83 2.26 1.99 2.57
SSRIs 2.78 1.52 1.34 1.71
(age, year, practice and gender matched)
*Adjusted for all other variables in table and in figure 8.1
Restricting the analysis to those over 65 years old increased the proportion of
cases attributable to the combined effect of all exposures from 48% to 63%, and
reduced the additional proportion of cases attributable to non gastrointestinal
co-morbidity from 19.8% to 16.1%. Re-estimating the model using multiple
imputation for missing alcohol and smoking status (modelled as binary expo-
sures), slightly reduced the PAF associated with co-morbidity from 22.9% to
22.4%. Restricting this multiple imputation sensitivity analysis to those older
than 65 years reduced the PAF associated with co-morbidity further to 18.7%.
Finally the full model was re-estimated for each component of the Charlson
index (table 8.8). The contribution of these individual co-morbidities was min-
imal in comparison to their combined weighted effect in the Charlson index in
the main analysis.
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Table 8.8: The adjusted association of the component co-morbidities of
Charlson index with non variceal bleeding
Cases exposed(%) OR* Lower
95%
CI
Upper
95%
CI
PAF*(%)
Myocardial Infarction 13.98 1.04 0.97 1.10 0.12
Congestive Cardiac Disease 19.90 1.49 1.41 1.58 1.95
Peripheral Vascular Disease 11.17 1.31 1.23 1.41 0.70
Cerebrovascular Disease 23.13 1.13 1.08 1.19 0.79
Dementia 8.98 1.40 1.30 1.50 1.00
Chronic Pulmonary Disease 31.80 1.11 1.06 1.16 1.10
Rheumatological Disease 10.13 1.06 0.99 1.13 0.17
Uncomplicated Diabetes 17.88 1.01 0.96 1.06 0.04
Hemiplegia 4.73 1.79 1.62 1.97 0.67
Renal Disease 14.42 1.71 1.61 1.82 1.74
Diabetes with Complications 12.30 1.00 0.94 1.06 -0.01
Any Malignancy 13.11 1.21 1.14 1.28 0.78
Lymphoproliferative disorders 2.21 1.95 1.70 2.24 0.43
Metastatic Solid Tumour 5.89 2.35 2.14 2.57 1.29
HIV / AIDS 0.06 0.69 0.31 1.55 -0.00
(year, practice and gender matched)
*Adjusted for all other variables in table and in figure 8.1
8.3.5 Regression diagnostics
Delta beta statistics were calculated and were all less than one. These mea-
sure the standardised change in the coefficients when that matched group was
deleted. This indicated that no individual matched group’s covariate pattern
was particularly influential on the estimated co-efficients. Outliers with influ-
ence on the overall model fit were estimated by delta chi-squared statistics val-
ues over 3. These measured the change in the overall chi-squared value for the
model with the deletion of eachmatched group. These outliers were found to be
patients with no recorded risk factors who nevertheless had a bleed event. Ex-
cluding these patients (about 10%) from the model obviously improved its pre-
dictive ability and increased the association of serious or multiple co-morbidity
with bleeding to an odds ratio of 3. However these exclusions were judged as
inappropriate as the resulting estimates would no longer represent the study
population. This was a useful reminder that there remain further unmeasured
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risk factors in the population not included in this study.
8.4 Discussion
This study has demonstrated that a combined measure of non gastrointestinal
co-morbidity is a significant independent predictor of upper gastrointestinal
bleeding, even after accounting for all other recognised and measured risk fac-
tors. Furthermore it explained a greater proportion of the burden of bleeding
than any other risk factor in the population. The effect of this combined mea-
sure of non gastrointestinal co-morbidity was far in excess of that which would
be expected from its constituent diseases.
The association of co-morbidities with upper gastrointestinal bleeding has been
studied previously, but only in smaller secondary care surveyswith co-morbidity
as a confounder and not as the primary exposure. I searched PubMed using
variants of co-morbidity, aetiology, causality, risk factors and gastrointestinal
haemorrhage, however no studies were identified that set out to address the
question of this chapter. Studies were most frequently designed to measure
the association of a single medication whilst adjusting for any confounding by
co-morbidity.98,99 Two assessed a larger range of medications in cross sectional
hospital based surveys.80,103 However peptic ulcer disease was included in the
measure of overall co-morbidity in the latter study and in the former study the
authors used an unmatched analysis on matched data, incorrectly summed the
adjusted population attributable fractions and assumed the remaining propor-
tion were due to ‘unmeasured factors’. Other studies assessed higher alcohol
intake,111 Helicobacter pylori,81 smoking,114 acute renal failure,109 and acute
myocardial infarction107 and found associations with upper gastrointestinal
bleeding. However these studies were in small selected hospitalised cohorts
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(n<1000 bleeds) with limited assessments of individual co-morbidity and no
measure of their population attributable fractions.
My study has a number of important strengths when compared to these previ-
ous works because I set out specifically to assess the degree to which non gas-
trointestinal co-morbidity predicts non variceal upper gastrointestinal bleed-
ing after removing the effects of all the available known risk factors in a much
larger general population. My method of defining cases and exposures utilised
information from both primary and secondary care, maximising the evidence
supporting each case whilst not excluding severe events.178 Furthermore due to
the comprehensive coverage of the English primary care system my study’s re-
sults are likely to be generalisable to the whole English population and further
afield. Consequently I was able to estimate the additional attributable fraction
for co-morbidity in the English population that was not already attributable to
other risk factors.181
However I need to consider other explanations for my observed association of
co-morbidity with upper gastrointestinal bleeding. A potential weakness of my
study is the inevitable imperfect data on some recognised risk factors which
may have caused us to underestimate their importance. The GPRD contains
comprehensive recording of all available diagnoses and prescriptions. How-
ever underreporting is likely to have occurred for Helicobacter pylori infec-
tion, NSAID use, alcohol and smoking. In the case of Helicobacter pylori there
was inevitably under-reporting since there was no population screening. How-
ever if the underreporting of Helicobacter pylori infection were to explain my
study’s findings it would have to be strongly associated with co-morbidity and
the evidence for this is conflicting and underpowered.186,187 Furthermore in
studies of ischaemic heart disease, for which there is the largest body of evi-
dence, any significant association with Helicobacter pylori was minimal after
adjustments for confounding.188 In my study the apparent protective effect of
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recognised Helicobacter pylori after adjustments for confounding was not sur-
prising, since Helicobacter pylori will have been eradicated when found.
NSAID usemight also have been underreported as NSAIDs can be bought from
a pharmacy without a prescription, potentially explaining the low association
between NSAIDs and bleeding in my study compared to a previous meta anal-
ysis.87 However the studies used in this particular meta analysis excluded pa-
tients with other known gastrointestinal bleeding risk factors, and when I made
the same exclusions in my study the association of bleeding with NSAIDs in-
creased and became comparable to the figures in the literature. Furthermore
although the association with co-morbidity reduced when I restricted my anal-
ysis to those over 65 (who were less likely to buy their own medications due
to free prescriptions), it was not to the extent needed to explain my findings.
Indeed part of this reduction was merely due to the increase in other risk fac-
tors seen with age. Finally alcohol and smoking status had missing data, but
there was only a minimal effect on the PAF of co-morbidity when missing data
was imputed conditional on all available data and socioeconomic status. The
assumption in the sensitivity analysis that the data was ’missing at random’,
conditional on the available information, might have been incorrect. However
as the addition of alcohol and smoking did not alter the association with co-
morbidity after adjusting for the other risk factors, the effect of this data being
’missing not at random’ will have been minimal.
I believe potential under reporting of exposures therefore does not explain the
association that I have found between upper gastrointestinal bleeding and a
general measure of co-morbidity. This suggests that co-morbidity itself or other
factors not included in my study that are associated with co-morbidity might
be causing the association. It is possible that other medications not included
in the study were responsible for some of this association, however we are not
aware of any additional prescribed or non prescribed medication that would
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fulfil the requirements of common usage and a strong association with bleed-
ing. Historically non gastrointestinal co-morbidity itself was commonly recog-
nised as a risk factor for upper gastrointestinal bleeding.175 However this con-
cept of stress ulceration is no longer accepted and is only recognised in patients
on ITU exposed to severe acute physiological stresses from ventilation, coagu-
lopathy, liver failure, renal failure, septic shock or nutritional support.177 The
stresses from chronic co-morbidities in our study are unlikely to be as severe
as on ITU, and therefore what we are describing is likely to have a different
mechanism to that seen in stress ulceration as it is currently recognised. Many
potential mechanisms can be hypothesised; for example reduced epithelial mi-
croperfusion in cardiac failure,189 decreased oxygen levels in chronic obstruc-
tive pulmonary disease,190,191 the poor nutritional status in many diseases, or
the platelet and clotting dysfunction in end stage renal failure.109,192 However it
is unlikely that there is a single mechanism that accounts for the association we
found but rather that multiple illnesses and mechanisms have a cumulative ef-
fect, as shown by the graded effect of the Charlson index and by table 6 where
no individual disease accounted for the magnitude of the overall association
with co-morbidity.
My findings contrast with current beliefs that the main burden of bleeding in
the general population comes from known iatrogenic causes, such as NSAIDs
prescribed for analgesia or anti-platelet agents prescribed for cardiac and cere-
brovascular disease,193 and that this burden would be reduced by increasing
PPI use.194 I have demonstrated that the extra contribution of thesemedications
to bleeding cases was not large after considering the contributions of other risk
factors present in the population. Therefore simply increasing PPI prescrip-
tions in patients on high risk medications may not have as large an impact as
previously thought. In contrast, the largest measurable burden of upper gas-
trointestinal haemorrhage in this studywas clearly attributable to co-morbidity.
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Although this might be interpreted as a reason for the incidence of bleeding to
remain stubbornly high in an ageing population necessitating increased gas-
troenterology services, it alternatively suggests that focusing preventative ef-
forts on those with co-morbid disease might provide greater gains.
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9.1 Introduction
The causes of excess deaths following an acute medical event can demonstrate
areas where mortality can be improved. For example three quarters of deaths
following a myocardial infarction were due to the cardiovascular disease itself,
but after a stroke, two fifths of deaths were due to related respiratory infections
and cardiovascular disease.195,196 In contrast, the long term outcomes of upper
gastrointestinal haemorrhage are poorly understood, despite it being the most
frequent gastroenterology admission to acute medicine. There has rightly been
a focus on the high mortality in the first 30 days of which 60-80%was attributed
to co-morbidity.121,122 However these were uncontrolled studies of hospital de-
rived peptic ulcer bleed cohorts and they did not assess whether the deaths
were in excess of those expected from a comparable group without bleeding.
Controlled studies have been limited to 2 peptic ulcer cohorts from the early
1990s with fewer than 150 deaths.9,10 These showed an excess mortality un-
related to the bleeding event itself but the studies disagreed on which causes
of death were increased. Other studies were not population based,126 or were
so long ago as to be mostly irrelevant with respect to current management of
bleeding.197 On this point an increasing proportion of non variceal bleeds over
the last 2 decades do not have underlying peptic ulcers, thereby reducing the
relevance of these previous cause of death studies to current clinical practice.198
Therefore to identify where interventions might reduce mortality following an
upper gastrointestinal non variceal bleed I have investigated the causes of death
by age and time in the 5 years following a non variceal bleed, and compared
them with deaths in a matched sample of the general population.
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9.2 Methods
9.2.1 Data
To provide the detailed longitudinal data and necessary power for this study I
have used the recently linked English Hospital Episodes Statistics (HES) data,
General Practice Research Database (GPRD) and Office for National Statistics
death register described in chapter 7. Ethical approval for this study was ob-
tained from the Independent Scientific Advisory Committee forMHRAdatabase
research.
9.2.2 Cohort
Population
I selected as exposed all patients with a first non variceal upper gastrointesti-
nal bleed. A bleed was defined by a specific code for an upper gastrointestinal
non variceal bleed in either primary or secondary care who had a supporting
code in the linked dataset (see chapter 7).178 All patients in the study therefore
had a hospital admission at the time of their bleed, reflecting national guide-
lines at the time of the study.148 Variceal bleeds or non specific gastrointestinal
bleed codes with either a lower gastrointestinal diagnosis or procedure were
excluded. Further exclusions were temporary patients, children under 16 years
old, cases with invalid date codes or cases outside the up to research standard
observed time periods. Patients were required to be registeredwith the primary
care practice for at least 3 months prior to an upper gastrointestinal bleed event
to avoid including prevalent cases that might have been coded at the initial
registration consultation. Follow up started on the day of the first bleed.
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Comparison group
For each case five age (+/−5 years) and sex matched controls were selected
who were alive at the time of the bleed and registered to the same general
practice. Controls were required to have been registered with the primary care
practice for at least 3 months prior to the match date to be consistent with the
definition for cases. These were the same controls used in chapter 8.
Causes of death
Dates of death for the whole cohort were extracted from the linked data using
the Office of National Statistics death register. All deaths in England are coded
and recorded in the Office of National Statistics Death register from death cer-
tificates using the WHO guidelines.199 These define causes of death by ICD 10
codes with the main underlying cause established for each death using stan-
dardised rules. For this study I analysed the underlying cause of death by the
4 most frequent ICD 10 chapter headings of Neoplasms (ICD chapters C & D),
Circulatory (ICD chapter I : including cerebrovascular and ischaemic heart dis-
ease), Respiratory (ICD chapter J), Digestive disease (ICD chapter K) and the re-
maining less frequent chapter headings grouped together in an “Other causes”
category. Neoplasms were further subdivided between upper gastrointestinal
malignancies and other neoplasms. Causes of death prior to 2001 were coded
under the ICD 9 classification in the Office of National Statistics death register
and were therefore assigned to the relevant ICD 10 chapter headings.
Follow up
Patients were followed up from the date of gastrointestinal bleed or matching
until either death or censoring of the patient record (defined as the earliest of the
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end of registration with GPRD practice, end of practice data, or the end of the
linked Office of National Statistics data linkage (31st December 2010)). Follow
up did not stop if a subsequent bleed occurred, but continued until death or
censoring of the patient record.
9.2.3 Analysis
Crude mortality rates
Crude numbers of deaths and rates per 1000 person years following upper gas-
trointestinal bleed were calculated overall and by the most frequent ICD 10
chapter headings. These rates were then stratified by age group and year post
bleed. Age was grouped into <50, 50-59, 60-69, 70-79, and ≥80 years old. The
time post bleed was stratified into the first 30 days, 1 month to 1 year, and 1
year to 5 years.
Adjusted analysis
Crude mortality rates are calculated for those still alive and at risk at each time
point. However, when studying specific causes of death, this group of survivors
might not be representative of the initial cohort, since deaths from other causes
can select out those with relevant risk factors. One method to adjust for this
bias uses cumulative incidence functions (CIF) that calculate the probability of
overall survival from all causes, combined with the instantaneous hazard of
death for each specific cause (see algorithm 2).200 CIF were therefore calculated
for each cause of death using baseline survival functions and hazard ratios from
Cox proportional hazards modelling. The models were stratified by age group,
adjusted for gender, and split at 1 month, 1 year, 3 years and 5 years. The
excess risk was calculated as the difference between the CIF for cases exposed
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to a bleed and the CIF for unexposed controls. 95% confidence intervals were
derived by bootstrapping (500 iterations). All analysis was performed using
Stata version 12 (StataCorp LP, Texas).
Algorithm 2Cumulative incidence function (CIF) adjusting for competing risks
CIF at timei=I for cause of deathj=J = survival from all causes to timei=I−1 *
hazard of death from causej=J at timei=I
=
i
∑
0
{
i=I−1
∏
0
(
1−
j
∑
1
(baseline hazard(i,j).HR(i,j))
)
.(baseline hazard(i=I,j=J).HR(i=I,j=J))
}
HR= Hazard Ratio
Sensitivity analyses
I assessed whether the excess mortality associated with a bleed for each cause
of death was confounded by pre-existing co-morbidity, excess alcohol, or smok-
ing status, and whether it varied by the site of bleed. Pre-existing co-morbidity
was measured by the Charlson index (a weighted co-morbidity score predict-
ing one year mortality142) using both hospital and primary care records prior
to 2 months before the bleeding episode. Smoking status was defined as a cur-
rent smoker, and excess alcohol status as excess alcohol use or alcohol related
complications. Site of bleed was categorised as oesophageal, gastric, duodenal
or unspecified.
9.3 Results
16,355 unique people who had a non variceal upper gastrointestinal bleed were
identified in the linked primary and secondary care dataset with 6242 subse-
quent deaths. 8 cases (0.05%) could not be matched to controls and were there-
fore excluded from the study. Baseline demographics are shown for the bleed
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cases and the matched controls in table 9.1 along with the numbers of deaths
for each of the ICD 10 chapter headings. For clarity of presentation in the re-
mainder of the results, deaths not attributed to one of the most frequent ICD
10 chapter headings were grouped together as “Other causes”. The overall me-
dian follow up time from index date was 3.2 years (interquartile range 0.4 - 5.2),
and for those who were censored without death was 4.8 years .
Table 9.1: Numbers, deaths and follow up time by exposure to upper gas-
trointestinal bleeding within 5 years of bleeding
Exposed % Unexposed %
COHORT (N) 16355 . 81523 .
Deaths 6424 . 11643 .
Personyears 40137 . 274043 .
GENDER (N = PATIENTS) . . . .
Male 8800 53.8 43836 53.8
Female 7555 46.2 37687 46.2
AGE (N = PATIENTS) . . . .
<60 years 4698 28.7 24009 29.5
60-69 years 2512 15.4 13223 16.2
70-79 years 4178 25.5 22110 27.1
≥80 years 4967 30.4 22181 27.2
NUMBER (& %) OF DEATHS . . . .
Neoplasms 1948 30.3 2615 22.5
Circulatory 1704 26.5 4443 38.2
Digestive 1042 16.2 390 3.3
Respiratory 787 12.3 1724 14.8
Genitourinary 138 2.1 265 2.3
Psychiatric 119 1.9 398 3.4
Neurological 110 1.7 321 2.8
Infections 99 1.5 122 1.0
External 88 1.4 228 2.0
Symptoms 80 1.2 346 3.0
Endocrine 77 1.2 158 1.4
Musculoskeletal 49 0.8 95 0.8
Dermatological 27 0.4 35 0.3
Haematological 26 0.4 19 0.2
Poisoning 13 0.2 9 0.1
Congenital 6 0.1 6 0.1
Unassigned code 7 0.1 7 0.1
Uncoded 104 1.6 462 4.0
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9.3.1 Crude mortality rates
The crude mortality rate in the first 5 years following an upper gastrointesti-
nal bleed was 16.0 per 100 person years, 95% confidence interval 15.6 - 16.4.
This changed over time from 35.7 deaths per 100 person years (95% confidence
interval 34.7- 36.8) in the first year to 7.3 deaths per 100 person years (95% confi-
dence interval 7.0- 7.7) over the subsequent 4 years. The rates and risk of death
were 10-15% lower for women than men, but the relative differences between
causes of death were similar. Therefore table 9.2 shows the numbers of deaths
and crude rates by ICD 10 category stratified by time post bleed. In the first
month after a bleed the mortality rate was increased for all causes of death, but
the highest mortality rate was from nonmalignant digestive disease (48 per 100
person years), and this was mostly due to causes related to the upper gastroin-
testinal tract (35 per 100 person years). For the remainder of the first year the
highest mortality rates were from neoplasms (8.4 per 100 person years), half of
which were from sites outside the gastrointestinal tract. Circulatory and res-
piratory mortality rates were also increased over the first year, but to a lesser
extent than for digestive disease and neoplasms. However by 5 years the cate-
gory with the highest mortality rate was circulatory disease (2.5 per 100 person
years).
Table 9.3 shows the crude rates by cause of death by different age groups. The
mortality rates for each of the causes of death increased with age except for the
mortality rate from liver disease, which decreased with age. The highest mor-
tality rate in the younger age groupswas from neoplasms and digestive disease,
whereas in older age groups the highest mortality rates were from circulatory
disease, comprisingmainly of ischaemic heart disease (3.2 per 100 person years)
and cerebrovascular disease (3.3 per 100 person years).
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Table 9.2: Mortality rate per 100 person years, stratified by cause of death by ICD 10 headings in the 5 years post bleed.
1st month
deaths (n)
Rate 95% CI 1 month
to 1 year
deaths (n)
Rate 95% CI 1 year to
5 years
deaths (n)
Rate 95% CI
Neoplasms 521 41.3 (37.9-45.0) 920 8.4 (7.8-8.9) 507 1.8 (1.7-2.0)
Oesophagus 85 6.7 (5.5-8.3) 151 1.4 (1.2-1.6) 53 0.2 (0.1-0.2)
Stomach 61 4.8 (3.8-6.2) 152 1.4 (1.2-1.6) 52 0.2 (0.1-0.2)
Colon 21 1.7 (1.1-2.6) 37 0.3 (0.2-0.5) 35 0.1 (0.1-0.2)
Pancreas 37 2.9 (2.1-4.1) 66 0.6 (0.5-0.8) 19 0.1 (0.0-0.1)
Digestive(other) 39 3.1 (2.3-4.2) 58 0.5 (0.4-0.7) 46 0.2 (0.1-0.2)
Respiratory 50 4.0 (3.0-5.2) 88 0.8 (0.6-1.0) 75 0.3 (0.2-0.3)
Skin or Bone 12 1.0 (0.5-1.7) 18 0.2 (0.1-0.3) 9 0.0 (0.0-0.1)
Breast 28 2.2 (1.5-3.2) 27 0.2 (0.2-0.4) 21 0.1 (0.0-0.1)
Prostate 34 2.7 (1.9-3.8) 55 0.5 (0.4-0.7) 43 0.2 (0.1-0.2)
Circulatory 378 30.0 (27.1-33.2) 621 5.6 (5.2-6.1) 705 2.5 (2.3-2.7)
IHD 134 10.6 (9.0-12.6) 209 1.9 (1.7-2.2) 292 1.0 (0.9-1.2)
Pulmonary circulatory disease 20 1.6 (1.0-2.5) 12 0.1 (0.1-0.2) 16 0.1 (0.0-0.1)
Heart - other 50 4.0 (3.0-5.2) 104 0.9 (0.8-1.1) 113 0.4 (0.3-0.5)
CVA 83 6.6 (5.3-8.2) 197 1.8 (1.6-2.1) 197 0.7 (0.6-0.8)
Respiratory 189 15.0 (13.0-17.3) 302 2.7 (2.5-3.1) 296 1.1 (0.9-1.2)
Respiratory infections 86 6.8 (5.5-8.4) 130 1.2 (1.0-1.4) 119 0.4 (0.4-0.5)
Chronic Airway disease 48 3.8 (2.9-5.1) 71 0.6 (0.5-0.8) 108 0.4 (0.3-0.5)
ILD 16 1.3 (0.8-2.1) 23 0.2 (0.1-0.3) 22 0.1 (0.1-0.1)
Digestive 608 48.2 (44.6-52.2) 258 2.3 (2.1-2.7) 176 0.6 (0.5-0.7)
Upper GI 436 34.6 (31.5-38.0) 96 0.9 (0.7-1.1) 43 0.2 (0.1-0.2)
Lower GI 80 6.3 (5.1-7.9) 52 0.5 (0.4-0.6) 51 0.2 (0.1-0.2)
Liver or gallbladder 82 6.5 (5.2-8.1) 100 0.9 (0.7-1.1) 74 0.3 (0.2-0.3)
Pancreas 6 0.5 (0.2-1.1) 8 0.1 (0.0-0.1) 8 0.0 (0.0-0.1)
Other 171 13.6 (11.7-15.8) 329 3.0 (2.7-3.3) 339 1.2 (1.1-1.4)
Uncoded 45 3.6 (2.7-4.8) 38 0.3 (0.3-0.5) 21 0.1 (0.0-0.1)
Total 1912 151.7 (145.1-158.7) 2468 22.4 (21.6-23.4) 2044 7.3 (7.0-7.7)
Rows containing cells with 5 or less events are not shown.
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Table 9.3: Mortality rate per 100 person years, stratified by cause of death by ICD 10 headings and age group in the 5 years post
bleed.
≤60
yrs
deaths
(n)
Rate 95% CI 60-69
yrs
deaths
(n)
Rate 95% CI 70-79
yrs
deaths
(n)
Rate 95% CI ≥80
yrs
deaths
(n)
Rate 95% CI
Neoplasms 158 1.1 (0.9-1.3) 296 4.5 (4.0-5.0) 487 4.8 (4.4-5.2) 486 6.4 (5.9-7.0)
Oesophagus 21 0.1 (0.1-0.2) 55 0.8 (0.6-1.1) 73 0.7 (0.6-0.9) 55 0.7 (0.6-0.9)
Stomach 20 0.1 (0.1-0.2) 37 0.6 (0.4-0.8) 74 0.7 (0.6-0.9) 73 1.0 (0.8-1.2)
Colon 7 0.0 (0.0-0.1) 9 0.1 (0.1-0.3) 23 0.2 (0.1-0.3) 33 0.4 (0.3-0.6)
Pancreas 9 0.1 (0.0-0.1) 27 0.4 (0.3-0.6) 26 0.3 (0.2-0.4) 23 0.3 (0.2-0.5)
Digestive(other) 17 0.1 (0.1-0.2) 21 0.3 (0.2-0.5) 32 0.3 (0.2-0.4) 34 0.4 (0.3-0.6)
Respiratory 16 0.1 (0.1-0.2) 37 0.6 (0.4-0.8) 65 0.6 (0.5-0.8) 45 0.6 (0.4-0.8)
Breast 8 0.1 (0.0-0.1) 13 0.2 (0.1-0.3) 14 0.1 (0.1-0.2) 13 0.2 (0.1-0.3)
Circulatory 68 0.5 (0.4-0.6) 135 2.0 (1.7-2.4) 388 3.8 (3.4-4.2) 735 9.7 (9.0-10.4)
IHD 33 0.2 (0.2-0.3) 58 0.9 (0.7-1.1) 165 1.6 (1.4-1.9) 245 3.2 (2.9-3.7)
Heart - other 13 0.1 (0.1-0.2) 21 0.3 (0.2-0.5) 46 0.4 (0.3-0.6) 137 1.8 (1.5-2.1)
CVA 12 0.1 (0.0-0.1) 30 0.5 (0.3-0.6) 99 1.0 (0.8-1.2) 253 3.3 (3.0-3.8)
Respiratory 28 0.2 (0.1-0.3) 54 0.8 (0.6-1.1) 176 1.7 (1.5-2.0) 340 4.5 (4.0-5.0)
Respiratory infections 11 0.1 (0.0-0.1) 10 0.2 (0.1-0.3) 57 0.6 (0.4-0.7) 171 2.3 (1.9-2.6)
Chronic Airway disease 10 0.1 (0.0-0.1) 31 0.5 (0.3-0.7) 76 0.7 (0.6-0.9) 62 0.8 (0.6-1.0)
Digestive 120 0.8 (0.7-1.0) 59 0.9 (0.7-1.1) 106 1.0 (0.9-1.3) 149 2.0 (1.7-2.3)
Upper GI 11 0.1 (0.0-0.1) 8 0.1 (0.1-0.2) 43 0.4 (0.3-0.6) 77 1.0 (0.8-1.3)
Lower GI 11 0.1 (0.0-0.1) 9 0.1 (0.1-0.3) 34 0.3 (0.2-0.5) 49 0.6 (0.5-0.9)
Liver or gallbladder 95 0.7 (0.5-0.8) 36 0.5 (0.4-0.8) 24 0.2 (0.2-0.3) 19 0.3 (0.2-0.4)
Other 91 0.6 (0.5-0.8) 53 0.8 (0.6-1.0) 181 1.8 (1.5-2.0) 343 4.5 (4.1-5.0)
Uncoded 7 0.0 (0.0-0.1) 13 0.2 (0.1-0.3) 9 0.1 (0.0-0.2) 30 0.4 (0.3-0.6)
Total 472 3.3 (3.0-3.6) 610 9.2 (8.5-9.9) 1347 13.2 (12.5-13.9) 2083 27.5 (26.3-28.7)
1st year excluded. Rows containing cells with 5 or less events are not shown.
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9.3.2 Adjusted analysis
The graphs in the lefthand columns of figures 9.1- 9.5 show the cumulative in-
cidence functions unadjusted for competing risks for the most frequent causes
of death by ICD 10 chapter headings stratified by age group. These can be seen
to be increasingly overestimating the risks of death with increasing age, and
therefore mortality, when compared with the graphs in panels (a). The graphs
in panels (a) show the absolute cumulative risk (CIF) now appropriately ad-
justed for competing risks. By 5 years after an upper gastrointestinal bleed
the cumulative risk of death due to malignant or non malignant gastrointesti-
nal causes ranged from 3.7% (≤50 years) to 14.8% (≥80 years). In contrast the
cumulative risk of death due to non gastrointestinal causes ranged from 4.2%
(≤50 years) to 46.7% (≥80 years) by 5 years following an upper gastrointestinal
bleed.
The graphs in panels (b) of figures 9.1 - 9.5 show the excess risk of death (or
excess CIF) associated with a bleed adjusted for competing risks. Overall there
was an absolute excess risk of death of 26% compared to matched controls and
this peaked in the 70 to 79 year old age group. The excess cumulative risk of
death due to malignant or non malignant gastrointestinal causes ranged from
3.7% (≤50 years) to 13.0% (≥80 years). In contrast the excess cumulative risk of
death due to non gastrointestinal causes ranged from 3.9% (≤50 years) to 19.1%
(≥80 years). Therefore over half the excess cumulative risk of death was due to
non gastrointestinal causes of death. Table 9.4 shows that the 95% confidence
intervals for the excess CIF values exclude the null for all causes of death apart
from respiratory disease (which was limited by small numbers).
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Figure 9.1: Cumulative incidence functions and excess mortality following non variceal bleeding: ≤50 years.
143
C
H
A
P
T
E
R
9
:
C
A
U
S
E
S
O
F
E
X
C
E
S
S
L
O
N
G
T
E
R
M
M
O
R
T
A
L
IT
Y
:
R
esu
lts
Figure 9.2: Cumulative incidence functions and excess mortality following non variceal bleeding: 50-59 years.
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Figure 9.3: Cumulative incidence functions and excess mortality following non variceal bleeding: 60-69 years.
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Figure 9.4: Cumulative incidence functions and excess mortality following non variceal bleeding: 70-79 years.
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Figure 9.5: Cumulative incidence functions and excess mortality following non variceal bleeding: ≥ 80 years.
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Table 9.4: Excess cumulative incidence function post bleed by time post
bleed.
95% confidence intervals obtained by bootstrapping (500 iterations).
1 month 1 year 5 years
eCIF (95% CI) eCIF (95% CI) eCIF (95% CI)
Upper GI Neoplasms ≤ 50 years 0.11 (-0.00-0.22) 0.43 (0.22-0.64) 0.61 (0.33-0.89)
50-59 years 1.15 (-0.30-2.59) 3.11 (1.53-4.68) 3.62 (2.02-5.22)
60-69 years 1.76 (-0.35-3.87) 5.58 (3.33-7.82) 6.58 (4.28-8.89)
70-79 years 1.47 (-0.28-3.21) 4.76 (2.91-6.61) 5.65 (3.70-7.59)
≥ 80 years 1.20 (-0.12-2.52) 3.83 (2.35-5.31) 4.41 (2.79-6.03)
Other Neoplasms ≤ 50 years 0.51 (0.27-0.75) 1.00 (0.64-1.36) 1.29 (0.86-1.72)
(Not Upper GI) 50-59 years 1.45 (0.93-1.96) 3.45 (2.63-4.27) 4.17 (3.17-5.18)
60-69 years 2.39 (1.83-2.96) 5.65 (4.54-6.75) 6.64 (5.22-8.06)
70-79 years 1.82 (1.39-2.25) 4.68 (3.70-5.65) 5.23 (3.87-6.59)
≥ 80 years 1.95 (1.50-2.40) 4.82 (3.52-6.11) 4.38 (2.65-6.12)
Cardiovascular ≤ 50 years 0.14 (0.02-0.26) 0.38 (0.17-0.60) 0.62 (0.32-0.92)
50-59 years 0.37 (0.11-0.64) 1.44 (0.92-1.96) 2.36 (1.53-3.19)
60-69 years 1.12 (0.74-1.49) 3.04 (2.31-3.78) 4.66 (3.52-5.80)
70-79 years 2.40 (1.89-2.91) 5.25 (4.19-6.32) 6.44 (4.76-8.12)
≥ 80 years 3.92 (3.21-4.63) 8.66 (6.30-11.03) 7.64 (3.97-11.30)
Respiratory* ≤ 50 years 0.03 (.) 0.24 (.) 0.31 (.)
50-59 years 0.16 (.) 0.58 (.) 1.04 (.)
60-69 years 0.56 (.) 1.28 (.) 2.08 (.)
70-79 years 0.97 (.) 2.46 (.) 3.24 (.)
≥ 80 years 2.28 (.) 4.95 (.) 4.56 (.)
Digestive ≤ 50 years 1.01 (0.28-1.75) 2.28 (1.43-3.14) 3.04 (2.06-4.02)
50-59 years 1.96 (0.25-3.67) 4.04 (2.23-5.84) 5.33 (3.45-7.22)
60-69 years 1.93 (0.27-3.59) 3.15 (1.47-4.83) 3.90 (2.17-5.63)
70-79 years 2.60 (0.67-4.53) 4.01 (2.05-5.98) 4.45 (2.46-6.43)
≥ 80 years 6.43 (2.43-10.42) 8.19 (4.20-12.17) 8.56 (4.58-12.54)
Other ≤ 50 years 0.26 (0.09-0.44) 0.95 (0.61-1.29) 1.65 (1.10-2.19)
50-59 years 0.53 (0.21-0.85) 1.90 (1.26-2.53) 3.09 (2.17-4.02)
60-69 years 0.70 (0.42-0.98) 1.85 (1.31-2.38) 2.37 (1.63-3.11)
70-79 years 0.92 (0.65-1.19) 2.58 (1.99-3.17) 3.06 (2.15-3.97)
≥ 80 years 2.29 (1.78-2.80) 4.37 (2.96-5.78) 2.54 (0.58-4.50)
eCIF - The absolute difference in the cumulative incidence function between patients with non
variceal bleeding and age, sex, year, and general practice matched controls without non
variceal bleeding. * Unable to calculate confidence intervals for respiratory causes of death
due to small numbers.
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9.3.3 Sensitivity analyses
Table 9.5 shows the excess mortality at 5 years associated with a bleed when
adjusted for prior co-morbidity, alcohol or smoking. Adjusting for smoking
and alcohol had no effect on the excess mortality, whilst adjusting for prior
co-morbidity slightly reduced the point estimates for non gastrointestinal co-
morbidity. However the significant excess risk of death for all causes persisted
with confidence intervals overlappingwith those from themain analysis. When
I examined in more detail the prior medical history of patients exposed to a
bleed, 54% of those who subsequently died from a neoplasm did not have a
neoplasm coded before the bleed, and 41% of those who died from a cardiovas-
cular death did not have cardiovascular disease coded before the bleed. Finally
when examined by bleed site the excess risks were unchanged from the main
analysis.
9.4 Discussion
I have determined the cumulative excess risk of death in the 5 years following
a non variceal upper gastrointestinal bleed. I have done this in a large unse-
lected population cohort by underlying cause whilst adjusting for competing
risks. This showed that although there was an excess risk of death from gas-
trointestinal causes, over half the total excess risk of death was from unrelated
non gastrointestinal causes. The largest absolute increases were from neoplastic
and cardiovascular disease, but half of those who died from these two causes
were not diagnosed prior to the upper gastrointestinal bleed. This suggests
that in addition to indicating upper gastrointestinal pathology an upper gas-
trointestinal bleed is either a cause of non gastrointestinal co-morbidity, a flag
for undiagnosed co-morbidity, or an indicator of a decline in health from ex-
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Table 9.5: Excess cumulative incidence function at 5 years post bleed by age
group adjusted for lifestyle factors and co-morbidity
95% confidence intervals obtained by bootstrapping (500 iterations).
Adjusted for: Gender only+ Alcohol and smoking Co-morbidity
eCIF (95% CI) eCIF (95% CI) eCIF (95% CI)
Upper GI Neoplasms ≤ 50 years 0.61 (0.33-0.89) 0.63 (0.33-0.92) 0.60 (0.32-0.87)
50-59 years 3.62 (2.02-5.22) 3.79 (2.55-5.03) 3.44 (2.3-4.59)
60-69 years 6.58 (4.28-8.89) 6.67 (4.88-8.46) 5.97 (4.18-7.76)
70-79 years 5.65 (3.70-7.59) 5.63 (4.21-7.05) 5.03 (3.31-6.74)
≥ 80 years 4.41 (2.79-6.03) 4.39 (3.07-5.71) 4.07 (2.57-5.56)
Other Neoplasms ≤ 50 years 1.29 (0.86-1.72) 1.26 (0.78-1.75) 1.18 (0.73-1.63)
(Not Upper GI) 50-59 years 4.17 (3.17-5.18) 4.05 (2.67-5.42) 3.23 (2.11-4.34)
60-69 years 6.64 (5.22-8.06) 6.39 (4.38-8.39) 4.75 (3.1-6.4)
70-79 years 5.23 (3.87-6.59) 5.11 (3.39-6.82) 3.66 (2.04-5.28)
≥ 80 years 4.38 (2.65-6.12) 4.34 (2.4-6.28) 3.19 (1.53-4.84)
Cardiovascular ≤ 50 years 0.62 (0.32-0.92) 0.65 (0.32-0.97) 0.50 (0.25-0.76)
50-59 years 2.36 (1.53-3.19) 2.21 (1.29-3.14) 1.50 (0.85-2.16)
60-69 years 4.66 (3.52-5.80) 4.50 (2.95-6.04) 2.93 (1.83-4.02)
70-79 years 6.44 (4.76-8.12) 6.32 (4.05-8.59) 4.05 (2.14-5.96)
≥ 80 years 7.64 (3.97-11.30) 7.66 (3.41-11.91) 5.31 (1.97-8.65)
Respiratory* ≤ 50 years 0.31 (.) 0.26 (.) 0.21 (.)
50-59 years 1.04 (.) 0.99 (.) 0.72 (.)
60-69 years 2.08 (.) 1.92 (.) 1.33 (.)
70-79 years 3.24 (.) 3.15 (.) 2.14 (.)
≥ 80 years 4.56 (.) 4.51 (.) 3.22 (.)
Digestive ≤ 50 years 3.04 (2.06-4.02) 2.38 (1.7-3.05) 2.86 (2.05-3.68)
50-59 years 5.33 (3.45-7.22) 4.20 (2.98-5.42) 4.70 (3.34-6.06)
60-69 years 3.90 (2.17-5.63) 3.53 (2.51-4.55) 3.66 (2.55-4.77)
70-79 years 4.45 (2.46-6.43) 4.09 (3.13-5.06) 4.12 (2.8-5.44)
≥ 80 years 8.56 (4.58-12.54) 8.23 (6.33-10.13) 8.18 (5.78-10.57)
Other ≤ 50 years 1.65 (1.10-2.19) 1.55 (0.95-2.14) 1.33 (0.83-1.83)
50-59 years 3.09 (2.17-4.02) 3.11 (2.01-4.21) 2.53 (1.63-3.44)
60-69 years 2.37 (1.63-3.11) 2.46 (1.51-3.41) 1.97 (1.15-2.79)
70-79 years 3.06 (2.15-3.97) 3.29 (2.09-4.48) 2.70 (1.45-3.95)
≥ 80 years 2.54 (0.58-4.50) 2.73 (0.45-5.01) 2.68 (0.28-5.07)
eCIF - The absolute difference in the cumulative incidence function between patients with non
variceal bleeding and age, sex, year, and general practice matched controls without non
variceal bleeding. Co-morbidity was measured by the Charlson Index, alcohol defined as
excess alcohol or alcohol complications, and smoking status as current smoker.
+As in table 9.4.
* Unable to calculate confidence intervals for respiratory causes of death due to small
numbers.
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isting co-morbidity. My findings contrast with that for other acute life limiting
medical events where three quarters of the excess death following a myocardial
infarction were shown to be due to the cardiovascular disease, and two thirds of
the excess death following a stroke were shown to be due to related respiratory
infections, cardiovascular or the cereberovascular disease itself.195,196
The main strengths of this study compared to previous studies are its larger
size, follow up, competing risk adjustment, and general population setting.
This allowed us to calculate more accurate, unbiased and detailed mortality
rates for different causes of death than has previously been done. To achieve
this I have used linked electronic primary and secondary health care records in
which the definition of bleeding has previously been found to be accurate. In
HES the incidence of peptic ulcer haemorrhage (1992-1995) was comparable to
the 1993 regional BSG audit (32 v 29 per 100,000 per year respectively).6 More
recently similar numbers of all upper gastrointestinal bleed hospital admissions
and related procedures were recorded in HES compared with those recorded in
the 2007 prospective national UK audit.151 In the GPRD the positive predictive
value of an upper gastrointestinal bleed code was 99% using anonymised chart
review.100,201 I have further strengthened the case definition for my study by
requiring evidence from both databases to be present to define a bleed.178
The information on the fact and cause of death in my study was likely to be ac-
curate, as this was extracted from the Office of National Statistics death registry
that uses standardised WHO guidelines. This was the only feasible method to
to ascertain cause of death in a standardised way for my large study popula-
tion. Underlying cause of death information was used to avoid the effect of
changes in coding requirements over time.202
There have been a number of studies of cause of death during the first 30 days
following an upper gastrointestinal bleed.121,122,125,203,204 The largest was from
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Hong Kong. However it assessed only peptic ulcer bleeds from one hospital
and only reported the proportion of deaths from each causewith no comparison
group.121
In contrast, there have been only a few studies examining causes of death in
the long term following a bleed. Studies in the 1980s and 1990s followed up
peptic ulcer cohorts post surgical treatment rather than upper gastrointestinal
bleeds (shown in table 9.6). These studies were susceptible to the selection bias
inherent in surgical cohorts205 and furthermore they are now dated as the co-
horts were completed in the 1980s before ulcer treatment was radically changed
by the introduction of Helicobacter pylori eradication206 and proton pump in-
hibitors.207,208 The studies that did follow up upper gastrointestinal bleeding
included only patients with proven peptic ulcers who had survived the first 30
days.(table 9.6)
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Table 9.6: Previous literature on long term outcome following peptic ulcer cohorts > 30 days
Operated peptic ulcer
First Author Caygill McIntosh Macintyre Lindell Staël von Hol-
stein
Svanes Duggan
Operation Vago-
tomy
Gastric
ulcer cohort
Duodenal
ulcer
operation
Unoperated
peptic ulcer
Partial
gastrectomy
Perforated
peptic ulcer
Peptic
ulcer
operation
Year published 1991209 1991210 1994211 1994212 1995205 1999213 1999214
Follow up (years) ? 10 <20 12 <20 18.8 <20
Total deaths 577 305 791 121 399 817 224
Neoplasms 32.8 17.4 31.7 26.4 22.3 10.8 10.7
Upper GI 2.6 1.6 0.02 5.0 1.8 1.2
Respiratory 12.3 4.6 0.03 7.5 3.8
Cardiovascular* 51.5 35.5 47.1 49.9 13.8 42.9
Respiratory 10.8 8.0 9.5 4.0 13.8
Digestive** 7.2 2.8 9.9 5.3 8.8 10.3
Bleeding peptic ulcer
First Author Smart Rorbaek-
Madsen
Kubba Hudson Ruigomez
Year published 1986197 1994215 1997126 19959 200010
Follow up (years) <8 <8 <6.5 2.8 (mean) 2.8 (mean)
Total deaths 77 45 30 142 155
Neoplasms 16.9 10.0 23.9 12.9
Upper GI 1.3 0.0 3.5
Respiratory 1.3 0.0 7.0
Cardiovascular* 24.7 66.7 34.5 36.8
Respiratory 5.2 16.7 19.7 17.4
Digestive** 6.5 6.7 6.7 5.6 9.0
*Cardiovascular definitions varied from ischaemic heart disease only to including cereberovascular disease. **Digestive
disease definitions varied from peptic ulcer related to non malignant GI disease
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The largest study by Ruigomez et al consisted of 978 patients with 155 deaths.10
However cause of death information was not available, and cause of death
was imputed by the most recently recorded co-morbidity, increasing the risk
of missclassification. An upper age limit also meant that the study’s age dis-
tribution differed considerably from my unselected cohort, so it was no longer
representative of those currently presenting with bleeds. The next largest and
arguably better study was able to obtain death certificate data from the national
death register, and was therefore similar to my study in being able to ascer-
tain the causes of death in a standardised manner.9 However the study was
restricted to one city and to patients over 60 years old who were hospitalised
with endoscopically proven peptic ulcers (n=487, deaths=142). This limits its
generalisability to a contemporary population and introduces a selection bias
towards those deemed suitable for an endoscopy. In both studies, mortality
rates were not calculated, no adjustment for competing risks was made, and
neither study had the power to assess causes of death by age or time post
bleed. In contrast, I have been able to calculate stratified excess risks for dif-
ferent causes of death adjusted for competing risks within a large population
based cohort.
I have shown that following an upper gastrointestinal bleed there was a con-
siderable excess of all causes of death, and over half of this was due to non gas-
trointestinal co-morbidity, particularly neoplastic and cardiovascular disease.
This excess in death was not explained by co-morbidity such as cancer or car-
diovascular disease diagnosed prior to the admission. An upper gastrointesti-
nal bleed is therefore either a cause or an indicator of a deterioration in non
gastrointestinal co-morbidity. This means a patient who has an upper gastroin-
testinal bleed warrants a re-assessment of their co-morbidity in the follow up
period to their bleeding episode.
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10.1 Summary of findings in this thesis
• Chapter 4: Hospital Episodes Statistics data recorded reassuringly similar
numbers for upper gastrointestinal bleed hospital admissions and proce-
dures to those in a national audit.
• Chapter 5: The occurrence of upper gastrointestinal haemorrhage was
unchanged over the last decade. This was contrary to what was expected
given the trends in known risk factors, for example increased PPI use and
Helicobacter pylori eradication.
• Chapter 5: A higher incidence of upper gastrointestinal haemorrhage was
observed in the north of England, but this was dwarfed by the variation in
occurrence associated with deprivation. Areas of greater deprivation had
2-3 fold higher rates of hospitalisation for upper gastrointestinal haem-
orrhage than areas of less deprivation suggesting strong modifiable risk
factors.
• Chapter 6: There has been an improvement in 28 day mortality following
upper gastrointestinal haemorrhage over the last decade.
• Chapter 6: Those admittedwith bleedingwere increasingly older and had
more co-morbidity, and these confounders partially obscured the changes
in mortality.
• Chapter 7: Linked primary and secondary cared data can provide de-
tailed longitudinal data and allows assessment of potential selection bi-
ases in the individual datasets.
• Chapter 8: A combined measure of non gastrointestinal co-morbidity was
a significant independent predictor of upper gastrointestinal bleeding and
explained a greater proportion of the burden of bleeding than any other
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risk factor in the population, including common medications such as as-
pirin and NSAIDs.
• Chapter 8: The effect of a combined measure of non gastrointestinal co-
morbidity was far in excess of that expected from the effect of its con-
stituent diseases.
• Chapter 9: Non gastrointestinal co-morbidity contributed to the majority
of the excess risk of death following upper gastrointestinal bleeding, even
after adjusting for pre-existing co-morbidity.
10.2 Interpretation and clinical consequences
This thesis has shown in a series of studies that, on a population level, non
variceal upper gastrointestinal bleeding occurrence and its mortality was a con-
sequence of the burden of co-morbidity in that population. This association
was less marked in younger patients, however both bleeds and co-morbidity
were less prevalent in younger age groups. Therefore the association with
co-morbidity explained some of the trends in mortality and occurrence, and
given the large population attributable fraction of bleeding associated with co-
morbidity was likely to account for at least some of the steep socioeconomic
gradient I identified.
One possible explanation for the contribution of co-morbidity to upper gas-
trointestinal bleeding would be the under reporting of Helicobacter pylori in-
fection if the infection was strongly associated with co-morbidity. However
the evidence for this is currently conflicting and underpowered.186,188 Alter-
natively the association of co-morbidity and upper gastrointestinal bleeding
might be due to a form of stress ulceration occurring similar to that observed
on ITU.177 Although this has been disregarded as unimportant,8 on a popu-
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lation level the effect might become measurable and important and therefore
produce the results observed in this thesis.
Caution is always needed when attempts are made to derive clinical messages
for use at an individual level from associations averaged across a whole pop-
ulation. However my studies provide a useful balance to the messages from
previous research (many linked to pharmaceutical funding) that often implied
that NSAID misuse and the underutilisation of PPIs or selective NSAIDs were
the main contribution to the burden of bleeds in the population.193,194,216–219
The studies in this thesis also suggest that bleeding should not be treated in iso-
lation by gastroenterologists, and that gastroenterologists need to retain awider
medical perspective. In the short term there was the expected excess mortality
from upper gastrointestinal pathology that gastroenterologists appropriately
focus on managing. However the strong association with non gastrointestinal
co-morbidity and deathmean that the status andmanagement of co-existing ill-
ness needs to be re-assessed at the time of the bleed, particularly in the elderly.
10.3 Future work
I have identified and planned three initial avenues of investigation following
this thesis.
The results in this thesis have relied on the Charlson index as a measure of co-
morbidity. This was chosen as it has been used in a wide range of settings and
consistently been shown to predict mortality. However it was derived in 1987
in a hospitalised cohort and validated in breast cancer patients. Contemporary
scores for use in linked primary and secondary care data such as in this thesis
are therefore lacking. I have obtained funding to derive a score in the linked
data which will initially involve Bayesian data mining to ensure that diagnoses
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are not being missed, as well as bootstrapping the model building, and per-
forming extensive validation and calibration.
Cardiovascular disease consistently is associated with gastrointestinal bleed-
ing, and gastrointestinal bleeding following a myocardial infarction is associ-
ated with worse outcomes. Furthermore cardiovascular disease remained an
important cause of excess death in my study following a bleed. However there
is ongoing debate as to the risk of bleeding after myocardial infarction, partic-
ularly because of the risk of the combinations of medications used in its treat-
ment. I therefore intend to explore in detail the specific risks associated with
the combinations of medications following amyocardial infarction and the time
periods of highest risk.
The socioeconomic gradient I identified in this thesis deserves further detailed
investigation into the underlying causes. To do this I require detailed lifestyle,
prescribing and co-morbidity information in the underlying population. This
is now available in the linked data I used in this PhD. However I was not able
to examine this within this thesis due to the matching performed. A future
unmatched study will therefore be able to identify what the aetiological factors
are that contribute to this inequality.
10.4 Conclusion
This thesis has used newly available linked population data that provides a
complete longitudinal record of a patients’ diagnoses, admissions, demograph-
ics and prescriptions within the general population. Therefore, in addition to
describing trends in mortality and occurrence in the largest population based
studies to date, I have also been able to show for the first time the population at-
tributable fractions of the risk factors for bleeding and the predictors and causes
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of its excess death properly adjusted for competing risks. All these studies have
clearly shown the importance of co-morbidity in the occurrence and outcome
of upper gastrointestinal bleeding and provided a comprehensive description
of its contemporary epidemiology.
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APPENDIX A
Supporting ICD 10 and Read codes
Table A.1: Category of supporting ICD 10 codes in Hospital Episodes Statis-
tics for cases defined by a specific Read code in the General Prac-
tice Research Database
Category ICD 10 codes Frequency
GI bleed symp-
tom
D62 , K922 , K9229
5595
Upper GI bleed
cause
C150 , C152 , C153 , C154 , C155 , C158 , C159 , C160 , C161 ,
C162 , C163, C164 , C165 , C166 , C168 , C169 , C170 , D001 ,
D130 , D131 , D132 , D139, D371 , D379 , I81 , I850 , I864 , I982
, K20 , K210 , K221 , K223 , K226 K250 , K252 , K254 , K255 ,
K256 , K260 , K261 , K262 , K264 , K265 , K266, K270 , K274 ,
K275 , K280 , K284 , K285 , K290 , K291 , K292 , K293 , K294
K295 , K296 , K297 , K298 , K299 , K317 , K500 , K508 , K509 ,
K766 , K767, S363 , T390 , T393 , Y451 , Y453 , Z850
5521
Upper GI en-
doscopy
Y604 , Y614
3923
Upper GI bleed
symptom
K920 , K921
884
Continued on next page
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Table A.1 –ICD 10 codes continued from previous page
Category ICD 10 codes Frequency
GI symptom or
diagnosis
B161 , B169 , B171 , B178 , B180 , B181 , B182 , B188 , B189 ,
C171 , C178, C220 , C229 , C250 , C258 , C259 , C269 , C482
, C762 , C787 , C788 , C798, C80 , C97 , D099 , D133 , D134
, D367 , D369 , D372 , D377 , E164 , I780, I820 , K550 , K551 ,
K558 , K559 , K561 , K562 , K563 , K564 , K565 , K566, K630 ,
K631 , K632 , K633 , K638 , K639 , K710 , K711 , K713 , K716
, K718 K719 , K720 , K721 , K729 , K730 , K732 , K738 , K739
, K740 , K741 , K743 K744 , K745 , K746 , K750 , K751 , K753
, K754 , K758 , K759 , K760 , K761 K762 , K763 , K765 , K768
, K769 , K770 , K860 , K910 , K911 , K912 , K913 K918 , K928 ,
K929 , K938 , M352 , O266 , Q433 , Q438 , Q439 , Q446 , Q447
Q458 , R100 , R101 , R102 , R103 , R104 , R160 , R162 , R17
, R18 , R190, R193 , R198 , R850 , R855 , R857 , R859 , R890 ,
R895 , R897 , R899 , R933, R945 , R948 , T478 , T479 , Y538 ,
Y539 , Z221 , Z225 , Z400 , Z434 , Z871, Z8713 , Z904
535
Upper GI diag-
nosis
K219 , K220 , K222 , K224 , K225 , K228 , K229 , K230 , K231
, K238 , K30 K310 , K311 , K312 , K313 , K314 , K315 , K316 ,
K318 , K319 , K440 , K441, K449 , K450 , K451 , K458 , K460 ,
K469 , Q391 , Q393 , Q394 , Q396 , Q401,Q402 , Q403 , S368 ,
T181 , T182 , T183 , T189 , Z903
453
Upper GI
symptom
O210 , O211 , O218 , O219 , R11 , R12 , R13
347
Continued on next page
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Table A.1 –ICD 10 codes continued from previous page
Category ICD 10 codes Frequency
General care
W000 , W002 , W004 , W008 , W009 , W010 , W0109 , W011 ,
W0114 , W0119 , W012, W0129 , W013 , W014 , W0149 , W015
, W016 , W018 , W0188 , W019 , W0199 , W021, W023 , W024
, W029 , W030 , W031 , W033 , W034 , W035 , W038 , W039
, W040, W042 , W044 , W049 , W050 , W051 , W052 , W054 ,
W058 , W059 , W060 , W0609, W061 , W0619 , W062 , W0629
, W068 , W069 , W070 , W0709 , W071 , W072 , W0729, W074
, W075 , W079 , W080 , W081 , W082 , W088 , W089 , W090 ,
W091 , W098, W099 , W100 ,
W1009 , W101 , W102 , W103 , W104 , W105 , W108 , W109
, W110, W115 , W116 , W118 , W119 , W125 , W129 , W130
, W131 , W132 , W134 , W138, W139 , W140 , W148 , W149
, W160 , W170, W171 , W172 , W174 , W175 , W177, W178 ,
W179 , W1799 , W180 , W1809 , W181 , W1819 , W182 , W1829
, W183 , W184, W185 , W186 , W188 , W189 , W190 , W1909 ,
W191 , W1919 , W192 , W1923 , W1929, W193 , W194 , W1949
, W195 , W198 , W199 , W1999 , W200 , W205 , W206 , W209
W213 , W220
, W221 , W222 , W223 , W224 , W225 , W226 , W227 , W228
, W229, W230 , W231 , W232 , W234 , W236 , W238 , W239
, W241 , W250 , W2508 , W252, W254 , W255 , W256 , W258
, W259 , W260 , W268 , W269 , W270 , W272 , W274, W276
, W279 , W280 , W289 , W290 , W298 , W299 , W310 , W312
, W315 , W316, W3162 , W318 , W319 , W344 , W349 , W4059
, W406 , W440 , W441 , W442 , W449, W4499 , W450 , W451
, W455 , W458 , W459 , W490 , W492 , W496 , W499 , W500,
W503 , W508 ,
Continued on next page
192
APPENDIX A: SUPPORTING ICD 10 AND READ CODES:
Table A.1 –ICD 10 codes continued from previous page
Category ICD 10 codes Frequency
W509 , W5098 , W510 , W511 , W513 , W514 , W518 , W519
, W540, W544 , W548 , W549 , W550 , W558 , W559 , W570 ,
W573 , W579 , W5799 , W599, W600 , W609 , W6099 , W640
, W642 , W649 , W699 , W740 , W748 , W780 , W781, W782 ,
W789 , W790 , W791 , W792 , W799 , W7999 , W800 , W802
, W809 , W839, W840 , W842 , W849 , W850 , W877 , W882 ,
W909 , W948 , X000 , X011 , X020, X039 , X049 , X060 , X069
, X080 , X089 , X090 , X099 , X100 , X102 , X109, X110 , X120 ,
X121 , X129 ,
X149 , X150 , X159 , X160 , X162 , X169 , X175, X186 , X190 ,
X195 , X199 , X209 , X219 , X239 , X258 , X292 , X310 , X314,
X318 , X319 , X329 , X332 , X360 , X391 , X394 , X398 , X399
, X400 , X401, X402 , X408 , X409 , X4099 , X410 , X411 , X412
, X418 , X419 , X420 , X421, X422, X424 , X428 , X429 , X430
, X439 , X440 , X441 , X442 , X448 , X449, X450 , X458 , X459
, X469 , X470 , X476 , X478 , X479 , X490 , X491 , X498, X499
, X4999 , X500 , X5008 , X5009 , X501 , X502 , X503 , X504 ,
X505 , X506, X508 , X5089 , X509 , X5099 , X519 , X530 , X539 ,
X580 , X581 , X582 , X588, X589 , X5899 , X590 ,
X5909 , X591 , X592 , X593 , X594 , X595 , X596 , X598, X5989 ,
X599 , X5999 , X600 , X6009 , X601 , X602 , X604 , X608 , X609
, X6099, X610, X6109 , X611 , X612 , X614 , X615 , X618 , X619
, X6199 , X620 , X622, X624 , X628 , X629 , X6299 , X630 , X638
, X639 , X640 , X642 , X648 , X649, X6499 , X650 , X651 , X652
, X654 , X658 , X659 , X6599 , X660 , X669 , X670, X678 , X680
, X689 , X690 , X691 , X698 , X699 , X700 , X701 , X702 , X709,
X718 , X749 , X760 , X770 , X771 , X780 , X781 , X782 , X788
, X789 , X790, X791 , X792 , X795 , X799 , X800 , X804 , X808 ,
X818 , X824 , X830 , X831, X832 , X834 ,
Continued on next page
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Table A.1 –ICD 10 codes continued from previous page
Category ICD 10 codes Frequency
X838 , X839 , X840 , X841 , X842 , X849 , X853 , X866 , X870,
X900 , X932 , X950 , X979 , X990 , X992 , X994 , X999 , Y000
, Y001 , Y004, Y008 , Y009 , Y010 , Y040 , Y041 , Y042 , Y044
, Y045 , Y048 , Y049 , Y0499, Y053 , Y070 , Y079 , Y080 , Y084
, Y088 , Y089 , Y090 , Y094 , Y095 , Y098, Y099 , Y100 , Y109
, Y110 , Y112 , Y119 , Y120 , Y129 , Y139 , Y140 , Y149, Y150 ,
Y159 , Y179 , Y190 , Y199 , Y218 , Y219 , Y249 , Y280 , Y281
, Y289, Y292 , Y294 , Y300 , Y304 , Y309 , Y331 , Y332 , Y340 ,
Y341 , Y342 ,
Y349, Y3499 , Y95 , Z000 , Z005 , Z006 , Z008 , Z013 , Z018 ,
Z0180 , Z019 , Z031, Z036 , Z038 , Z039 , Z040 , Z043 , Z048
, Z049 , Z080 , Z081 , Z082 , Z087, Z088 , Z089 , Z090 , Z092
, Z097 , Z098 , Z099 , Z120 , Z121 , Z128 , Z129 Z132 , Z138 ,
Z1380 , Z480 , Z488 , Z489 , Z508 , Z515 , Z518 , Z519 , Z530,
Z531 , Z532 , Z538 , Z539 , Z547 , Z548 , Z549 , Z593 Z728 ,
Z729 , Z750, Z751 , Z752 , Z753 , Z758 , Z759 , Z764 , Z858,
Z878 , Z910 , Z911 , Z922, Z924 , Z929
329
Alcohol
E244 , F100 , F101 , F102 , F103 , F104 , F105 , F108 , F109 ,
G312 , G621, G721 , I426 , K700 , K701 , K702 , K703 , K704
, K709 , R780 , T510 , T511 T519 , Y905 , Y906 , Y908 , Y910 ,
Y911, Y912 , Y913 , Y919 , Z502 , Z714, Z721
268
Anaemia D649 176
Upper GI pro-
cedure
Z431 , Z931 140
Continued on next page
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Category ICD 10 codes Frequency
General symp-
tom or diagno-
sis
B378 , B379 , B948 , C768 , C772 , C778 , C779 , C786 , D479
, D484 , D487 D489 , D630 , E519 , G92 , G934 , R231 , R402 ,
R520 , R529 , R53 , R54, R58 , R688 , R69 , T394 , T398 , T399
, T475 , T485 , T490 , T509 , T658, T659 , T788 , T789 , Y430
, Y431 , Y433 , Y454 , Y458 , Y459 , Y560 , Y578 Y579 , Z511 ,
Z514 , Z859 , Z860
137
Collapse
E86 , I950 , I951 , I952 , I958 , I959 , R031 , R42 , R55 , R570 ,
R571, R578 , T794 , T795 , Z990 , Z991 , Z998 , Z999
105
General proce-
dure
T412 , T801 , T802 , T808 , T809 , T810 , T811 , T812 , T813
, T814 , T815, T816 , T817 , T818 , T819 , T855 , T864 , T868
, T869 , T884 , T885 , T886, T887 , T888 , T889 , T915 , T96 ,
T981 , T983 , Y482 , Y484 , Y600 , Y606, Y610 , Y618 , Y638 ,
Y649 , Y652 , Y654 , Y658 , Y66 , Y701 , Y703 , Y710, Y711 ,
Y712 , Y730 , Y732 , Y733 , Y738 , Y741 , Y772 , Y773 , Y778
, Y780 Y792 , Y793 , Y801 , Y808 , Y812 , Y822 , Y828 , Y830
, Y831 , Y832 , Y833, Y834 , Y836 , Y838 , Y839 , Y842 , Y845
, Y847 , Y848 , Y849 , Y880 , Y881, Y882 , Y883 , Y899 , Z540 ,
Z948 , Z988
67
Coagulation
D65 , D683 , D684 , D688 , D689 , D698 , D699 , E561 , O723 ,
T455 , T456, Y442 , Y443 , Y444 , Y445 , Z921
63
Nutrition R630 , R634 , R638 , R64 , Z594 26
Confusion R401 , R410 17
Death I460 , I469 , R092 , R960 , R99 16
Blood transfu-
sion
Y446 , Y449 , Z513 3
GI procedure Z934 , Z944 , Z980 2
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Table A.2: Category of supporting Read code in the General Practice Re-
search Database for cases defined in Hospital Episodes Statistics
Category Read codes Frequency
Upper GI bleed
symptom
14C8.00, 14C9.00, 14CD.00, 14CD.11, 1994 1994.11, 1995,
19E4.00, 19E4.11, 19E4.12, 4736 4737, 4737.11, 4A23.00,
4A23.11, 4A24.00 4A24.11, J680.00, J680.11, J681.00, J681.12
J681.13, J68z000 J68z200
7527
Upper GI bleed
cause
14C1.00, 14C1.11, 14C1.12, 14C5.00, 14C6.00, 14CB.00, 1675,
1675.11, 1675.12, 1956, 1J0D.00 2274, 2274.11, 67I8.00, 7609300
, 760C.00 760C000, 760C100, 760C300, 760C400, 760C500,
760C600, 760C700, 760Cy00, 760Cz00, 760F.00, 760F100,
760F400, 760H000, 761D.00, 761D.11, 761D000, 761D100,
761D200, 761D300, 761D400, 761D500 , 761D600, 761D700,
761D800, 761Dy00, 761Dz00 ,761J.00, 761J.11, 761J000, 761J100,
761J111, 761Jy00 761Jz00, 761K.00, 761K000, 761M.00, 761M000
,7624000, 7624011, 7625000, 7627, 7627000 7627100, 7627200,
8Hn9.00, A074313 B1...11, B10..00, B10z.00,
B10z.11, B11..00, B11..11, B110.00, B110000, B110100,
B110111, B110z00, B111.00, B111000, B111100, B111z00,
B112.00, B113.00, B114.00, B115.00, B116.00, B117.00, B118.00,
B119.00, B11y.00, B11y000, B11y100, B11yz00, B11z.00, B12..00,
B120.00, B121.00, B574.00, B574000, B574z00, B70X.00, B71..00,
B710.00, B710.11, B710100, B710300, B710z00, B711.00, B711.11,
B711000, B711100, B711200, B711300, B711400, B711z00,
B712.00, B712000, B712011, B712z00, C310400, G762000,
G81..00, G85..11, G85..12, G850.00, G851.00, G852.00,
G852000, G852100, G852200, G852300, G852z00,
Continued on next page
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Category Read codes Frequency
G857.00, G858.00, J101.00, J101100, J101112, J101113, J101114,
J101115, J101200, J101300, J101400, J101500, J101600, J101611,
J101y00, J101z00, J102.00, J102000, J102100, J102200, J102300,
J102400, J102500, J102z00, J103.00, J103.11, J103.12, J103400,
J103z00, J104.00, J107.00, J108.00, J10y000, J10y300, J10y400,
J10y411, J10y412, J11..00, J11..11, J11..12, J110.00, J110000,
J110100, J110111, J110200, J110300, J110y00, J110z00, J111.00,
J111000, J111100, J111111, J111200, J111211, J111300, J111400,
J111y00, J111z00, J112.00, J112z00, J113.00, J113z00, J11y.00,
J11y000,
J11y100, J11y200, J11y400, J11yy00, J11yz00, J11z.00, J11z.11,
J11z.12, J12..00, J120.00, J120000, J120100, J120200, J120300,
J120400, J120y00, J120z00, J121.00, J121000, J121100, J121111,
J121200, J121211, J121300, J121400, J121y00, J121z00, J122.00,
J123.00, J124.00, J125.00, J126.00, J12y.00, J12y000, J12y100,
J12y200, J12y300, J12y400, J12yy00, J12yz00, J12z.00, J13..00,
J13..11, J130.00, J130000, J130100, J130200, J130300, J130y00,
J130z00, J131.00, J131000, J131100, J131200, J131400, J131y00,
J131z00, J13y.00, J13y000, J13y100, J13y200, J13y300, J13y400,
J13yz00,
J13z.00, J14..00, J14..11, J14..12, J14..13, J14..14, J14..15,
J140.00, J140100, J140z00, J141.00, J14y.00, J14y100, J14y200,
J14yz00, J14z.00, J15..00, J150.00, J150000, J151.00, J151000,
J151100, J151200, J151z00, J152.00, J153.00, J154.00, J154000,
J154100, J154200, J154300, J154400, J154z00, J155.00, J156.00,
J157.00, J15z.00, J17y800, J17y900, J40..11, J400000, J431000,
J4z0.00, J502000, J612.00, J612.11, J612.12, J612000, J615.11,
J615100, J615300, J615400, J615500, J615600, J615700, J615800,
J615812, J615C00, J615D00, J615H00, J615y00, J615z00, J615z11,
J615z12,
Continued on next page
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Category Read codes Frequency
J615z13, J61y300, J622.00, J622.11, J623.00, J624.00, Jyu1200,
Jyu1300, Jyu4000, R024.00, R024111, R095.00, TJ53.00, TJ53.11,
TJ56.11, U605100, U605111, U605112, U605200, U605211,
U605212, U605213, U605214, U605215, U605216, U605300,
U605311, U605312, U605313, U605314, & U605315
3722
GI bleed symp-
tom
14CA.00, 14CA.11, 25T0.00, J68..00, J68z.00, J68z.11, J68z100,
J68zz00 2335
Upper GI en-
doscopy
316C.00, 36...00, 361..00, 3611, 3612, 3613, 3614, 3614000,
3615, 3615000, 361Z.00, 36Z..00, 4, JO..00, 4, JO0.00,
760D.00, 760D000, 760D100, 760D200, 760D300, 760D311,
760D313, 760D400, 760D500, 760D600, 760D700, 760Dy00,
760Dz00, 760E.00, 760E.11, 760E000, 760E100, 760E200,
760E300, 760Ey00, 760Ez00, 760Ez11, 760F300, 760G.00,
760G.11, 760G000, 760G100, 760G200, 760G300, 760G311,
760G400, 760Gy00, 760H.00, 760H100, 760Hy00, 761E.00,
761E.11, 761E000, 761E100,
761E200, 761E211, 761E300, 761E500, 761E600, 761E700,
761E800, 761Ey00, 761Ez00, 761F.00, 761F.11, 761F000,
761F100, 761F200, 761F300, 761F400, 761F500, 761F700,
761Fy00, 761Fz00, 761Fz11, 761Fz12, 761G200, 761G211,
761G400, 761L.00, 761L000, 761Ly00, 761Lz00, 761y.00,
761z.00, 7624100, 7624200, 7624y00, 7624z00, 7625, 7625.11,
7625y00, 7625z00, 7625z11
2240
Continued on next page
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Death
22J..00, 22J..11, 22J..12, 22J..13, 22J..14, 22J1.00, 22J2.00,
22J3.00, 22J4.00, 22J5.00, 22J6.00, 22J7.00, 22JZ.00, 4K9..00,
4K91.00, 4K92.00, 4K94.00, 4K95.00, 4K96.00, 4K9Z.00,
8HG..00, 8HG..11, 94...00, 94...11, 941..00, 9411, 9412, 9413,
9414, 941Z.00, 942..00, 943..00, 9431, 9432, 9433, 943Z.00,
944..00, 9441, 9442, 9443, 944Z.00, 945..00, 9451, 9452, 9453,
9454, 945Z.00, 946..00, 947..00, 947..11, 9471, 9472, 9473,
947Z.00, 948..00, 948..11, 9481, 9482, 9483, 9484, 948Z.00,
949..00, 949..11, 949..12, 949..13, 949..14, 9491, 9492, 9493,
9494, 9495, 9496, 9497, 9498, 9499, 949A.00, 949B.00, 949C.00,
949Z.00, 94A..00, 94A..11, 94B..00, 94B..11, 94C..00, 94C0.00,
94D..00, 94E..00, 94F..00, 94Z..00, 94Z0.00, 94Z1.00, 94Z2.00,
94Z3.00, 94Z4.00, 94Z5.00, R2...12, R21..00, R210.00, R210000,
R210100, R210200, R210z00, R211.00, R212.00, R212000,
R212100, R212z00, R213.00, R213000, R213100, R213z00,
R21z.00, R2y..00, R2yz.00, R2z..00
1305
Upper GI
symptom
194..00, 194..11, 1942, 1943, 1944, 1944.11, 194Z.00, 1952,
1952.11, 1954, 1955, 1955.11, 1957, 1958, 1972, 198..00,
198..11, 198..12, 1982, 1983, 1984, 198Z.00, 199..00, 199..11,
199..12, 199..14, 1992, 1992.11, 1992.12, 1993, 1996, 1997,
1998, 199Z.00, 19FZ.11, 4A25.11, 4A26.11, 4A27.00, 4A2A.11,
4A2Z.00, 4A3..00, 4A4..00, 4, A4..11, 4, A42.00, 4, A4Z.00, 4,
A5..00, 4, A5..11, 4, A51.00, 4, A5Z.00, 4, A6..00, 4, AZ..00,
4, JD7.00, 4JN1.00, 4JS4.00, 7N3..00, 7N30.00,
Continued on next page
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7N30000, 7N30100, 7N30200, 7N30300, 7N30700, 7N30z00,
7N35000, J101111, J10y500, J10yz00, J10z.00, J162.00, J162.11,
J162000, J162100, J162z00, J16y.00, J16y000, J16y100, J16y200,
J16y211, J16y300, J16y400, J16y411, J16y500, J16y700, J16y800,
J16y900, J16yz00, J16z.00, J16z100, J17..00, R070.00, R070000,
R070100, R070200, R070300, R070400, R070z00, R070z11,
R070z12, R071.00, R071000, R071z00, R072.00, R072000,
R072z00, R07A.00
835
Anaemia
145..11, 1674, 1674.11, 2272, 2272.11, 2272.12, 2C2..11, 421B.00,
4222, 423..00, 423..11, 4234, 4235, 4243, 4254, 4255, 4256,
426..00, 4262, 4263, 4266, 4267, 426Z.00, 42E8.00, 42R4200,
42X..00, 42X0.00, 42X2.00, 42bC.00, D211.00, D211.11, D21y.00,
D21yy00, D21yz00, D21z.00, D2y..00, D2z..00, R026000,
R026011
722
General symp-
tom or diagno-
sis
1....00, 13C6.00, 13C6.11, 13CA.00, 13CC.00, 142..12, 142..13,
14O..00, 14Z..00, 16...00, 16...11, 16...12, 16...13, 16E..00,
16E..11, 16E..12, 16E0.00, 16G..00, 16Z..00, 16Z3.00, 16Z7.00,
16Z8.00, 16Z9.00, 16ZZ.00, 1828, 1829, 182Z.00, 1D...00, 1,
D1..00, 1, D13.00, 1D13.11, 1D13.12, 1D18.00, 1D1Z.00, 1J...00,
1M...00, 1O0..00, 1W...00, 1Y...00, 1Z...00, 1Z0..00, 1Z00.00,
1Z01.00, 2....00, 2....11, 2....12, 21...00, 211..00, 212..00, 2121,
2122, 2123, 2124, 2125, 2125.11, 2126, 2126.11, 2126.12, 2126.13,
2126.14, 2127,
Continued on next page
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2127.11, 2128, 2128.11, 2129, 212A.00, 212A.11, 212B.00,
212C.00, 212D.00, 212E.00, 212F.00, 212Z.00, 21Z..00, 22...00,
221..00, 2211, 2212, 2213, 2214, 2215, 221Z.00, 222..00,
2221, 2222, 2224, 2229, 2229.11, 2229.12, 2229.13, 222F.00,
222G.00, 222M.00, 223..00, 2231, 2252, 2253, 2271, 66W..00,
7N22000, 87...00, 87...11, 871..00, 8711, 8712, 8713,
8713.11, 871Z.00, 872..00, 872..11, 872..12, 8721, 8722,
8723, 8724, 872Z.00, 873..00, 8731, 8732, 8733, 8733000,
8733100, 8734, 8735, 873Z.00, C19..00, G8y0.00, R....00,
R....11, R....12, R0...00, R00..00, R00z200, R00z211, R00zB00,
R07..00, R070111, R073300, R073400, R2...00, R2...11, R2...13,
R2...14, R200.00, R200.11, R201.00, R2y4.00, R2y4000, R2y4z00,
R2yy.00, ZQ1..00, ZQ32.00
494
Coagulation
1455.11, 1456, 14P1.00, 16B..00, 16B2.00, 16B3.00, 1928, 4130,
4224, 42Q..12, 42Q..13, 42Q2.00, 42Q3.00, 42Q4.00, 42Q5.00,
42Q5000, 42Q6.00, 42Q7.00, 42Q8.00, 42Q8100, 42QE.00,
42QE100, 42QV.00, 42QW.00, 42QX.00, 42QZ.00, 42Qn.00,
42Qt.00, 42Qu.00, 42Qv.00, 42h0.00, 66Q..00, 66Q..11,
66Q1.00, 66Q2.00, 66Q3.00, 66Q4.00, 66Q5.00, 66Q6.00,
66Q7.00, 66Q8.00, 66Q9.00, 66QA.00, 66QB.00, 66QC.00,
66QD.00, 66QE.00, 66QF.00, 66QG.00, 88A5.00, B937.14,
B937W00, B937W11, D1...00, D10y.00,
Continued on next page
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D10z.00, D11..00, D110.00, D110.11, D110000, D110100,
D110200, D110400, D110z00, D111.00, D111000, D111100,
D111300, D111400, D111500, D111y00, D111z00, D3...00,
D30..00, D30..11, D300.00, D300.11, D300.12, D301.00, D301.11,
D301.12, D302.00, D302.11, D302.12, D303.00, D303000,
D303100, D303111, D303200, D303300, D303400, D303500,
D303600, D303611, D303700,
D303800, D303900, D303y00, D303z00, D304.00, D305.00,
D305000, D305100, D306.00, D306.11, D306.12, D307.00,
D307000, D307100, D307200, D307211, D307y00, D307z00,
D308.00, D309.00, D30A.00, D30B.00, D30z.00, D31..00,
D310.00, D310000, D310011, D310012, D310100, D310z00,
D311.00, D311.11, D311000, D311011, D311z00, D312.00,
D312.11, D312.12, D312000, D312100, D312z00, D313.00,
D313.11, D313.12, D313.13, D313.14, D313.15, D313000,
D313011, D313012,
D313100, D313111, D313200, D313211, D313300, D313y00,
D313z00, D313z11, D314.00, D314100, D314y00, D314z00,
D315.00, D31X.00, D31y.00, D31y000, D31y011, D31yz00,
D31z.00, D3y..00, D3y0.00, D3z..00, R027.00, R027.11,
R027000, R027z00, TJ42.00, TJ42000, TJ42100, TJ42z00, TJ43.00
329
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GI symptom or
diagnosis
1612.12, 19...00, 19...11, 19...12, 195..00, 195Z.00, 196..00,
196..11, 196..12, 1962, 1963, 1964, 1965, 1965.11, 1968, 1969,
196Z.00, 197..00, 197..11, 197..12, 197..13, 197..14, 1971,
1973, 1974, 1975, 1976, 1977, 1978, 197A.00, 197A.11, 197B.00,
197C.00, 197D.00, 197Z.00, 19A..00, 19A1.00, 19A2.00, 19A3.00,
19A4.00, 19AZ.00, 19Z..00, 19ZZ.00, 25...00, 25...11, 25...12,
251..00, 2511, 2512, 2513, 2514, 2515, 2516, 2516.11, 251Z.00,
258..00, 258..11, 2581, 2582, 2583, 2584, 2584.11, 2585, 2586,
2587, 2587.11, 2587.12, 258Z.00, 259..00, 2591, 2592,
2593, 259Z.00, 25A..00, 25A1.00, 25A2.00, 25A3.00, 25AZ.00,
25B..00, 25B1.00, 25B2.00, 25B3.00, 25B4.00, 25C..00, 25C..11,
25C..12, 25C..14, 25C..15, 25C1.00, 25C2.00, 25C3.00, 25C4.00,
25C5.00, 25C6.00, 25C7.00, 25C8.00, 25C9.00, 25CA.00,
25CZ.00, 25D..00, 25D..11, 25D1.00, 25D2.00, 25D3.00,
25D4.00, 25D6.00, 25D8.00, 25D9.00, 25DA.00, 25DZ.00,
25E..00, 25E1.00, 25E2.00, 25E3.00, 25E5.00, 25E6.00, 25E8.00,
25EA.00, 25EZ.00, 25F..00, 25F1.00, 25F2.00, 25F2.11, 25FZ.00,
25G..00, 25G..11, 25G1.00, 25G2.00, 25G3.00, 25G4.00,
25GZ.00,
25H..00, 25H1.00, 25H2.00, 25H3.00, 25H9.00, 25HA.00,
25HZ.00, 25I..00, 25I1.00, 25I2.00, 25I3.00, 25I5.00, 25I6.00,
25J..00, 25J1.00, 25J2.00, 25J3.00, 25J4.00, 25J5.00, 25J6.00,
25J7.00, 25J8.00, 25J9.00, 25JA.00, 25JZ.00, 25K..00, 25K1.00,
25K2.00, 25K3.00, 25K4.00, 25KZ.00, 25L..00, 25L1.00, 25L2.00,
25LZ.00, 25M..00, 25M1.00, 25M2.00, 25MZ.00, 25N..00,
25N1.00, 25N2.00, 25NZ.00, 25O..00, 25O1.00, 25O2.00,
25O3.00, 25O4.00, 25OZ.00, 25P..00, 25P..11, 25P..12, 25P1.00,
25P2.00, 25P3.00, 25P4.00, 25P5.00, 25P6.00, 25PZ.00,
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25Q..00, 25Q..11, 25Q1.00, 25Q5.00, 25Q6.00, 25QZ.00,
25R..00, 25R1.00, 25R2.00, 25R3.00, 25RZ.00, 25S..00, 25S1.00,
25S2.00, 25S3.00, 25S3.11, 25S4.00, 25S5.00, 25SZ.00, 25V..00,
25V0.00, 25Z..00, 3167, 43W9.00, 43WA.00, 4A25.00, 4A26.00,
4JD6.00, 4JM..00, 4JM0.00, 4JM2.00, 4JM3.00, 4JN0.00, 4JO1.00,
68W3.00, 68W4.00, 761H300, 7N30400, 7N30500, 7N30600,
7N33.00, 7N33000, 7N33100, 7N33200, 7N33300, 7N33311,
7N33400, 7N33500, 7N33600, 7N33z00, 7N34.00, 7N34000,
7N34100, 7N34y00, 7N3z.00, J....00, J1...00, J1...11, J1...12,
J10y200,
J154111, J16y412, J16y600, J344.00, J502100, J521.00, J521.11,
J57z.00, J6y..00, J6z..00, Jy...00, R07z.00, R07z.11, R07zz00,
R09..00, R090.00, R090000, R090100, R090200, R090300,
R090311, R090312, R090400, R090500, R090600, R090700,
R090800, R090900, R090A00, R090B00, R090C00, R090D00,
R090E00, R090F00, R090H00, R090J00, R090K00, R090N00,
R090y00, R090z00, R091.00, R091000, R091z00, R093.00,
R093000, R093100, R093111, R093200, R094.00, R095000,
R095z00, R096.00, Ryu1.00, Ryu1100, Ryu1200, Ryu1300
328
Hospital
13F8.00, 13F8.11, 13F8100, 13F8200, 67IL.00, 67IM.00, 6A1..00,
6A1..11, 8B1..00, 8H...00, 8H1..00, 8H1..11, 8H11.00,
8H12.00, 8H13.00, 8H14.00, 8H2..00, 8H21.00, 8H22.00,
8H24.00, 8H2Z.00, 8H36.00, 8H37.00, 8H39.00, 8H3Z.00,
8H4..00, 8H4..11, 8H4..12, 8H41.00, 8H42.00, 8H47.00,
8H48.00, 8H4D.00, 8H4J.00, 8H4Z.00, 8H4b.00, 8H4l.00,
8H5..00, 8H5..11, 8H51.00, 8H5J.00, 8H5K.00, 8H5Z.00,
8H6..00, 8H61.00, 8H61.11, 8H63.00, 8H64.00, 8H65.00,
8H66.00, 8H68.00, 8H6D.00, 8H6Z.00, 8H7..00,
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8H7a.00, 8H7h.00, 8H7o.00, 8HC1.00, 8HE..00, 8HE2.00,
8HEZ.00, 8HF..00, 8HF..11, 8HF..12, 8HM..00, 8HM1.00,
8HM8.00, 8HMG.00, 8HMS.00, 8HMZ.00, 8HN..00, 8HN0.00,
8HN1.00, 8HN2.00, 8HN3.00, 8HN4.00, 8HN5.00, 8HN6.00,
8HN7.00, 8HN8.00, 8HN9.00, 8HNA.00, 8HNB.00, 8HNC.00,
8HND.00, 8HNE.00, 8HNZ.00, 8HO..00, 8HO1.00, 8HO2.00,
8HOZ.00, 8HV0.00, 8HVF.00, 8HVG.00, 8HVM.00, 8HVN.00,
8HVY.00, 8HX..00, 8HX0.00, 8HX1.00, 8HX2.00, 8HY..00,
8HZ..00, 8HZ0.00, 8Ha..00,
8Hb..00, 8Hd..00, 8, Hd0.00, 8Hg5.00, 8Hi..00, 8Hk5.00,
8Hl..00, 8Hl0.00, 8Hm..00, 8Hm1.00, 9N19.00, 9N19.11,
9N1B.00, 9N36.00, 9N36.11, 9N3L.00, 9NC..00, 9NC1.00,
9NC8.11, 9Y...00, 9Y0..00, 9Y1..00, 9Y2..00, ZL16.00, ZL16.11,
ZL16100, ZL16111, ZL16200, ZL16211, ZL17.00, ZL18.00,
ZL18C00, ZL18D00, ZL18L00, ZL18L11, ZL18R00, ZL18S00,
ZL19.00, ZL19100, ZL1A100, ZL1G.00, ZL1GD00, ZL1GD11,
ZL1GE00, ZL1GE11, ZL1GF00, ZL1GF11, ZL1GH00, ZL1GJ00,
ZL5..00, ZL51.00, ZL51.11, ZL51.12, ZL51.13, ZL52.00,
ZL56.00, ZL56.11, ZL56100,
ZL56200, ZL56211, ZL57.00, ZL57100, ZL5A.00, ZL5A200,
ZL5A211, ZL5AD00, ZL5AE00, ZL5G500, ZL5GA00,
ZL5GA11, ZL5GB00, ZL5GB11, ZL5GC00, ZL5GC11,
ZL5GE00, ZL9..00, ZL91.00, ZL91.11, ZL91.12, ZL92.00,
ZL96.00, ZL96.11, ZL96100, ZL96111, ZL96200, ZL96211,
ZL97.00, ZL97100, ZL9A.00, ZL9AE00, ZL9AF00, ZL9AL00,
ZL9AL11, ZL9AL12, ZL9G.00, ZL9GC00, ZL9GC11, ZL9GD00,
ZL9GD11, ZL9GE00, ZL9GE11, ZL9GG00, ZL9GM00,
ZL9GN00, ZL9GP00, ZLD2G00, ZLD2G11, ZLD2H00,
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ZLD2H11, ZLD2I00, ZLD2I11, ZLD2L00, ZLD2R00, ZLD3.00,
ZLD3E00, ZLD3F00, ZLD3L00, ZLD3L11, ZLD4.00, ZLD4700,
ZLD4711, ZLD4800, ZLD4811, ZLD4900, ZLD4911, ZLD4A00,
ZLD4B00, ZLD4D00, ZLEQ700, ZLEQ711, ZLEQ800,
ZLEQ811, ZLEQ900, ZLEQ911, ZLF3.00, ZLG..00, ZLG1.00,
ZLG2.00, ZLG3.00, ZLG3100, ZLG3200, ZLG4.00, ZLG4100,
ZLG5.00, ZLG5100, ZLG5200, ZLG6.00, ZLG6100, ZLG6300,
ZLG6400, ZLG6411, ZLG6500, ZLG6511, ZLG8.00
294
Collapse
1479, 147A.00, 147B.00, 147C.00, 147D.00, 16D..00, 16D1.00,
16D5.00, 1B6..00, 1B6..11, 1B6..12, 1B6..13, 1B62.00, 1B65.00,
1B65.11, 1B66.00, 1B66.11, 1B68.00, 2225, 2235, 2236, 2236.11,
2236.12, 2236.13, 2236.14, 2237, 2238, 2239, 223Z.00, 224..00,
2241, 2242, 2243, 2244, 224Z.00, C365.00, C365000, C365100,
C365200, C365z00, G575.00, G575.11, G575.12, G575000,
G575100, G575200, G575300, G575z00, G87..00, G870.11,
R000.00, R000.11, R000.12, R000000, R000200, R000300,
R000311, R000400,
R000500, R000z00, R002.00, R002.11, R002000, R002100,
R002200, R002300, R002400, R002500, R002600, R002700,
R002z00, R003.00, R003000, R004000, R004100, R004200,
R055.00, R055000, R055011, R055100, R055111, R200.12,
R2y0.00, R2y0100, R2y1.00, R2y1000, R2y1100, R2y1z00,
SP20.11, U10..00, U100.00, U100000, U100200, U100300,
U100400, U100500, U100z00, U101.00, U101000, U101100,
U101200, U101300, U101400, U101500, U101600, U101700,
U101y00, U101z00,
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U102.00, U102000, U102300, U102400, U102700, U102y00,
U102z00, U103.00, U103000, U103300, U103y00, U103z00,
U104.00, U104000, U104100, U104600, U105.00, U105000,
U105100, U105500, U105700, U106.00, U106000, U106100,
U106200, U107.00, U107000, U107200, U107600, U107y00,
U107z00, U108.00, U108000, U108100, U108600, U108z00,
U109.00, U109000, U109200, U109z00, U10A.00, U10A000,
U10A100, U10A400, U10A500, U10A511, U10Ay00, U10Az00,
U10B.00, U10B000,
U10B600, U10By00, U10Bz00, U10C.00, U10C600, U10Cz00,
U10D.00, U10D000, U10D100, U10D300, U10D600, U10Dz00,
U10E.00, U10E000, U10Ez00, U10F000, U10F100, U10F300,
U10G.00, U10G300, U10G600, U10H.00, U10H000, U10H200,
U10H300, U10H400, U10H500, U10H600, U10Hy00, U10Hz00,
U10J.00, U10J000, U10J100, U10J200, U10J300, U10J400,
U10J600, U10Jy00, U10Jz00, U10z.00, U10z000, U10z100,
U10z300, U10z400, U10z600, U10zy00, U10zz00
280
Alcohol
136..00, 1361.11, 1363, 1364, 1365, 1366, 1368, 1369, 136C.00,
136D.00, 136E.00, 136F.00, 136G.00, 136H.00, 136I.00, 136J.00,
136K.00, 136L.00, 136O.00, 136P.00, 136Q.00, 136R.00, 136S.00,
136T.00, 136V.00, 136W.00, 136X.00, 136Z.00, 13Y8.00, 1462,
1B1c.00, 2577, 2577.11, 66e..00, 66e0.00, 6792, 67H0.00,
8H35.00, 8H7p.00, 8HkG.00, E01..00, E010.00, E010.11,
E010.12, E011.00, E011000, E011100, E011200, E011z00,
E012.00, E012.11, E012000, E013.00, E014.00, E014.11, E015.00,
E01y.00, E01y000,
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E01yz00, E01z.00, E23..00, E23..11, E23..12, E230.00, E230.11,
E230000, E230100, E230200, E230300, E230z00, E231.00,
E231.11, E231000, E231100, E231200, E231300, E231z00,
E23z.00, E250.00, E250.11, E250.12, E250.13, E250.14, E250000,
E250100, E250200, E250300, E250z00, Eu10.00, Eu10000,
Eu10011, Eu10100, Eu10200, Eu10211, Eu10212, Eu10213,
Eu10300,
Eu10400, Eu10411, Eu10500, Eu10511, Eu10512, Eu10513,
Eu10514, Eu10600, Eu10611, Eu10700, Eu10711, Eu10712,
Eu10800, Eu10y00, Eu10z00, F375.00, J610.00, J611.00, J613.00,
J613000, J617.00, J617000, J671000, R103.00, U80..00, U800.00,
U801.00, U802.00, U803.00, U804.00, U805.00, U806.00,
U807.00, U808.00, U81..00, U811.00, U812.00, U813.00,
U814.00
251
Upper GI diag-
nosis
43k7.00, 4JM1.00, 4JN..00, A074500, AB20100, AB20z00,
J10..00, J100.00, J100.11, J100.12, J100000, J101000, J103000,
J103100, J103200, J103211, J103300, J103311, J105.00, J105.11,
J105.13, J105.14, J105.15, J105000, J106.00, J106000, J106100,
J106200, J106300, J106400, J106500, J106z00, J10y.00, J10y100,
J10y413, J160.00, J161.00, J170.00, J170.11, J170000, J170100,
J170200, J170z00, J171.00, J172.00, J174000, J175.00, J176.00,
J17y.00, J17y000, J17y100, J17y300, J17y500, J17y600,
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J17yz00, J17z.00, J1y..00, J1z..00, J34..00, J34..11, J34..12,
J340.00, J341.00, J342.00, J343.00, J347.00, J348.00,
J34y.00, J34y.11, J34z.00, J34z000, Jyu1000, Jyu1400, PA30.00,
PA31.00, PA31.11, PA32.00, PA32000, PA32100, PA32111,
PA32z00, PA33.00, PA34.00, PA35.00, PA36.00, PA37.00,
PA3y.00, PA3z.00, PA4..00, PA40.00, PA42.00, PA43.00,
PA44.00, PA45.00, PA4z.00, PA5..00, PA50.00, PA51.00,
PA51.11, PA52.00, PA52.11, PA5y.00, PA5z.00, PA6..00,
PA7..00, PA70.00, PA70.11, PA71.00, PA73.00, PA74.00,
PA75.00, PA76.00, PA77.00, PA78.00, PA7z.00, PAy..00, PAz..00,
PAz0.00, PAz1.00, PAz2.00, PAzz.00, PAzz.11, PB13000
152
Confusion
1B67.00, 1B67.11, 1B69.00, 1B6A.00, 2232, 2232.11, 2233, 2234,
225..00, 225..11, 2251, 2841, 2841.11, E030.00, E030.11,
E030.12, E030000, E030100, E030200, E030300, E030400,
E030z00, E031.00, E031.11, E031000, E031z00, Eu04.12,
R009.00, R009.11, R009000
92
Upper GI pro-
cedure
7022000, 7022012, 7022100, 7022111, 7022112, 7022200,
7022300, 7022400, 7022y00, 7022z00, 7022z11, 76...00, 76...11,
760..00, 760..11, 7600, 7600.11, 7600000, 7600011, 7600012,
7600013, 7600100, 7600111, 7600300, 7600y00, 7600z00, 7601,
7601.11, 7601000, 7601111, 7601200, 7601213, 7601400, 7601y00,
7601z00, 7602, 7602.11, 7602000, 7602300, 7602y00, 7602z00,
7602z11, 7603, 7603000, 7603100, 7604, 7604000, 7604100,
7604300, 7604500, 7604z00, 7605, 7605000, 7605100, 7605200,
7605y00, 7606, 7606200,
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7606300, 7606y00, 7606z00, 7607, 7607.11, 7607000, 7607200,
7607211, 7607300, 7607y00, 7607z00, 7607z11, 7608, 7608000,
7608011, 7608100, 7608200, 7608300, 7608311, 7608y00,
7608z00, 7609, 7609000, 7609100, 7609200, 7609400, 7609y11,
7609z00, 760A.00, 760A.11, 760A000, 760A011, 760A100,
760A200, 760B.00, 760B000, 760B100, 760By00, 760Bz00,
760Hz00, 760J.00, 760J300, 760J312, 760J500, 760Jy00, 760Jz00,
760K.00, 760y.00, 760z.00, 761..00, 761..11, 7610, 7610.11,
7610.12,
7610000, 7610100, 7610300, 7610400, 7610y00, 7610z00, 7611,
7611.11, 7611000, 7611011, 7611012, 7611100, 7611200, 7611211,
7611212, 7611213, 7611214, 7611215, 7611216, 7611300,
7611400, 7611500, 7611600, 7611700, 7611800, 7611900,
7611A00, 7611y00, 7611z00, 7612, 7612000, 7612100, 7612111,
7612200, 7612300, 7612400, 7612500, 7612y00, 7614, 7614000,
7614100, 7614111, 7614200, 7614y00, 7614z00, 7615, 7615.11,
7615000, 7615100, 7615200, 7615y00, 7615z00,
7616, 7616000, 7616011, 7616012, 7616013, 7616014, 7616015,
7616100, 7616200, 7616300, 7616600, 7616y00, 7616z00, 7617,
7617.11, 7617.12, 7617000, 7617111, 7617112, 7617200, 7617300,
7617500, 7617y00, 7617z00, 7618, 7618000, 7618100, 7618200,
7618y00, 7618z00, 7619, 7619.11, 7619000, 7619100, 7619y00,
7619z00, 761A.00, 761A000, 761A100, 761A200, 761A300,
761A400, 761Ay00, 761Az00, 761B.00, 761B.11, 761B000,
761B011, 761B100, 761B200, 761B211, 761B212, 761B213,
761B300,
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761B500, 761B600, 761By00, 761Bz00, 761C.00, 761C000,
761C100, 761Cy00, 761Cz00, 761Gy00, 761Gz00, 761Hy00,
761Hz00, 762..00, 7620, 7620.11, 7620000, 7620100, 7620200,
7620y00, 7620z00, 7620z11, 7621000, 7621100, 7621z00, 7622,
7622100, 7622200, 7622y00, 7622z00, 7623, 7623000, 7623100,
7623200, 7623300, 7623400, 7623411, 7623500, 7623700,
7623y00, 7623z00, 7624, 7626, 7626100, 7626y00, 7626z00,
7627y00, 7627z00, 762y.00, 762z.00, 8HS..00, 8HS..11, J522.00,
J522000, J522100, J522200, J522211, J522212, J522z00, J523.00,
J524100
39
Blood transfu-
sion
14S1.00, 4311, 434..00, 4341, 4342, 4343, 434Z.00, 435..00,
435..11, 7L13.00, 7L13000, 7L13100, 7L13200, 7L13300,
7L13500, 7L13y00, 7L13z00, 7L14.00, 7L14000, 7L14100,
7L14200, 7L14300, 7L14311, 7L14y00, 7L14z00, 7L15.00,
7L15000, 7L15100, 7L15200, 7L15300, 7L15400, 7L15800,
7L15y00, 7L15z00, 7L16.00, 88...11
36
GI procedure
14U2.00, 14U5.00, 1984.11, 585F.00, 7603300, 7603311, 7606000,
7606011, 7606100, 760D312, 760J000, 760J100, 760J200, 760K.11,
760K.12, 760K000, 760K011, 760K012, 760K100, 760K200,
760K300, 760K400, 760K500, 760Ky00, 760Kz00, 760L.00,
760L.11, 760L000, 760L011, 760L012, 760L100, 760L111,
760L200, 760L211, 760L300, 760L311, 760L312, 760L500,
760L600, 760L611, 760L700, 760L800, 760Ly00, 760Lz00,
760M.00,
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760M000, 760M200, 760Mz00, 7613, 7613000, 7613100, 7613111,
7613200, 7613300, 7613400, 7613500, 7613600, 7613y00,
7613z00, 7617100, 7617400, 7617600, 761A500, 761E400,
761E900, 761EA00, 761G000, 761G100, 761G212, 761G300,
761H.00, 761H000, 761H100, 761H200, 7623711, 7626000,
782B.00, 782B.11, 782B000, 782B011, 782B100, 782B111,
782By00, 782Bz00, 782C.00, 782C000, 782Cy00, 782Cz00,
782D.00, 782D000, 782D100, 782D200, 782D300, 782D400,
782D500, 782D600,
782Dy00, 782Dz00, 782E.00, 782E000, 782E100, 782E200,
782Ey00, 782Ez00, 782F.00, 782F000, 782F100, 782F200,
782F300, 782F400, 782Fy00, 782Fz00, 782G.00, 782G000,
782G100, 782G200, 782Gy00, 782Gz00, 782Gz11, 782Gz12,
782H.00, 782H000, 782Hy00, 782Hz00, 782J.00, 782J000,
782J100, 782Jy00, 782Jz00, 782K.11, 782Kz00, 782L.00, 782L300,
782L400, 782Ly00, 782Lz00, 782M.12, 782M000, 782M100,
782M200, 782M400, 782M500, 782Mz00, 782N.00, 782N000,
782Nz00, J16..00, J173.00, J173100, J173200, J173300, J173z00,
J174.00, J174100, J174200, J174300, J174400, J174z00, J177.00,
J177.11, J178.00, J178.11, J17y200, J17y400, J17y700, J345.00,
J346.00, J500000, J500100
34
Nutrition
161..00, 1612, 1612.11, 1623, 1625, 1625.11, C2...00, C20..00,
C201.00, C20z.00, C20zX00, C21..00, C22..00, C23..00,
C230.00, C231.00, C232.00, C233.00, C234.00, C23y.00, C23z.00,
C23z.11, C23z.12
25
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1GZ..00, 1H...00, 1H0..00, 1H0..11, 1H1..00, 1H2..00, 1H3..00,
1I...00, 1J0..00, 1R...00, 1R0..00, 1R1..00, 431..00, 431..11,
4312, 4313, 4314, 4315, 431Z.00, 432..00, 4321, 4322, 4323,
4324, 4325, 432Z.00, 433..00, 4331, 4332, 4333, 4334, 4334000,
4335, 4336, 4337, 4338, 433Z.00, 4344, 436..00, 4361, 4362,
436Z.00, 437..00, 437..11, 4371, 4372, 4373, 4374, 4375, 4376,
437Z.00, 43S..00, 43S0.00, 43c0.00, 43x0.00, 43x1.00, 43x2.00,
43x3.00, 43x4.00, 43x5.00, 43x6.00, 62L..00, 62L2.00, 62LZ.00,
6A...00, 8CB..00, 8H3U.00, ZLG6200
15
General proce-
dure
89...00, 89...11, 89...12, 89...13, 89...14, 891..00, 892..00, 8920,
8921, 8922, 8923, 893..00, 8934, 8935, 89Z..00, 8A...00, 8A1..00
15
213
